0000875320-20-000019.txt : 20200501 0000875320-20-000019.hdr.sgml : 20200501 20200501163749 ACCESSION NUMBER: 0000875320-20-000019 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 76 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200501 DATE AS OF CHANGE: 20200501 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 20841395 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 10-Q 1 a2020q110-q.htm 10-Q Document
false--12-31Q120200000875320VERTEX PHARMACEUTICALS INC / MA0.010.01500000000500000000258993000259079000258993000259079000P1M0150000050000000.010.01100000010000000000120.01140.01160.01180.0129.07100.0140.0160.0180.01140.00160.00180.00189.38401206080100 0000875320 2020-01-01 2020-03-31 0000875320 2020-04-24 0000875320 2019-01-01 2019-03-31 0000875320 us-gaap:ProductMember 2019-01-01 2019-03-31 0000875320 vrtx:CollaborativeandRoyaltyMember 2019-01-01 2019-03-31 0000875320 vrtx:CollaborativeandRoyaltyMember 2020-01-01 2020-03-31 0000875320 us-gaap:ProductMember 2020-01-01 2020-03-31 0000875320 2019-12-31 0000875320 2020-03-31 0000875320 us-gaap:CommonStockMember 2019-03-31 0000875320 us-gaap:CommonStockMember 2020-03-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000875320 us-gaap:RetainedEarningsMember 2019-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000875320 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000875320 2018-12-31 0000875320 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000875320 us-gaap:CommonStockMember 2018-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000875320 us-gaap:RetainedEarningsMember 2019-03-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000875320 us-gaap:CommonStockMember 2019-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000875320 2019-01-01 0000875320 us-gaap:RetainedEarningsMember 2020-03-31 0000875320 us-gaap:RetainedEarningsMember 2018-12-31 0000875320 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000875320 2019-03-31 0000875320 us-gaap:RetainedEarningsMember 2019-01-01 0000875320 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000875320 us-gaap:AccountingStandardsUpdate201602Member us-gaap:RetainedEarningsMember 2019-01-01 0000875320 vrtx:ORKAMBIMember 2020-01-01 2020-03-31 0000875320 vrtx:TRIKAFTAMember 2019-01-01 2019-03-31 0000875320 vrtx:ORKAMBIMember 2019-01-01 2019-03-31 0000875320 vrtx:TRIKAFTAMember 2020-01-01 2020-03-31 0000875320 vrtx:KalydecoMember 2020-01-01 2020-03-31 0000875320 vrtx:SYMDEKOSYMKEVIMember 2019-01-01 2019-03-31 0000875320 vrtx:KalydecoMember 2019-01-01 2019-03-31 0000875320 vrtx:SYMDEKOSYMKEVIMember 2020-01-01 2020-03-31 0000875320 srt:EuropeMember 2019-01-01 2019-03-31 0000875320 us-gaap:NonUsMember 2019-01-01 2019-03-31 0000875320 us-gaap:NonUsMember 2020-01-01 2020-03-31 0000875320 country:US 2020-01-01 2020-03-31 0000875320 vrtx:OtherNonU.S.Member 2019-01-01 2019-03-31 0000875320 srt:EuropeMember 2020-01-01 2020-03-31 0000875320 vrtx:OtherNonU.S.Member 2020-01-01 2020-03-31 0000875320 country:US 2019-01-01 2019-03-31 0000875320 vrtx:CTX001CoCoAgreementMember 2019-01-01 2019-03-31 0000875320 vrtx:CRISPRTherapeuticsAGMember 2020-01-01 2020-03-31 0000875320 vrtx:CRISPRTherapeuticsAGMember 2019-10-01 2019-12-31 0000875320 vrtx:CRISPRDMDDM1Member 2020-01-01 2020-03-31 0000875320 vrtx:CTX001CoCoAgreementMember 2020-01-01 2020-03-31 0000875320 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0000875320 us-gaap:RestrictedStockMember 2020-01-01 2020-03-31 0000875320 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0000875320 us-gaap:RestrictedStockMember 2019-01-01 2019-03-31 0000875320 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0000875320 us-gaap:RestrictedStockMember 2019-01-01 2019-03-31 0000875320 us-gaap:RestrictedStockMember 2020-01-01 2020-03-31 0000875320 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0000875320 us-gaap:FairValueInputsLevel3Member 2020-03-31 0000875320 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember 2020-03-31 0000875320 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2020-03-31 0000875320 us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember us-gaap:CommercialPaperMember 2019-12-31 0000875320 us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember 2019-12-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2020-03-31 0000875320 us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember us-gaap:CommercialPaperMember 2020-03-31 0000875320 vrtx:MarketableSecuritiesMember 2020-03-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2019-12-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2019-12-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2020-03-31 0000875320 vrtx:MarketableSecuritiesMember 2019-12-31 0000875320 us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember vrtx:CashAndMoneyMarketFundsMember 2020-03-31 0000875320 us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember vrtx:CashAndMoneyMarketFundsMember 2019-12-31 0000875320 us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember 2020-03-31 0000875320 2019-01-01 2019-12-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000875320 us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0000875320 us-gaap:OtherAssetsMember 2020-03-31 0000875320 us-gaap:EquitySecuritiesMember 2019-12-31 0000875320 us-gaap:EquitySecuritiesMember 2020-03-31 0000875320 vrtx:CRISPRSaleMember 2020-03-31 0000875320 vrtx:CRISPRSaleMember 2020-01-01 2020-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2020-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-03-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-03-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2019-03-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-01-01 2020-03-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-03-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-03-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-03-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000875320 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 currency:CAD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000875320 currency:CAD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:NondesignatedMember 2020-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2020-01-01 2020-03-31 0000875320 srt:MaximumMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2020-01-01 2020-03-31 0000875320 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0000875320 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0000875320 srt:MinimumMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2020-01-01 2020-03-31 0000875320 vrtx:ExercisePriceRangeFromDollars120.01toDollars140.0Member 2020-01-01 2020-03-31 0000875320 vrtx:ExercisePriceRangeFromDollars160.01toDollars180.00Member 2020-03-31 0000875320 vrtx:ExercisePriceRangeFromDollars120.01toDollars140.0Member 2020-03-31 0000875320 vrtx:ExercisePriceRangeFromDollars160.01toDollars180.00Member 2020-01-01 2020-03-31 0000875320 vrtx:ExercisePriceRangeFromDollars140.01toDollars160.0Member 2020-03-31 0000875320 vrtx:ExercisePriceRangefromDollars100.01toDollars120.00Member 2020-03-31 0000875320 vrtx:ExercisePriceRangefromDollars100.01toDollars120.00Member 2020-01-01 2020-03-31 0000875320 vrtx:ExercisePriceRangefromDollars80.01toDollars100.00Member 2020-03-31 0000875320 vrtx:ExercisePriceRangefromDollars40.01toDollars60.00Member 2020-01-01 2020-03-31 0000875320 vrtx:ExercisePriceRangefromDollars60.01toDollars80.00Member 2020-03-31 0000875320 vrtx:ExercisePriceRangefromDollars40.01toDollars60.00Member 2020-03-31 0000875320 vrtx:ExercisePriceRangeFromDollars140.01toDollars160.0Member 2020-01-01 2020-03-31 0000875320 vrtx:ExercisePriceRangeFromDollars29.07toDollars40.00Member 2020-01-01 2020-03-31 0000875320 vrtx:ExercisePriceRangeFromDollars180.01toDollars189.38Member 2020-01-01 2020-03-31 0000875320 vrtx:ExercisePriceRangefromDollars80.01toDollars100.00Member 2020-01-01 2020-03-31 0000875320 vrtx:ExercisePriceRangeFromDollars29.07toDollars40.00Member 2020-03-31 0000875320 vrtx:ExercisePriceRangefromDollars60.01toDollars80.00Member 2020-01-01 2020-03-31 0000875320 vrtx:ExercisePriceRangeFromDollars180.01toDollars189.38Member 2020-03-31 0000875320 vrtx:ShareRepurchaseProgram2019Member 2020-03-31 0000875320 vrtx:ShareRepurchaseProgram2018Member 2019-01-01 2019-03-31 0000875320 vrtx:ShareRepurchaseProgram2018Member 2019-06-30 0000875320 vrtx:ShareRepurchaseProgram2018Member 2018-12-31 0000875320 vrtx:ShareRepurchaseProgram2019Member 2020-01-01 2020-03-31 0000875320 vrtx:ShareRepurchaseProgram2019Member 2019-07-31 0000875320 us-gaap:EmployeeStockMember 2020-03-31 0000875320 us-gaap:EmployeeStockMember 2020-01-01 2020-03-31 0000875320 us-gaap:EmployeeStockOptionMember 2020-03-31 0000875320 us-gaap:RestrictedStockMember 2020-03-31 0000875320 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-03-31 0000875320 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-03-31 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0000875320 us-gaap:CostOfSalesMember 2019-01-01 2019-03-31 0000875320 us-gaap:EmployeeStockMember 2019-01-01 2019-03-31 0000875320 us-gaap:CostOfSalesMember 2020-01-01 2020-03-31 0000875320 us-gaap:RevolvingCreditFacilityMember 2020-01-01 2020-03-31 0000875320 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:EurodollarMember 2020-01-01 2020-03-31 0000875320 us-gaap:RevolvingCreditFacilityMember 2019-09-30 0000875320 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2020-01-01 2020-03-31 0000875320 us-gaap:LetterOfCreditMember 2019-09-30 0000875320 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:EurodollarMember 2020-01-01 2020-03-31 0000875320 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2020-01-01 2020-03-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2019-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2020-03-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2019-03-31 0000875320 us-gaap:OtherAssetsMember 2018-12-31 0000875320 us-gaap:OtherAssetsMember 2019-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2018-12-31 0000875320 us-gaap:OtherAssetsMember 2019-03-31 xbrli:shares iso4217:USD xbrli:shares vrtx:segment vrtx:target xbrli:pure iso4217:USD

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________________________
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2020
or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM    TO   
Commission file number 000-19319
____________________________________________
Vertex Pharmaceuticals Incorporated
(Exact name of registrant as specified in its charter)

Massachusetts
(State or other jurisdiction of
incorporation or organization)
50 Northern Avenue, Boston, Massachusetts
(Address of principal executive offices)
 

04-3039129
(I.R.S. Employer
Identification No.)
02210
(Zip Code)

Registrant’s telephone number, including area code (617) 341-6100
    
____________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Trading Symbol
 
Name of each exchange on which registered
Common Stock, $0.01 Par Value Per Share
 
VRTX
 
The Nasdaq Global Select Market
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒ 
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Common Stock, par value $0.01 per share
259,276,709
Outstanding at April 24, 2020
 


VERTEX PHARMACEUTICALS INCORPORATED
FORM 10-Q
FOR THE QUARTER ENDED MARCH 31, 2020

TABLE OF CONTENTS
 
 
Page
 
 
Condensed Consolidated Statements of Operations - Three Months Ended March 31, 2020 and 2019
 
Condensed Consolidated Statements of Comprehensive Income - Three Months Ended March 31, 2020 and 2019
 
Condensed Consolidated Balance Sheets - March 31, 2020 and December 31, 2019
 
Condensed Consolidated Statements of Shareholders' Equity - Three Months Ended March 31, 2020 and 2019
 
Condensed Consolidated Statements of Cash Flows - Three Months Ended March 31, 2020 and 2019
 
Item 5.
Other Information.
 
“We,” “us,” “Vertex” and the “Company” as used in this Quarterly Report on Form 10-Q refer to Vertex Pharmaceuticals Incorporated, a Massachusetts corporation, and its subsidiaries.
“Vertex,” “KALYDECO®,” “ORKAMBI®,” “SYMDEKO®,” “SYMKEVI®” and “TRIKAFTA®” are registered trademarks of Vertex. Other brands, names and trademarks contained in this Quarterly Report on Form 10-Q are the property of their respective owners.
We use the brand name for our products when we refer to the product that has been approved and with respect to the indications on the approved label. Otherwise, including in discussions of our cystic fibrosis development programs, we refer to our compounds by their scientific (or generic) name or VX developmental designation.



Part I. Financial Information
Item 1.  Financial Statements

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except per share amounts)
 
Three Months Ended March 31,
 
2020
 
2019
Revenues:
 
 
 
Product revenues, net
$
1,515,107

 
$
857,253

Collaborative and royalty revenues
—

 
1,182

Total revenues
1,515,107

 
858,435

Costs and expenses:
 
 
 
Cost of sales
162,497

 
95,092

Research and development expenses
448,528

 
339,490

Sales, general and administrative expenses
182,258

 
147,045

Change in fair value of contingent consideration
1,600

 
—

Total costs and expenses
794,883

 
581,627

Income from operations
720,224

 
276,808

Interest income
12,576

 
15,615

Interest expense
(14,136
)
 
(14,868
)
Other (expense) income, net
(61,130
)
 
42,610

Income before provision for income taxes
657,534

 
320,165

Provision for income taxes
54,781

 
51,534

Net income
$
602,753

 
$
268,631

 
 
 
 
Net income per common share:
 
 
 
Basic
$
2.32

 
$
1.05

Diluted
$
2.29

 
$
1.03

Shares used in per share calculations:
 
 
 
Basic
259,815

 
255,695

Diluted
263,515

 
260,175

The accompanying notes are an integral part of these condensed consolidated financial statements.


2

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Comprehensive Income
(unaudited)
(in thousands)
 
Three Months Ended March 31,
 
2020
 
2019
Net income
$
602,753

 
$
268,631

Changes in other comprehensive income:
 
 
 
Unrealized holding (losses) gains on marketable securities, net
(764
)
 
596

Unrealized gains (losses) on foreign currency forward contracts, net of tax of $(5.0) million and $1.5 million, respectively
18,782

 
(222
)
Foreign currency translation adjustment
(2,662
)
 
4,967

Total changes in other comprehensive income
15,356

 
5,341

Comprehensive income
$
618,109

 
$
273,972

The accompanying notes are an integral part of these condensed consolidated financial statements.


3

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands, except per share amounts)
 
March 31,
 
December 31,
 
2020
 
2019
Assets
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
3,593,412

 
$
3,109,322

Marketable securities
596,984

 
698,972

Accounts receivable, net
845,269

 
633,518

Inventories
187,087

 
167,502

Prepaid expenses and other current assets
223,648

 
213,515

Total current assets
5,446,400

 
4,822,829

Property and equipment, net
736,303

 
745,080

Goodwill
1,002,158

 
1,002,158

Intangible assets
400,000

 
400,000

Deferred tax assets
1,147,705

 
1,190,815

Other assets
160,635

 
157,583

Total assets
$
8,893,201

 
$
8,318,465

Liabilities and Shareholders’ Equity
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
100,703

 
$
87,610

Accrued expenses
1,258,271

 
1,116,912

Other current liabilities
179,776

 
130,305

Total current liabilities
1,538,750

 
1,334,827

Long-term finance lease liabilities
532,952

 
538,576

Long-term contingent consideration
178,100

 
176,500

Other long-term liabilities
181,745

 
183,318

Total liabilities
2,431,547

 
2,233,221

Commitments and contingencies
—

 
—

Shareholders’ equity:
 
 
 
Preferred stock, $0.01 par value; 1,000 shares authorized; none issued and outstanding
—

 
—

Common stock, $0.01 par value; 500,000 shares authorized, 259,079 and 258,993 shares issued and outstanding, respectively
2,591

 
2,589

Additional paid-in capital
7,695,905

 
7,937,606

Accumulated other comprehensive income (loss)
13,383

 
(1,973
)
Accumulated deficit
(1,250,225
)
 
(1,852,978
)
Total shareholders’ equity
6,461,654

 
6,085,244

Total liabilities and shareholders’ equity
$
8,893,201

 
$
8,318,465


The accompanying notes are an integral part of these condensed consolidated financial statements.


4

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Shareholders’ Equity
(unaudited)
(in thousands)
 
Three Months Ended
 
Common Stock
 
Additional
Paid-in Capital
 
Accumulated Other Comprehensive Income (Loss)
 
Accumulated Deficit
 
Total
Shareholders’ Equity
 
Shares
 
Amount
 
 
 
 
Balance at December 31, 2018
255,172

 
$
2,546

 
$
7,421,476

 
$
659

 
$
(2,989,478
)
 
$
4,435,203

Cumulative effect adjustment for adoption of new accounting guidance
—

 
—

 
—

 
—

 
(40,310
)
 
(40,310
)
Other comprehensive income, net of tax
—

 
—

 
—

 
5,341

 
—

 
5,341

Net income
—

 
—

 
—

 
—

 
268,631

 
268,631

Repurchase of common stock
(537
)
 
(6
)
 
(98,001
)
 
—

 
—

 
(98,007
)
Common stock withheld for employee tax obligations
(27
)
 
—

 
(5,832
)
 
—

 
—

 
(5,832
)
Issuance of common stock under benefit plans
1,743

 
21

 
64,023

 
—

 
—

 
64,044

Stock-based compensation expense
—

 
—

 
94,243

 
—

 
—

 
94,243

Balance at March 31, 2019
256,351

 
$
2,561

 
$
7,475,909

 
$
6,000

 
$
(2,761,157
)
 
$
4,723,313

 
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2019
258,993

 
$
2,589

 
$
7,937,606

 
$
(1,973
)
 
$
(1,852,978
)
 
$
6,085,244

Other comprehensive income, net of tax
—

 
—

 
—

 
15,356

 
—

 
15,356

Net income
—

 
—

 
—

 
—

 
602,753

 
602,753

Repurchase of common stock
(1,404
)
 
(14
)
 
(300,012
)
 
—

 
—

 
(300,026
)
Common stock withheld for employee tax obligations
(575
)
 
(6
)
 
(136,161
)
 
 
 
 
 
(136,167
)
Issuance of common stock under benefit plans
2,065

 
22

 
77,572

 
—

 
—

 
77,594

Stock-based compensation expense
—

 
—

 
116,900

 
—

 
—

 
116,900

Balance at March 31, 2020
259,079

 
$
2,591

 
$
7,695,905

 
$
13,383

 
$
(1,250,225
)
 
$
6,461,654

The accompanying notes are an integral part of these condensed consolidated financial statements.


5

VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Cash Flows
(unaudited)
(in thousands)
 
Three Months Ended March 31,
 
2020
 
2019
Cash flows from operating activities:
 
 
 
Net income
$
602,753

 
$
268,631

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
Stock-based compensation expense
115,706

 
93,791

Depreciation expense
26,821

 
27,140

Increase in fair value of contingent consideration
1,600

 
—

Deferred income taxes
36,705

 
43,425

Losses (gains) on equity securities
44,870

 
(43,551
)
Other non-cash items, net
9,668

 
(2,431
)
Changes in operating assets and liabilities:
 
 
 
Accounts receivable, net
(223,672
)
 
(30,136
)
Inventories
(27,450
)
 
(13,139
)
Prepaid expenses and other assets
2,790

 
7,941

Accounts payable
14,285

 
(24,145
)
Accrued expenses
153,814

 
(27,279
)
Other liabilities
57,808

 
24,537

Net cash provided by operating activities
815,698

 
324,784

Cash flows from investing activities:
 
 
 
Purchases of available-for-sale debt securities
(75,265
)
 
(128,215
)
Maturities of available-for-sale debt securities
60,145

 
107,118

Sale of equity securities
72,036

 
—

Expenditures for property and equipment
(19,450
)
 
(18,041
)
Investment in equity securities
(5,800
)
 
—

Net cash provided by (used in) investing activities
31,666

 
(39,138
)
Cash flows from financing activities:
 
 
 
Issuances of common stock under benefit plans
79,597

 
63,620

Repurchases of common stock
(300,026
)
 
(94,007
)
Payments in connection with common stock withheld for employee tax obligations
(136,167
)
 
(5,832
)
Payments on finance leases
(10,287
)
 
(9,385
)
Proceeds related to finance leases
5,833

 
—

Advance from collaborator
2,500

 
5,000

Repayments of advanced funding
(880
)
 
(1,385
)
Net cash used in financing activities
(359,430
)
 
(41,989
)
Effect of changes in exchange rates on cash
(6,651
)
 
(378
)
Net increase in cash and cash equivalents
481,283

 
243,279

Cash, cash equivalents and restricted cash—beginning of period
3,120,681

 
2,658,253

Cash, cash equivalents and restricted cash—end of period
$
3,601,964

 
$
2,901,532

 
 
 
 
Supplemental disclosure of cash flow information:
 
 
 
Cash paid for interest
$
13,771

 
$
13,148

Cash paid for income taxes
$
5,845

 
$
1,835

Issuances of common stock from employee benefit plans receivable
$
817

 
$
510

Accrued share repurchase liability
$
—

 
$
4,000

The accompanying notes are an integral part of these condensed consolidated financial statements.

6
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)


A.
Basis of Presentation and Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex” or the “Company”) in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
The condensed consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. The Company operates in one segment, pharmaceuticals. The Company has reclassified certain items from the prior year’s condensed consolidated financial statements to conform to the current year’s presentation.
Certain information and footnote disclosures normally included in the Company’s 2019 Annual Report on Form 10-K have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended March 31, 2020 and 2019.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2019, which are contained in the Company’s 2019 Annual Report on Form 10-K.
Use of Estimates
The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with (i) determining the transaction price of revenues and (ii) accounting for intangible assets and contingent consideration. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
Recently Adopted Accounting Standards
Leases
On January 1, 2019, the Company adopted Accounting Standards Codification (“ASC”) 842, Leases (“ASC 842”) using the modified-retrospective method, which amended a number of aspects of lease accounting and required the Company to recognize right-of-use assets and liabilities on the balance sheet. As of January 1, 2019, the Company recorded a cumulative effect adjustment to increase its “Accumulated deficit” by $40.3 million, which related to its leases that were accounted for as build-to-suit leases under the previous accounting guidance.
Internal-Use Software
In 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (“ASU 2018-15”), which clarifies the accounting for implementation costs in cloud computing arrangements.  ASU 2018-15 became effective on January 1, 2020. The adoption of ASU 2018-15 resulted in an insignificant amount of additional assets recorded on the Company’s condensed consolidated balance sheet.
Fair Value Measurement
In 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which modifies the disclosure requirements for fair


7
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

value measurements. ASU 2018-13 became effective on January 1, 2020. The adoption of ASU 2018-13 resulted in additional disclosures related to the Company’s Level 3 inputs. Please refer to Note E, “Fair Value Measurements,” for further information.
Credit Losses
In 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 became effective on January 1, 2020. The adoption of ASU 2016-13 did not have a significant impact on its condensed consolidated financial statements.
Recently Issued Accounting Standards
Income Taxes
In 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) (“ASU 2019-12”), which simplifies the accounting for income taxes. ASU 2019-12 is effective on January 1, 2021. The Company is evaluating the impact the adoption of ASU 2019-12 may have on its condensed consolidated financial statements.
For a discussion of other recent accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies,” in the Company’s 2019 Annual Report on Form 10-K.
Summary of Significant Accounting Policies
The Company’s significant accounting policies are described in Note A, “Nature of Business and Accounting Policies,” in its 2019 Annual Report on Form 10-K.
B.
Revenue Recognition
Disaggregation of Revenue
Revenues by Product
Product revenues, net consisted of the following:
 
Three Months Ended March 31,
 
2020
 
2019
 
(in thousands)
TRIKAFTA
$
895,233

 
$
—

SYMDEKO/SYMKEVI
173,159

 
320,275

ORKAMBI
234,138

 
293,007

KALYDECO
212,577

 
243,971

Total product revenues, net*
$
1,515,107

 
$
857,253


* The preceding table does not include collaborative and royalty revenues.


8
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

Revenues by Geographic Location
Net product revenues are attributed to countries based on the location of the customer. Collaborative and royalty revenues are attributed to countries based on the location of the Company’s subsidiary associated with the collaborative arrangement related to such revenues. Total revenues from external customers and collaborators by geographic region consisted of the following:
 
Three Months Ended March 31,
 
2020
 
2019
 
(in thousands)
United States
$
1,187,588

 
$
641,104

Outside of the United States
 
 
 
Europe
257,391

 
167,751

Other
70,128

 
49,580

Total revenues outside of the United States
327,519

 
217,331

Total revenues
$
1,515,107

 
$
858,435


Contract Liabilities
The Company recorded contract liabilities of $76.3 million and $62.3 million as of March 31, 2020 and December 31, 2019, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement the Company can receive. Upon exceeding the annual reimbursement amount, products are provided free of charge, which is a material right. These contracts include upfront payments and fees.  The Company defers a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” The deferred amount is recognized as revenue when the free products are shipped. The Company’s product revenue contracts include performance obligations that are one year or less.
The Company’s contract liabilities at the end of each fiscal year relate to contracts with annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as the Company’s fiscal year. In these markets, the Company recognizes revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year.
C.
Collaborative Arrangements
The Company has entered into numerous agreements pursuant to which it collaborates with third parties on research, development and commercialization programs, including in-license and out-license agreements.
The Company’s in-license and out-license agreements that had a significant impact on its financial statements for the three months ended March 31, 2020 and 2019, or were new during the three months ended March 31, 2020, are described below. Additional in-license and out-license agreements were described in Note B, “Collaborative Arrangements,” of the Company’s 2019 Annual Report on Form 10-K.
In-license Agreements
The Company has entered into a number of license agreements in order to advance and obtain access to technologies and services related to its research and early-development activities. The Company is generally required to make an upfront payment upon execution of the license agreement; development, regulatory and commercialization milestones payments upon the achievement of certain product research, development and commercialization objectives; and royalty payments on future sales, if any, of commercial products resulting from the collaboration.
Pursuant to the terms of its in-license agreements, the Company’s collaborators typically lead the discovery efforts and the Company leads all preclinical, development and commercialization activities associated with the advancement of any drug candidates and funds all expenses.


9
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

The Company typically can terminate its in-license agreements by providing advance notice to its collaborators; the required length of notice is dependent on whether any product developed under the license agreement has received marketing approval. The Company’s license agreements may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, these license agreements generally remain in effect until the date on which the royalty term and all payment obligations with respect to all products in all countries have expired.
CRISPR Therapeutics AG
In 2015, the Company entered into a strategic collaboration, option and license agreement (the “CRISPR Agreement”) with CRISPR Therapeutics AG and its affiliates (“CRISPR”) to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene-editing technology. The Company had the exclusive right to license certain CRISPR-Cas9-based targets. In the fourth quarter of 2019, the Company elected to exclusively license three CRISPR-Cas9-based targets, including cystic fibrosis, pursuant to the CRISPR Agreement. For each of the three targets that the Company elected to license, CRISPR has the potential to receive up to an additional $410.0 million in development, regulatory and commercial milestones as well as royalties on net product sales.
In 2017, the Company entered into a co-development and co-commercialization agreement with CRISPR pursuant to the terms of the CRISPR Agreement, under which the Company and CRISPR are co-developing and will co-commercialize CTX001 (the “CTX001 Co-Co Agreement”) for the treatment of hemoglobinopathies, including treatments for sickle cell disease and beta thalassemia. As part of the collaboration, the Company and CRISPR share equally all development costs and potential worldwide revenues related to potential hemoglobinopathy treatments. The Company concluded that the CTX001 Co-Co Agreement is a cost-sharing arrangement, which results in the net impact of the arrangement being recorded in “Research and development expenses” in its condensed consolidated statements of operations. During the three months ended March 31, 2020 and 2019, the net expense related to the CTX001 Co-Co Agreement was $9.3 million and $7.0 million, respectively.
In July 2019, the Company entered into a separate strategic collaboration and license agreement (the “CRISPR DMD/DM1 Agreement”) with CRISPR. Pursuant to this agreement, the Company received an exclusive worldwide license to CRISPR’s existing and future intellectual property for duchenne muscular dystrophy (“DMD”) and myotonic dystrophy type 1 (“DM1”). In the first quarter of 2020, the Company recorded $25.0 million to “Research and development expenses” related to a pre-clinical milestone earned by CRISPR under the CRISPR DMD/DM1 Agreement. CRISPR has the potential to receive up to an additional $800.0 million in research, development, regulatory and commercial milestones for the DMD and DM1 programs as well as royalties on net product sales. CRISPR has the option to co-develop and co-commercialize all DM1 products globally and forego the milestones and royalties associated with the DM1 program. The Company funds all expenses associated with the collaboration except for research costs for specified guide RNA research conducted by CRISPR, which the Company and CRISPR share equally.
Please refer to Note F, “Marketable Securities and Equity Investments,” for further information regarding the Company’s investment in CRISPR’s common stock.
Out-license Agreements
The Company has entered into licensing agreements pursuant to which it has out-licensed rights to certain drug candidates to third-party collaborators. Pursuant to these out-license agreements, the Company’s collaborators become responsible for all costs related to the continued development of such drug candidates and obtain development and commercialization rights to these drug candidates. Depending on the terms of the agreements, the Company’s collaborators may be required to make upfront payments, milestone payments upon the achievement of certain product research and development objectives and may also be required to pay royalties on future sales, if any, of commercial products resulting from the collaboration. The termination provisions associated with these collaborations are generally the same as those described above related to the Company’s in-license agreements. None of the Company’s out-license agreements had a significant impact on the Company’s condensed consolidated statement of operations during the three months ended March 31, 2020 and 2019.


10
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

Cystic Fibrosis Foundation
The Company has a research, development and commercialization agreement that was originally entered into in 2004 with Cystic Fibrosis Foundation (“CFF”), as successor in interest to the Cystic Fibrosis Foundation Therapeutics, Inc. This agreement was most recently amended in 2016. Pursuant to the agreement, as amended, the Company agreed to pay royalties ranging from low-single digits to mid-single digits on potential sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016, including elexacaftor, and tiered royalties ranging from single digits to sub-teens on covered compounds first synthesized and/or tested during a research term on or before February 28, 2014, including KALYDECO (ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor). For combination products, such as ORKAMBI, SYMDEKO/SYMKEVI and TRIKAFTA (elexacaftor, tezacaftor, and ivacaftor), sales are allocated equally to each of the active pharmaceutical ingredients in the combination product.
D.
Earnings Per Share
Basic net income per common share is based upon the weighted-average number of common shares outstanding. Diluted net income per common share utilizing the treasury method is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive.
The following table sets forth the computation of basic and diluted net income per common share for the periods ended:
 
Three Months Ended March 31,
 
2020
 
2019
 
(in thousands, except per share amounts)
Net income
$
602,753

 
$
268,631

 
 
 
 
Basic weighted-average common shares outstanding
259,815

 
255,695

Effect of potentially dilutive securities:
 
 
 
Stock options
1,868

 
2,585

Restricted stock and restricted stock units (including PSUs)
1,801

 
1,870

Employee stock purchase program
31

 
25

Diluted weighted-average common shares outstanding
263,515

 
260,175

 
 
 
 
Basic net income per common share
$
2.32

 
$
1.05

Diluted net income per common share
$
2.29

 
$
1.03


The Company did not include the securities in the following table in the computation of the net income per common share because the effect would have been anti-dilutive during each period:
 
Three Months Ended March 31,
 
2020
 
2019
 
(in thousands)
Stock options
879

 
2,837

Unvested restricted stock and restricted stock units (including PSUs)
430

 
6


E.
Fair Value Measurements
The fair value of the Company’s financial assets and liabilities reflects the Company’s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market


11
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:
Level 1:
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable inputs based on the Company’s assessment of the assumptions that market participants would use in pricing the asset or liability.
The Company’s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit quality standards outlined in the Company’s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument. The Company maintains strategic investments separately from the investment policy that governs its other cash, cash equivalents and marketable securities as described in “Note F, “Marketable Securities and Equity Investments.” As of March 31, 2020, the Company’s investments were in money market funds, corporate debt securities, commercial paper, government-sponsored enterprise securities and corporate equity securities. Additionally, the Company utilizes foreign currency forward contracts intended to mitigate the effect of changes in foreign exchange rates on its condensed consolidated statement of operations.
As of March 31, 2020, the Company’s financial assets and liabilities that were subject to fair value measurements were valued using both observable and unobservable inputs. The Company’s financial assets valued based on Level 1 inputs consisted of money market funds, government-sponsored enterprise securities and corporate equity securities. The Company’s financial assets and liabilities valued based on Level 2 inputs consisted of certain corporate equity securities as described below, corporate debt securities, commercial paper, which consisted of investments in highly-rated investment-grade corporations, and foreign currency forward contracts with reputable and creditworthy counterparties. As discussed further below, the Company’s financial liabilities valued based on Level 3 inputs consisted of acquisition-related contingent milestones. During the three months ended March 31, 2020 and 2019, the Company did not record any other-than-temporary impairment charges related to its financial assets.


12
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

The following tables set forth the Company’s financial assets and liabilities subject to fair value measurements (and does not include $1.8 billion and $2.3 billion of cash as of March 31, 2020 and December 31, 2019, respectively):
 
Fair Value Measurements as of March 31, 2020
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial instruments carried at fair value (asset positions):
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
1,736,913

 
$
1,736,913

 
$
—

 
$
—

Commercial paper
30,700

 
—

 
30,700

 
—

Marketable securities:
 
 
 
 
 
 
 
Corporate equity securities
165,178

 
145,465

 
19,713

 
—

Government-sponsored enterprise securities
7,791

 
7,791

 
—

 
—

Corporate debt securities
305,051

 
—

 
305,051

 
—

Commercial paper
118,964

 
—

 
118,964

 
—

Prepaid expenses and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
25,434

 
—

 
25,434

 
—

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
1,798

 
—

 
1,798

 
—

Total financial assets
$
2,391,829


$
1,890,169

 
$
501,660

 
$
—

Financial instruments carried at fair value (liability positions):
 
 
 
 
 
 
 
Other current liabilities:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(459
)
 
$
—

 
$
(459
)
 
$
—

Long-term contingent consideration
(178,100
)
 
—

 
—

 
(178,100
)
Other long-term liabilities:
 
 
 
 
 
 
 
Foreign currency forward contracts
(637
)
 
—

 
(637
)
 
—

Total financial liabilities
$
(179,196
)
 
$
—

 
$
(1,096
)
 
$
(178,100
)



13
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

 
Fair Value Measurements as of December 31, 2019
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial instruments carried at fair value (asset positions):
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
791,039

 
$
791,039

 
$
—

 
$
—

Corporate debt securities
6,070

 
—

 
6,070

 
—

Commercial paper
29,472

 
—

 
29,472

 
—

Marketable securities:
 
 
 
 
 
 
 
Corporate equity securities
282,084

 
261,797

 
20,287

 
—

Government-sponsored enterprise securities
12,733

 
12,733

 
—

 
—

Corporate debt securities
301,799

 
—

 
301,799

 
—

Commercial paper
102,356

 
—

 
102,356

 
—

Prepaid expenses and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
9,725

 
—

 
9,725

 
—

Total financial assets
$
1,535,278

 
$
1,065,569

 
$
469,709

 
$
—

Financial instruments carried at fair value (liability positions):
 
 
 
 
 
 
 
Other current liabilities:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(5,533
)
 
$
—

 
$
(5,533
)
 
$
—

Long-term contingent consideration
(176,500
)
 
—

 
—

 
(176,500
)
Other long-term liabilities:
 
 
 
 
 
 
 
Foreign currency forward contracts
(1,821
)
 
—

 
(1,821
)
 
—

Total financial liabilities
$
(183,854
)
 
$
—

 
$
(7,354
)
 
$
(176,500
)

Please refer to Note F, “Marketable Securities and Equity Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.
Fair Value of Corporate Equity Securities
The Company maintains strategic investments in corporate equity securities separately from the investment policy that governs its other cash, cash equivalents and marketable securities. The Company classifies its investments in publicly traded companies as “Marketable securities” on its condensed consolidated balance sheets. Generally, the Company’s investments in the common stock of these publicly traded companies are valued based on Level 1 inputs because they have readily determinable fair values. However, certain of the Company’s investments in publicly traded companies have been or continue to be valued based on Level 2 inputs due to transfer restrictions associated with these investments. Please refer to Note F, “Marketable Securities and Equity Investments,” for further information on these investments.
Fair Value of Contingent Consideration
The Company’s contingent consideration liabilities, which are related to $678.3 million of development and regulatory milestones potentially payable to Exonics’ former equity holders, are classified as Level 3 within the valuation hierarchy. The Company bases its estimates of the probability of achieving the milestones relevant to the fair value of contingent payments on industry data attributable to rare diseases. The discount rates used in the valuation model for contingent payments, which were between 1.8% and 3.1%, represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Due to the uncertainties associated with development and commercialization of a drug candidate in the pharmaceutical industry, the Company's estimates regarding the fair value of contingent consideration will change in the future, resulting in adjustments to the fair value of the Company’s contingent consideration liabilities, and the effect of any such adjustments could be material.


14
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

The following table represents a rollforward of the fair value of the Company’s contingent consideration liabilities:
 
Three Months Ended March 31, 2020
 
(in thousands)
Balance at December 31, 2019
$
176,500

Increase in fair value of contingent payments
1,600

Balance at March 31, 2020
$
178,100


The “Increase in fair value of contingent payments” in the table above was due to changes in market interest rates and the time value of money.
F.
Marketable Securities and Equity Investments
A summary of the Company’s cash equivalents and marketable securities, which are recorded at fair value (and do not include $1.8 billion and $2.3 billion of cash as of March 31, 2020 and December 31, 2019, respectively), is shown below:
 
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair Value
 
(in thousands)
As of March 31, 2020
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
1,736,913

 
$
—

 
$
—

 
$
1,736,913

Commercial paper
30,700

 
4

 
(4
)
 
30,700

Total cash equivalents
1,767,613

 
4

 
(4
)
 
1,767,613

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities
7,717

 
74

 
—

 
7,791

Corporate debt securities
305,808

 
255

 
(1,012
)
 
305,051

Commercial paper
118,542

 
426

 
(4
)
 
118,964

Total marketable debt securities
432,067

 
755

 
(1,016
)
 
431,806

Corporate equity securities
87,096

 
78,082

 
—

 
165,178

Total marketable securities
$
519,163

 
$
78,837

 
$
(1,016
)
 
$
596,984

 
 
 
 
 
 
 
 
As of December 31, 2019
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
791,039

 
$
—

 
$
—

 
$
791,039

Corporate debt securities
6,070

 
—

 
—

 
6,070

Commercial paper
29,470

 
3

 
(1
)
 
29,472

Total cash equivalents
826,579

 
3

 
(1
)
 
826,581

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities
12,689

 
44

 
—

 
12,733

Corporate debt securities
301,458


391

 
(50
)
 
301,799

Commercial paper
102,240

 
121

 
(5
)
 
102,356

Total marketable debt securities
416,387

 
556

 
(55
)
 
416,888

Corporate equity securities
113,829

 
168,255

 
—

 
282,084

Total marketable securities
$
530,216

 
$
168,811

 
$
(55
)
 
$
698,972




15
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

Available-for-sale debt securities were classified on the Company's condensed consolidated balance sheets at fair value as follows:
 
As of March 31, 2020
 
As of December 31, 2019
 
(in thousands)
Cash and cash equivalents
$
1,767,613

 
$
826,581

Marketable securities
431,806

 
416,888

Total
$
2,199,419

 
$
1,243,469


Available-for-sale debt securities by contractual maturity were as follows:
 
As of March 31, 2020
 
As of December 31, 2019
 
(in thousands)
Matures within one year
$
2,157,586

 
$
1,137,942

Matures after one year through five years
41,833

 
105,527

Total
$
2,199,419

 
$
1,243,469


The Company has a limited number of available-for-sale debt securities in insignificant loss positions as of March 31, 2020, which it does not intend to sell and has concluded it will not be required to sell before recovery of the amortized costs for the investments at maturity. The Company did not record any charges for other-than-temporary declines in the fair value of available-for-sale debt securities or gross realized gains or losses in the three months ended March 31, 2020 and 2019.
As of March 31, 2020 and December 31, 2019, the total fair value of the Company’s strategic investments in the common stock of publicly traded companies, which was primarily related to its investment in CRISPR, was $165.2 million and $282.1 million, respectively, and was classified as “Marketable securities” on its condensed consolidated balance sheets.
The Company records changes in the fair value of its investments in corporate equity securities, which are primarily attributable to its investment in CRISPR, to “Other (expense) income, net” on its condensed consolidated statements of operations. During the three months ended March 31, 2020 and 2019, the Company recorded a net unrealized loss of $39.4 million and a net unrealized gain of $43.6 million, respectively, on corporate equity securities held at the conclusion of each period. During the three months ended March 31, 2020, the Company received proceeds of $72.0 million related to sales of CRISPR’s common stock, which had an original weighted-average cost basis of $26.7 million. There were no sales of CRISPR’s common stock during the three months ended March 31, 2019.
As of March 31, 2020, the carrying value of the Company’s equity investments without readily determinable fair values, which are recorded in “Other assets” on its condensed consolidated balance sheets, was $46.6 million.


16
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

G.
Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss) by component:
 
 
 
Unrealized Holding Gains (Losses), Net of Tax
 
 
 
Foreign Currency Translation Adjustment
 
On Available-For-Sale Debt Securities
 
On Foreign Currency Forward Contracts
 
Total
 
(in thousands)
Balance at December 31, 2019
$
(895
)
 
$
503

 
$
(1,581
)
 
$
(1,973
)
Other comprehensive (loss) income before reclassifications
(2,662
)
 
(764
)
 
25,772

 
22,346

Amounts reclassified from accumulated other comprehensive income (loss)
—

 
—

 
(6,990
)
 
(6,990
)
Net current period other comprehensive (loss) income
(2,662
)
 
(764
)
 
18,782

 
15,356

Balance at March 31, 2020
$
(3,557
)
 
$
(261
)
 
$
17,201

 
$
13,383

 
 
 
 
 
 
 
 
Balance at December 31, 2018
$
(11,227
)
 
$
(536
)
 
$
12,422

 
$
659

Other comprehensive income before reclassifications
4,967

 
596

 
5,126

 
10,689

Amounts reclassified from accumulated other comprehensive income
—

 
—

 
(5,348
)
 
(5,348
)
Net current period other comprehensive income (loss)
4,967

 
596

 
(222
)
 
5,341

Balance at March 31, 2019
$
(6,260
)
 
$
60

 
$
12,200

 
$
6,000


H.
Hedging
Foreign currency forward contracts - Designated as hedging instruments
The Company maintains a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of the Company’s forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under GAAP having contractual durations from one to eighteen months. The Company recognizes realized gains and losses for the effective portion of such contracts in “Product revenues, net” in its condensed consolidated statements of operations in the same period that it recognizes the product revenues that were impacted by the hedged foreign exchange rate changes.
The Company formally documents the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as the Company’s risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. The Company also formally assesses, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If the Company were to determine that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, the Company would discontinue hedge accounting treatment prospectively. The Company measures effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of March 31, 2020, all hedges were determined to be highly effective.
The Company considers the impact of its counterparties’ credit risk on the fair value of the foreign currency forward contracts. As of March 31, 2020 and December 31, 2019, credit risk did not change the fair value of the Company’s foreign currency forward contracts.


17
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

The following table summarizes the notional amount of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP:
 
As of March 31, 2020
 
As of December 31, 2019
Foreign Currency
(in thousands)
Euro
$
581,764

 
$
501,197

British pound sterling
124,160

 
87,032

Australian dollar
74,643

 
89,705

Canadian dollar
46,390

 
50,452

Total foreign currency forward contracts
$
826,957

 
$
728,386


Foreign currency forward contracts - Not designated as hedging instruments
The Company also enters into foreign currency forward contracts with contractual maturities of less than one month, that are designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities, including intercompany balances. These contracts are not designated as hedging instruments under GAAP. The Company recognizes realized gains and losses for such contracts in “Other (expense) income, net” in its condensed consolidated statements of operations each period. As of March 31, 2020, the notional amount of the Company’s outstanding foreign currency forward contracts where hedge accounting under GAAP is not applied was $522.2 million.
During the three months ended March 31, 2020 and 2019, the Company recognized the following related to foreign currency forward contacts in its condensed consolidated statements of operations:
 
Three Months Ended March 31,
 
2020
 
2019
 
(in thousands)
Designated as hedging instruments - Reclassified from AOCI
 
 
 
Product revenues, net
$
8,922

 
$
6,839

Not designated as hedging instruments
 
 
 
Other (expense) income, net
$
16,229

 
$
3,151

 
 
 
 
Total reported in the Condensed Consolidated Statement of Operations
 
 
 
Product revenues, net
$
1,515,107

 
$
857,253

Other (expense) income, net
$
(61,130
)
 
$
42,610


The following table summarizes the fair value of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on its condensed consolidated balance sheets:
As of March 31, 2020
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid expenses and other current assets
 
$
25,434

 
Other current liabilities
 
$
(459
)
Other assets
 
1,798

 
Other long-term liabilities
 
(637
)
Total assets
 
$
27,232

 
Total liabilities
 
$
(1,096
)


18
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

As of December 31, 2019
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid expenses and other current assets
 
$
9,725

 
Other current liabilities
 
$
(5,533
)
Other assets
 
—

 
Other long-term liabilities
 
(1,821
)
Total assets
 
$
9,725

 
Total liabilities
 
$
(7,354
)
As of March 31, 2020, the Company expects the amounts that are related to foreign exchange forward contracts designated as cash flow hedges under GAAP recorded in “Prepaid expenses and other current assets” and “Other current liabilities” to be reclassified to earnings within twelve months.
The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under GAAP on the Company’s condensed consolidated balance sheets:
 
As of March 31, 2020
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
27,232

 
$
—

 
$
27,232

 
$
(1,096
)
 
$
26,136

Total liabilities
(1,096
)
 
—

 
(1,096
)
 
1,096

 
—

 
As of December 31, 2019
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
9,725

 
$
—

 
$
9,725

 
$
(7,354
)
 
$
2,371

Total liabilities
(7,354
)
 
—

 
(7,354
)
 
7,354

 
—


I.
Inventories
Inventories consisted of the following:
 
As of March 31, 2020
 
As of December 31, 2019
 
(in thousands)
Raw materials
$
24,835

 
$
26,247

Work-in-process
117,427

 
107,021

Finished goods
44,825

 
34,234

Total
$
187,087

 
$
167,502




19
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

J.
Stock-based Compensation Expense and Share Repurchase Programs
Stock-based compensation expense
During the three months ended March 31, 2020 and 2019, the Company recognized the following stock-based compensation expense:
 
Three Months Ended March 31,
 
2020
 
2019
 
(in thousands)
Stock-based compensation expense by type of award:
 
 
 
Restricted stock and restricted stock units (including PSUs)
$
97,149

 
$
63,510

Stock options
17,266

 
28,156

ESPP share issuances
2,485

 
2,577

Stock-based compensation expense related to inventories
(1,194
)
 
(452
)
Total stock-based compensation expense included in costs and expenses
$
115,706

 
$
93,791

 
 
 


Stock-based compensation expense by line item:
 
 


Cost of sales
$
1,361

 
$
1,338

Research and development expenses
72,687

 
59,715

Sales, general and administrative expenses
41,658

 
32,738

Total stock-based compensation expense included in costs and expenses
115,706

 
93,791

Income tax effect
(64,246
)
 
(39,524
)
Total stock-based compensation expense, net of tax
$
51,460

 
$
54,267


The following table sets forth the Company’s unrecognized stock-based compensation expense as of March 31, 2020, by type of award and the weighted-average period over which that expense is expected to be recognized:
 
As of March 31, 2020
 
Unrecognized Expense
 
Weighted-average
Recognition Period
 
(in thousands)
 
(in years)
Type of award:
 
 
 
Restricted stock and restricted stock units (including PSUs)
$
550,095

 
2.27
Stock options
$
109,086

 
2.33
ESPP share issuances
$
2,238

 
0.40



20
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

The following table summarizes information about stock options outstanding and exercisable as of March 31, 2020:
 
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
 
Number
Outstanding
 
Weighted-average
Remaining
Contractual Life
 
Weighted-average
Exercise Price
 
Number
Exercisable
 
Weighted-average
Exercise Price
 
 
(in thousands)
 
(in years)
 
(per share)
 
(in thousands)
 
(per share)
$29.07–$40.00
 
81

 
1.47
 
$
37.70

 
81

 
$
37.70

$40.01–$60.00
 
224

 
2.41
 
$
49.15

 
224

 
$
49.15

$60.01–$80.00
 
116

 
4.03
 
$
74.89

 
112

 
$
74.89

$80.01–$100.00
 
1,393

 
5.99
 
$
89.44

 
1,085

 
$
90.01

$100.01–$120.00
 
182

 
4.88
 
$
109.25

 
180

 
$
109.18

$120.01–$140.00
 
402

 
5.44
 
$
129.59

 
400

 
$
129.61

$140.01–$160.00
 
954

 
7.86
 
$
155.50

 
436

 
$
155.41

$160.01–$180.00
 
669

 
8.24
 
$
168.21

 
245

 
$
165.11

$180.01–$189.38
 
1,498

 
8.65
 
$
185.44

 
440

 
$
185.31

Total
 
5,519

 
6.98
 
$
137.34

 
3,203

 
$
119.05


Share repurchase programs
During 2018, the Company’s Board of Directors approved a share repurchase program (the “2018 Share Repurchase Program”), pursuant to which the Company repurchased $500.0 million of its common stock in 2018 and 2019. During the three months ended March 31, 2019, the Company repurchased 537,018 of its common stock under the share repurchase program for an aggregate of $98.0 million including commissions and fees. As of June 30, 2019, the Company had repurchased the entire $500.0 million it was authorized to repurchase of its common stock under the 2018 Share Repurchase Program.
During 2019, the Company’s Board of Directors approved a new share repurchase program (the “2019 Share Repurchase Program”), pursuant to which the Company is authorized to repurchase up to $500.0 million of its common stock between August 1, 2019 and December 31, 2020. The Company expects to fund further repurchases of its common stock through a combination of cash on hand and cash generated by operations. During the three months ended March 31, 2020, the Company repurchased 1,403,868 shares of its common stock under the 2019 Share Repurchase Program for an aggregate of $300.0 million including commissions and fees. As of March 31, 2020, there was a total of $164.0 million remaining for repurchases under the 2019 Share Repurchase Program.
Under the 2019 Share Repurchase Programs, the Company is authorized to purchase shares from time to time through open market or privately negotiated transactions. Such purchases are made pursuant to Rule 10b5-1 plans or other means as determined by the Company’s management and in accordance with the requirements of the SEC.
K.
Income Taxes
The Company is subject to U.S. federal, state, and foreign income taxes. For the three months ended March 31, 2020 and 2019, the Company recorded provisions for income taxes of $54.8 million and $51.5 million, respectively. The Company’s effective tax rate for the three months ended March 31, 2020 was lower than the U.S. statutory rate primarily due to a discrete benefit related to the write-off of a long-term intercompany receivable and excess tax benefits related to stock-based compensation. The Company’s effective tax rate for the three months ended March 31, 2019 was lower than the U.S. statutory rate primarily due to excess tax benefits related to stock-based compensation.
The Company released its valuation allowance on the majority of its net operating losses and other deferred tax assets as of December 31, 2018. Starting in 2019, the Company began recording a provision for income taxes on its pre-tax income using an effective tax rate approximating statutory rates. Due to the Company's ability to offset its pre-tax income against


21
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

previously benefited net operating losses, it expects a portion of its tax provision to represent a non-cash expense until its net operating losses have been fully utilized.
The Company maintained a valuation allowance of $205.2 million related primarily to U.S. state and foreign tax attributes as of December 31, 2019. On a periodic basis, the Company reassesses any valuation allowances that it maintains on its deferred tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets.  
In March 2020, the Coronavirus Aid, Relief and Economic Security Act (“the CARES Act”) was signed into law. The CARES Act includes provisions relating to several aspects of corporate income taxes. The Company does not currently expect the CARES Act to have a significant impact on its provision for income taxes; however, it will continue to monitor the provisions of the CARES Act in relation to its operations.
The Company has reviewed the tax positions taken, or to be taken, in its tax returns for all tax years currently open to examination by a taxing authority. Unrecognized tax benefits represent the aggregate tax effect of differences between tax return positions and the benefits recognized in the financial statements. As of March 31, 2020 and December 31, 2019, the Company had $43.0 million and $33.9 million, respectively, of gross unrecognized tax benefits, which would affect the Company’s tax rate if recognized. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company accrues interest and penalties related to unrecognized tax benefits as a component of its provision for income taxes. As of March 31, 2020, no significant interest or penalties were accrued. The Company did not recognize any material interest or penalties related to uncertain tax positions during the three months ended March 31, 2020 and 2019.
As of March 31, 2020, foreign earnings, which were not significant, have been retained by foreign subsidiaries for indefinite reinvestment. Upon repatriation of those earnings, in the form of dividends or otherwise, the Company could be subject to withholding taxes payable to the various foreign countries.
The Company files U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. The Company is no longer subject to any tax assessment from an income tax examination in the United States or any other major taxing jurisdiction for years before 2011, except where the Company has net operating losses or tax credit carryforwards that originate before 2011. The Company has various income tax audits ongoing at any time throughout the world. No significant adjustments have been reported for any jurisdiction under audit.
L.
Commitments and Contingencies
Revolving Credit Facility
In September 2019, the Company and certain of its subsidiaries entered into a Credit Agreement (the “2019 Credit Agreement”) with Bank of America, N.A., as administrative agent and the lenders referred to therein. The 2019 Credit Agreement provides for a $500.0 million unsecured revolving facility, which was not drawn upon at closing. Amounts drawn pursuant to the 2019 Credit Agreement, if any, may be used to finance the Company’s working capital needs, and for general corporate or other lawful purposes. The Company had no borrowings outstanding under the 2019 Credit Agreement as of March 31, 2020 and December 31, 2019. The 2019 Credit Agreement also provides that, subject to satisfaction of certain conditions, the Company may request that the borrowing capacity under the 2019 Credit Agreement be increased by an additional $500.0 million. The 2019 Credit Agreement, which matures on September 17, 2024, supersedes the Company’s credit agreement entered into in 2016 with Bank of America, N.A serving in the same capacity. Additionally, the 2019 Credit Agreement provides a sublimit of $50.0 million for letters of credit.
Direct costs related to the 2019 Credit Agreement, which were not material to the Company’s financial statements, were deferred and will be recorded over the term of the 2019 Credit Agreement.
Any amounts borrowed under the 2019 Credit Agreement will bear interest, at the Company’s option, at either a base rate or a Eurocurrency rate, in each case plus an applicable margin. Under the 2019 Credit Agreement, the applicable margins on base rate loans range from 0.125% to 0.50% and the applicable margins on Eurocurrency loans range from 1.125% to 1.50%, in each case based on the Company’s consolidated leverage ratio (the ratio of the Company’s total consolidated funded indebtedness to the Company’s consolidated EBITDA for the most recently completed four fiscal quarter period).


22
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

Any amounts borrowed pursuant to the 2019 Credit Agreement are guaranteed by certain of the Company’s existing and future domestic subsidiaries, subject to certain exceptions.
The 2019 Credit Agreement contains customary representations and warranties and affirmative and negative covenants, including financial covenants to maintain (i) subject to certain limited exceptions, a consolidated leverage ratio of 3.50 to 1.00, subject to an increase to 4.00 to 1.00 following a material acquisition and (ii) a consolidated interest coverage ratio (the ratio of the Company’s consolidated EBITDA to its consolidated interest expenses for the most recently completed four fiscal quarter period) of 2.50 to 1.00, in each case measured on a quarterly basis. The 2019 Credit Agreement also contains customary events of default. In the case of a continuing event of default, the administrative agent would be entitled to exercise various remedies, including the acceleration of amounts due under outstanding loans. As of March 31, 2020, the Company was in compliance with the covenants described above.
Guaranties and Indemnifications
As permitted under Massachusetts law, the Company’s Articles of Organization and By-laws provide that the Company will indemnify certain of its officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that the Company could be required to make under these indemnification provisions is unlimited. However, the Company has purchased directors’ and officers’ liability insurance policies that could reduce its monetary exposure and enable it to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and the Company believes the estimated fair value of these indemnification arrangements is minimal.
The Company customarily agrees in the ordinary course of its business to indemnification provisions in agreements with clinical trial investigators and sites in its drug development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for the Company and its real estate leases. The Company also customarily agrees to certain indemnification provisions in its drug discovery, development and commercialization collaboration agreements. With respect to the Company’s clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of the Company’s contractual obligations arising out of the research or clinical testing of the Company’s compounds or drug candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by the Company, to violations of law by the Company or to certain breaches of the Company’s contractual obligations. The indemnification provisions appearing in the Company’s collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for its collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although the Company believes the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that the Company could be required to make under these provisions is generally unlimited. The Company has purchased insurance policies covering personal injury, property damage and general liability that reduce its exposure for indemnification and would enable it in many cases to recover all or a portion of any future amounts paid. The Company has never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, the Company believes the estimated fair value of these indemnification arrangements is minimal.
Other Contingencies
The Company has certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a reserve for contingent liabilities when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. There were no material contingent liabilities accrued as of March 31, 2020 or December 31, 2019.


23
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements
(unaudited)

M.
Additional Cash Flow Information
The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in the Company’s condensed consolidated statements of cash flows consisted of the following:
 
Three Months Ended March 31,
 
2020
 
2019
 
Beginning of period
 
End of period
 
Beginning of period
 
End of period
 
(in thousands)
Cash and cash equivalents
$
3,109,322

 
$
3,593,412

 
$
2,650,134

 
$
2,893,885

Prepaid expenses and other current assets
8,004

 
8,552

 
4,910

 
6,250

Other assets
3,355

 
—

 
3,209

 
1,397

Cash, cash equivalents and restricted cash per statement of cash flows
$
3,120,681

 
$
3,601,964

 
$
2,658,253

 
$
2,901,532





24

Item 2.     Management’s Discussion and Analysis of Financial Condition and Results of Operations
OVERVIEW
We invest in scientific innovation to create transformative medicines for people with serious diseases with a focus on specialty markets. We continue to focus on developing and commercializing therapies for the treatment of cystic fibrosis, or CF. In 2019, we obtained approval in the United States, or U.S., for and launched TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor). We are broadening our pipeline through internal research efforts and accessing external innovation through business development transactions.
We have four approved medicines that treat the underlying cause of CF, which is a life-threatening genetic disease. In October 2019, TRIKAFTA, our triple-combination regimen, was approved by the United States Food and Drug Administration, or FDA, for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. This approval increased the number of patients eligible for our medicines in the U.S. by approximately 6,000 and provided an additional treatment option for many patients who are also eligible for one of our previously approved products. We have submitted a Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA, for this triple combination regimen. Our four medicines are collectively approved to treat approximately 60% of the 75,000 CF patients in North America, Europe and Australia. We are focused on obtaining approval for the triple combination in ex-U.S. markets for patients 12 years of age and older and evaluating our triple combination in younger patients with the goal of having treatments for up to 90% of patients with CF. We are also pursuing genetic therapies to address the remaining 10% of CF patients.
Our small molecule programs include programs focused on developing treatments for alpha-1 antitrypsin, or AAT, deficiency, APOL1-mediated kidney diseases and pain. We are evaluating CTX001, a genetic therapy as a potential treatment for sickle cell disease and beta thalassemia, in Phase 1/2 clinical trials in collaboration with CRISPR Therapeutics AG, or CRISPR. In 2019, through a series of strategic transactions, we acquired preclinical genetic therapy programs for Duchenne muscular dystrophy, or DMD, and myotonic dystrophy type 1, or DM1, and preclinical programs to develop cell-based therapies for type 1 diabetes, or T1D.
We are monitoring the potential impacts of the recent spread of the novel strain of the coronavirus (“COVID-19”) on our business. COVID-19 has not affected our supply chain or the demand for our medicines and we believe that we will be able to continue to supply all of our approved medicines to our patients globally. We have adjusted our business operations in response to COVID-19, with a majority of our employees working remotely, and COVID-19 has resulted in delays in certain research and development activities.
Financial Highlights
Revenues
In the first quarter of 2020, our net product revenues continued to increase due to the approval of TRIKAFTA in late 2019 and uptake of our medicines medicines in ex-U.S. markets following completion of reimbursement agreements in 2019.

chart-c6f6127e7bb55486951.jpg
 
Expenses
Our combined R&D and SG&A expenses increased to $630.8 million in the first quarter of 2020 from $486.5 million in the first quarter of 2019. In the first quarter of 2020, cost of sales was 11% of our net product revenues.
Balance Sheet
chart-46ee851a54315f11b13.jpg


25

Business Updates
COVID-19 has not affected our supply chain and we believe that we will be able to continue to supply all of our approved medicines to our patients globally.
TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor)
•
The majority of the approximately 18,000 eligible patients in the United States have now initiated treatment with TRIKAFTA following its approval in October 2019.
•
The MAA for the elexacaftor, tezacaftor and ivacaftor triple combination in patients 12 years of age and older with at least one F508del mutation that we submitted in 2019 is being reviewed by the EMA.
•
We recently submitted our applications for approval of the elexacaftor, tezacaftor and ivacaftor triple combination for patients 12 years of age and older with at least one F508del mutation in Australia and Switzerland.
 
•
We recently completed enrollment for a Phase 3 clinical trial evaluating the use of the elexacaftor, tezacaftor and ivacaftor triple combination in children 6 to 11 years of age with CF who have two copies of the F508del mutation or who have one F508del mutation and one minimal function mutation. If the data from this clinical trial is positive, we plan to submit a supplemental New Drug Application, or sNDA, to the FDA in the second half of 2020 for children 6 to 11 years of age with at least one F508del mutation, followed by regulatory submissions in other countries.
KALYDECO (ivacaftor)
•
We recently completed the submission of an sNDA to the FDA and Type 2 variation to the EMA for the use of KALYDECO in patients four to less than six months of age.
Pipeline
Depending on the disease, stage of development and type of clinical trial, and to ensure patient safety and reduce the burden on the healthcare system at a time of critical need, we have temporarily paused or delayed enrollment in certain clinical trials.
•
AAT Deficiency: We temporarily paused screening and enrollment in the Phase 2 proof-of-concept clinical trial for VX-814, our first investigational oral small molecule corrector for the treatment of alpha-1 antitrypsin, or AAT, deficiency, in patients with AAT deficiency who have two copies of the Z mutation. The Phase 2 clinical trial remains active and we continue to initiate new trial sites to enable future patient enrollment.
•
Focal Segmental Glomerulosclerosis: We recently initiated a Phase 2 proof-of-concept clinical trial designed to evaluate the reduction in proteinuria in patients with APOL1-mediated focal segmental glomerulosclerosis, or FSGS, receiving treatment with VX-147.
 
•
Beta Thalassemia and Sickle Cell Disease: We and our collaborator, CRISPR, expect to provide additional data from the two ongoing Phase 1/2 clinical trials of the investigational CRISPR/Cas9 gene-editing therapy CTX001, in patients with transfusion-dependent beta thalassemia and in patients with severe sickle cell disease in 2020.
•
T1D: We continue to advance our cell therapy program for the treatment of T1D and expect to initiate clinical development in patients in late 2020 or early 2021.
External Innovation
•
Affinia Therapeutics: In April 2020, we entered into a collaboration with Affinia Therapeutics Inc. to gain access to a novel library of AAV capsids to support our ongoing research and development efforts in genetic therapies. The goal of the collaboration will be to develop gene therapies for people affected by DMD, DM1 and CF.
 
•
Moderna: Based on preclinical data generated to date, we recently extended our collaboration with Moderna, aimed at the discovery and development of messenger ribonucleic acid, or mRNA, therapeutics for the treatment of CF.


26

Research
We are continuing to invest in our research programs and fostering scientific innovation in order to identify and develop transformative medicines. Our strategy is to combine transformative advances in the understanding of human disease and the science of therapeutics in order to identify and develop new medicines. We believe that pursuing research in diverse areas allows us to balance the risks inherent in drug development and may provide drug candidates that will form our pipeline in future years. To supplement our internal research programs, we acquire technologies and programs and collaborate with biopharmaceutical and technology companies, leading academic research institutions, government laboratories, foundations and other organizations, as needed, to advance research in our areas of therapeutic interest and to access technologies needed to execute on our strategy.
Drug Discovery and Development
Discovery and development of a new pharmaceutical product is a difficult and lengthy process that requires significant financial resources along with extensive technical and regulatory expertise. Potential drug candidates are subjected to rigorous evaluations, driven in part by stringent regulatory considerations, designed to generate information concerning efficacy, side effects, proper dosage levels and a variety of other physical and chemical characteristics that are important in determining whether a drug candidate should be approved for marketing as a pharmaceutical product. Most chemical compounds that are investigated as potential drug candidates never progress into development, and most drug candidates that do advance into development never receive marketing approval. Because our investments in drug candidates are subject to considerable risks, we closely monitor the results of our discovery, research, clinical trials and nonclinical studies and frequently evaluate our drug development programs in light of new data and scientific, business and commercial insights, with the objective of balancing risk and potential. This process can result in abrupt changes in focus and priorities as new information becomes available and as we gain additional understanding of our ongoing programs and potential new programs, as well as those of our competitors.
If we believe that data from a completed registration program support approval of a drug candidate, we submit an NDA to the FDA requesting approval to market the drug candidate in the United States and seek analogous approvals from comparable regulatory authorities in jurisdictions outside the United States. To obtain approval, we must, among other things, demonstrate with evidence gathered in nonclinical studies and well-controlled clinical trials that the drug candidate is safe and effective for the disease it is intended to treat and that the manufacturing facilities, processes and controls for the manufacture of the drug candidate are adequate. The FDA and ex-U.S. regulatory authorities have substantial discretion in deciding whether or not a drug candidate should be granted approval based on the benefits and risks of the drug candidate in the treatment of a particular disease, and could delay, limit or deny regulatory approval. If regulatory delays are significant or regulatory approval is limited or denied altogether, our financial results and the commercial prospects for the drug candidate involved will be harmed.
Regulatory Compliance
Our marketing of pharmaceutical products is subject to extensive and complex laws and regulations. We have a corporate compliance program designed to actively identify, prevent and mitigate risk through the implementation of compliance policies and systems and through the promotion of a culture of compliance. Among other laws, regulations and standards, we are subject to various U.S. federal and state laws, and comparable laws in other jurisdictions, pertaining to health care fraud and abuse, including anti-kickback and false claims laws, and laws prohibiting the promotion of drugs for unapproved or off-label uses. Anti-kickback laws generally make it illegal for a prescription drug manufacturer to knowingly and willfully solicit, offer, receive or pay any remuneration in return for or to induce the referral of business, including the purchase or prescription of a particular drug that is reimbursed by a state or federal health care program. False claims laws prohibit anyone from knowingly or willfully presenting for payment to third-party payors, including Medicare and Medicaid, claims for reimbursed drugs or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. We are subject to laws and regulations that regulate the sales and marketing practices of pharmaceutical manufacturers, as well as laws such as the U.S. Foreign Corrupt Practices Act, which govern our international business practices with respect to payments to government officials. In addition, we are subject to various data protection and privacy laws and regulations in the U.S., E.U., Canada, Australia and other jurisdictions. We expect to continue to devote substantial resources to maintain, administer and expand these compliance programs globally.
Reimbursement
Sales of our products depend, to a large degree, on the extent to which our products are reimbursed by third-party payors, such as government health programs, commercial insurance and managed health care organizations. We dedicate substantial management and other resources in order to obtain and maintain appropriate levels of reimbursement for our products from third-party payors, including governmental organizations in the United States and ex-U.S. markets.


27

In the United States, we have worked successfully with third party payors in order to promptly obtain appropriate levels of reimbursement for our first three CF medicines and are working with these stakeholders to obtain reimbursement for TRIKAFTA. We plan to continue to engage in discussions with numerous commercial insurers and managed health care organizations, along with government health programs that are typically managed by authorities in the individual states, to ensure that payors recognize the significant benefits that our medicines provide by treating the underlying cause of cystic fibrosis and continue to provide access to our medicines.
In Europe and other ex-U.S. markets, we seek government reimbursement for our medicines on a country-by-country basis. This is necessary for each new medicine, as well as, label expansions for our current medicines in most countries. We successfully obtained reimbursement for KALYDECO in each significant ex-U.S. market within two years of approval. We experienced significant challenges in obtaining reimbursement for ORKAMBI in certain ex-U.S. markets, however, we now have obtained reimbursement for ORKAMBI or SYMKEVI in most of our significant ex-U.S. markets. In some ex-U.S. markets, including Ireland, Denmark and Australia, our reimbursement agreements include innovative arrangements that provide a pathway to access and rapid reimbursement for certain future CF medicines. We filed a MAA with the EMA for the triple combination regimen of elexacaftor, tezacaftor and ivacaftor and, if approved, we would need to seek government reimbursement on a country-by-country basis, in most European markets. In December 2019, we reached an agreement with the government in Ireland to expand the existing reimbursement agreement to include the triple combination regimen pending approval by the EMA. We continue to seek government reimbursement and label expansions for our medicines in the applicable jurisdictions.
Strategic Transactions
Acquisitions
As part of our business strategy, we seek to acquire drugs, drug candidates and other technologies and businesses that have the potential to complement our ongoing research and development efforts. In 2019, we invested significantly in business development transactions designed to augment our pipeline, including the acquisition of Exonics, a privately-held company focused on creating transformative gene-editing therapies to repair mutations that cause DMD and other severe neuromuscular diseases, including DM1, and Semma, a privately-held company focused on the use of stem cell-derived human islets as a potentially curative treatment for T1D. In the Exonics acquisition, we paid approximately $245.0 million upfront to Exonics equity holders and agreed to additional payments based upon successful achievement of specified development and regulatory milestones. In the Semma acquisition, we paid approximately $950.0 million in cash to Semma equity holders. We expect to continue to identify and evaluate potential acquisitions that may be similar to or different from the transactions that we have engaged in previously.
Both of our 2019 acquisitions were accounted for as business combinations.  As of the acquisition date for each transaction, the cash payments, as well as the fair value of contingent consideration for Exonics, were allocated primarily to goodwill and the fair value of several in-process research and development assets that we acquired.  The fair value of contingent consideration related to Exonics was recorded as a liability and will be adjusted on a quarterly basis in the future.  As a result, these acquisitions are primarily reflected in additional assets and liabilities on our condensed consolidated balance sheet.  Please refer to Note C, “Acquisitions,” and our critical accounting policies, “Acquisitions,” in our 2019 Annual Report on Form 10-K for further information regarding the significant judgments and estimates related to our 2019 acquisitions.
Collaboration and Licensing Arrangements
We enter into arrangements with third parties, including collaboration and licensing arrangements, for the development, manufacture and commercialization of drugs, drug candidates and other technologies that have the potential to complement our ongoing research and development efforts. We expect to continue to identify and evaluate collaboration and licensing opportunities that may be similar to or different from the collaborations and licenses that we have engaged in previously.
In-License Agreements
We have entered into collaborations with biotechnology and pharmaceutical companies in order to acquire rights or to license drug candidates or technologies that enhance our pipeline and/or our research capabilities. Over the last several years, we entered into collaboration agreements with a number of companies, including Arbor Biotechnologies, Inc., CRISPR, Kymera Therapeutics, Inc. and Molecular Templates, Inc. Generally, when we in-license a technology or drug candidate, we make upfront payments to the collaborator, assume the costs of the program and/or agree to make contingent payments, which could consist of milestone, royalty and option payments. Most of these collaboration payments are expensed as research and development expenses; however, depending on many factors, including the structure of the collaboration, the significance of the drug candidate that we license to the collaborator’s operations and the other activities in which our collaborators are engaged, the accounting for these transactions can vary significantly. In the first quarter of 2020 and the first quarter of 2019,


28

our research and development expenses included $36.3 million and $5.3 million, respectively, related to upfront and milestones payments pursuant to our collaboration agreements.
Out-License Agreements
We also have out-licensed internally developed programs to collaborators who are leading the development of these programs. These out-license arrangements include our agreements with Janssen Pharmaceuticals, Inc., or Janssen, which is evaluating pimodivir in Phase 3 clinical trials for the treatment of influenza; and Merck KGaA, Darmstadt, Germany, which licensed oncology research and development programs from us in early 2017. Pursuant to these out-licensing arrangements, our collaborators are responsible for the research, development and commercialization costs associated with these programs, and we are entitled to receive contingent milestone and/or royalty payments. As a result, we do not expect to incur significant expenses in connection with these programs and have the potential for future collaborative and royalty revenues resulting from these programs.
Please refer to Note C, “Collaborative Arrangements,” for further information regarding our in-license agreements and out-license agreements.
Strategic Investments
In connection with our business development activities, we have periodically made equity investments in our collaborators. As of March 31, 2020, we held strategic equity investments in several public companies, including CRISPR, and certain private companies, and we plan to make additional strategic equity investments in the future. While we invest the majority of our cash, cash equivalents and marketable securities in instruments that meet specific credit quality standards and limit our exposure to any one issue or type of instrument, our strategic investments are maintained and managed separately from our other cash, cash equivalents and marketable securities. Any changes in the fair value of equity investments with readily determinable fair values (including publicly traded securities such as CRISPR) are recorded to other income (expense), net in our condensed consolidated statement of operations. For equity investments without readily determinable fair values including equity investments in private companies, each reporting period we are required to re-evaluate the carrying value of the investment, which may result in other income (expense).
In the first quarter of 2020 and the first quarter of 2019, we recorded within other income (expense), a net loss of $44.9 million and a net gain of $43.6 million, respectively, related to changes in the fair value of our strategic investments, and from sales of certain equity investments. To the extent that we continue to hold strategic investments, particularly strategic investments in publicly traded companies, we will record other income (expense) related to these strategic investments on a quarterly basis. Due to the high volatility of stocks in the biotechnology industry, we expect the value of these strategic investments to fluctuate and that the increases or decreases in the fair value of these strategic investments will continue to have material impacts on our net income (expense) and our profitability on a quarterly and/or annual basis.


29

RESULTS OF OPERATIONS
 
Three Months Ended March 31,
 
Increase/(Decrease)
 
2020
 
2019
 
$
 
%
 
(in thousands)
 
 
Revenues
$
1,515,107

 
$
858,435

 
$
656,672

 
76
%
Operating costs and expenses
794,883

 
581,627

 
213,256

 
37
%
Income from operations
720,224

 
276,808

 
443,416

 
160
%
Other non-operating (expense) income, net
(62,690
)
 
43,357

 
**

 
**

Provision for income taxes
54,781

 
51,534

 
3,247

 
6
%
Net income
$
602,753

 
$
268,631

 
$
334,122

 
124
%
 
 
 
 
 
 
 
 
Net income per diluted common share
$
2.29

 
$
1.03

 
 
 
 
Diluted shares used in per share calculations
263,515

 
260,175

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
** Not meaningful
 
Net Income
Our net income increased in the first quarter of 2020 as compared to the first quarter of 2019 due to significant increases in our revenues partially offset by increases in our operating expenses, non-operating expense and provision for income taxes. The increase in revenues was primarily due to the U.S. approval of TRIKAFTA in the fourth quarter of 2019. Increases in operating expenses were the result of increased cost of sales consistent with increased product revenues, increased investment in research and development and increased sales, general and administrative expenses to support our business. The change in non-operating (expense) income, net was primarily related to changes in the value of our strategic investments.
Earnings Per Share
Diluted net income per common share was $2.29 in the first quarter of 2020 as compared to diluted net income per common share of $1.03 in the first quarter of 2019.
Revenues
 
Three Months Ended March 31,
 
Increase/(Decrease)
 
2020
 
2019
 
$
 
%
 
(in thousands)
 
 
Product revenues, net
$
1,515,107

 
$
857,253

 
$
657,854

 
77
%
Collaborative and royalty revenues
—

 
1,182

 
(1,182
)
 
**

Total revenues
$
1,515,107

 
$
858,435

 
$
656,672

 
76
%
 
 
 
 
 
 
 
 
 
 
 
 
 
** Not meaningful
 
Product Revenues, Net
 
Three Months Ended March 31,
 
Increase/(Decrease)
 
2020
 
2019
 
$
 
%
 
(in thousands)
 
 
TRIKAFTA
$
895,233

 
$
—

 
$
895,233

 
**

SYMDEKO/SYMKEVI
173,159

 
320,275

 
(147,116
)
 
(46
)%
ORKAMBI
234,138

 
293,007

 
(58,869
)
 
(20
)%
KALYDECO
212,577

 
243,971

 
(31,394
)
 
(13
)%
Total product revenues, net
$
1,515,107

 
$
857,253

 
$
657,854

 
77
 %
 
 
 
 
 
 
 
 
 
 
 
 
 
** Not meaningful
 
In the first quarter of 2020, our net product revenues increased by $657.9 million as compared to the first quarter of 2019. The increase in total net product revenues in the first quarter of 2020 was primarily due to the launch of TRIKAFTA, which was approved in the United States in the fourth quarter of 2019. Decreases in revenues for our other products were the result of patients in the United States switching from these medicines to TRIKAFTA partially offset by label expansions and expanded access to our medicines in ex-U.S markets. In the first quarter of 2020 and 2019, our net product revenues included


30

product revenues of $327.5 million and $217.4 million, respectively, from ex-U.S. markets. Net product revenues in the first quarter of 2020 were also positively impacted by factors that may not be repeated in future periods, including early prescription refills, advance purchasing of medicines and initial compliance and persistence rates of patients who recently initiated treatment with TRIKAFTA. 
Collaborative and Royalty Revenues
We did not record any collaborative and royalty revenues in the first quarter of 2020. Our collaborative and royalty revenues were $1.2 million in the first quarter of 2019. Our collaborative revenues have historically fluctuated significantly from one period to another and may continue to fluctuate in the future. Our future royalty revenues will be dependent on if, and when, our collaborators, including Janssen and Merck KGaA, Darmstadt, Germany are able to successfully develop drug candidates that we have out-licensed to them.
Operating Costs and Expenses
`
Three Months Ended March 31,
 
Increase/(Decrease)
 
2020
 
2019
 
$
 
%
 
(in thousands)
 
 
Cost of sales
$
162,497

 
$
95,092

 
$
67,405

 
71
%
Research and development expenses
448,528

 
339,490

 
109,038

 
32
%
Sales, general and administrative expenses
182,258

 
147,045

 
35,213

 
24
%
Change in fair value of contingent consideration
1,600

 
—

 
1,600

 
**

Total costs and expenses
$
794,883

 
$
581,627

 
$
213,256

 
37
%
 
 
 
 
 
 
 
 
 
 
 
 
 
** Not Meaningful
Cost of Sales
Our cost of sales primarily consists of the cost of producing inventories that corresponded to product revenues for the reporting period, plus the third-party royalties payable on our net sales of our products. Pursuant to our agreement with the CFF, our tiered third-party royalties on sales of TRIKAFTA, SYMDEKO/SYMKEVI, KALYDECO and ORKAMBI, calculated as a percentage of net sales, range from the single digits to the sub-teens. Over the last several years, our cost of sales has been increasing due to increased net product revenues. Our cost of sales as a percentage of our net product revenues was approximately 11% in each of the first quarter of 2019 and 2020.
Research and Development Expenses
 
Three Months Ended March 31,
 
Increase/(Decrease)
 
2020
 
2019
 
$
 
%
 
(in thousands)
 
 
Research expenses
$
157,270

 
$
90,463

 
$
66,807

 
74
%
Development expenses
291,258

 
249,027

 
42,231

 
17
%
Total research and development expenses
$
448,528

 
$
339,490

 
$
109,038

 
32
%
Our research and development expenses include internal and external costs incurred for research and development of our drugs and drug candidates and expenses related to certain technology that we acquire or license through business development transactions. We do not assign our internal costs, such as salary and benefits, stock-based compensation expense, laboratory supplies and other direct expenses and infrastructure costs, to individual drugs or drug candidates, because the employees within our research and development groups typically are deployed across multiple research and development programs. These internal costs are significantly greater than our external costs, such as the costs of services provided to us by clinical research organizations and other outsourced research, which we allocate by individual program. All research and development costs for our drugs and drug candidates are expensed as incurred.
Since January 2018, we have incurred approximately $3.6 billion in research and development expenses associated with drug discovery and development. The successful development of our drug candidates is highly uncertain and subject to a number of risks. In addition, the duration of clinical trials may vary substantially according to the type, complexity and novelty of the drug candidate and the disease indication being targeted. The FDA and comparable agencies in foreign countries impose substantial requirements on the introduction of therapeutic pharmaceutical products, typically requiring lengthy and detailed laboratory and clinical testing procedures, sampling activities and other costly and time-consuming procedures. Data obtained from nonclinical and clinical activities at any step in the testing process may be adverse and lead to


31

discontinuation or redirection of development activities. Data obtained from these activities also are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The duration and cost of discovery, nonclinical studies and clinical trials may vary significantly over the life of a project and are difficult to predict. Therefore, accurate and meaningful estimates of the ultimate costs to bring our drug candidates to market are not available.
In 2019 and the first quarter of 2020, costs related to our CF programs represented the largest portion of our development costs. Any estimates regarding development and regulatory timelines for our drug candidates are highly subjective and subject to change. Until we have data from Phase 3 clinical trials, we cannot make a meaningful estimate regarding when, or if, a clinical development program will generate revenues and cash flows.
Research Expenses
 
Three Months Ended March 31,
 
Increase/(Decrease)
 
2020
 
2019
 
$
 
%
 
(in thousands)
 
 
Research Expenses:
 
 
 
 
 
 
 
Salary and benefits
$
34,269

 
$
24,379

 
$
9,890

 
41
%
Stock-based compensation expense
26,409

 
17,535

 
8,874

 
51
%
Outsourced services and other direct expenses
30,853

 
23,364

 
7,489

 
32
%
Collaboration and asset acquisition payments
36,250

 
—

 
36,250

 
**

Infrastructure costs
29,489

 
25,185

 
4,304

 
17
%
Total research expenses
$
157,270

 
$
90,463

 
$
66,807

 
74
%
 
 
 
 
 
 
 
 
 
 
 
 
 
** Not meaningful
We expect to continue to invest in our research programs with a focus on identifying drug candidates with the goal of creating transformative medicines for serious diseases. Our research expenses increased by 74% in the first quarter of 2020 compared to the first quarter of 2019 primarily as a result of collaboration and asset acquisition payments for which there were no similar expenses in the first quarter of 2019 as well as increased expenses to support our cell and genetic therapy programs.
Development Expenses
 
Three Months Ended March 31,
 
Increase/(Decrease)
 
2020
 
2019
 
$
 
%
 
(in thousands)
 
 
Development Expenses:
 
 
 
 
 
 
 
Salary and benefits
$
79,598

 
$
60,507

 
$
19,091

 
32
%
Stock-based compensation expense
46,278

 
42,180

 
4,098

 
10
%
Outsourced services and other direct expenses
116,433

 
97,768

 
18,665

 
19
%
Collaboration and asset acquisition payments
—

 
5,250

 
(5,250
)
 
**

Infrastructure costs
48,949

 
43,322

 
5,627

 
13
%
Total development expenses
$
291,258

 
$
249,027

 
$
42,231

 
17
%
 
 
 
 
 
 
 
 
 
 
 
 
 
** Not meaningful
Our development expenses increased by 17% in the first quarter of 2020 as compared to the first quarter of 2019, primarily due to increased expenses related to our advancing pipeline including clinical trials, headcount and infrastructure costs.
Sales, General and Administrative Expenses
 
Three Months Ended March 31,
 
Increase/(Decrease)
 
2020
 
2019
 
$
 
%
 
(in thousands)
 
 
Sales, general and administrative expenses
$
182,258

 
$
147,045

 
$
35,213

 
24
%
Sales, general and administrative expenses increased by 24% in the first quarter of 2020 as compared to the first quarter of 2019, primarily due to increased global support for our medicines and incremental investment to support the launch of our triple combination regimen.


32

Contingent Consideration
In the first quarter of 2020, the increase in the fair value of contingent consideration potentially payable to Exonics’ former equity holders was $1.6 million. There were no similar amounts for the first quarter of 2019.
Other Non-Operating Income (Expense), Net
Interest Income
Interest income decreased from $15.6 million in the first quarter of 2019 to $12.6 million in the first quarter of 2020 primarily due to prevailing market interest rates. Our future interest income will be dependent on the amount of, and prevailing market interest rates on, our outstanding cash equivalents and marketable securities.
Interest Expense
Interest expense was $14.1 million in the first quarter of 2020 as compared to $14.9 million in the first quarter of 2019. The majority of our interest expense in these periods was related to imputed interest expense associated with our leased corporate headquarters in Boston. Our future interest expense will be dependent on whether, and to what extent, we borrow amounts under our credit facility.
Other Income (Expense), Net
Other income (expense), net was an expense of $61.1 million in the first quarter of 2020 as compared to income of $42.6 million in the first quarter of 2019. Our other income (expense), net in these periods is primarily related to changes in the fair value of our strategic investments, as well as realized gains from sales of certain investments. We expect that due to the volatility of the stock price of biotechnology companies, our other income (expense), net will fluctuate in future periods based on increases or decreases in the fair value of our strategic investments.
Income Taxes
Our provision for income taxes in the first quarter of 2020 was $54.8 million as compared to $51.5 million in the first quarter of 2019. Our effective tax rate for the first quarter of 2020 was lower than the U.S. statutory rate primarily due to a discrete benefit related to the write off of a long-term intercompany receivable and excess tax benefits related to stock-based compensation. Our effective tax rate for the first quarter of 2019 was lower than the U.S. statutory rate primarily due to excess tax benefits related to stock-based compensation. We released our valuation allowance on the majority of our net operating losses and other deferred tax assets in the fourth quarter of 2018. Starting in 2019, we began recording a provision for income taxes on our pre-tax income using an effective tax rate approximating statutory rates. Due to our ability to offset our pre-tax income against previously benefited net operating losses, we expect a portion of our tax provision to represent a non-cash expense until our net operating losses have been fully utilized.
LIQUIDITY AND CAPITAL RESOURCES
The following table summarizes the components of our financial condition as of March 31, 2020 and December 31, 2019:
 
March 31,
 
December 31,
 
Increase/(Decrease)
 
2020
 
2019
 
$
 
%
 
(in thousands)
 
 
Cash, cash equivalents and marketable securities
$
4,190,396

 
$
3,808,294

 
$
382,102

 
10
%
Working Capital
 
 
 
 
 
 
 
Total current assets
5,446,400

 
4,822,829

 
623,571

 
13
%
Total current liabilities
(1,538,750
)
 
(1,334,827
)
 
203,923

 
15
%
Total working capital
$
3,907,650

 
$
3,488,002

 
$
419,648

 
12
%
As of March 31, 2020, total working capital was $3.9 billion, which represented an increase of $420 million from $3.5 billion as of December 31, 2019. The increase in total working capital in the first quarter of 2020 was primarily related to $815.7 million of cash provided by operations partially offset by $300.0 million of cash used to repurchase our common stock pursuant to our share repurchase program that we announced in July 2019.
Sources of Liquidity
As of March 31, 2020, we had cash, cash equivalents and marketable securities of $4.2 billion, which represented an increase of $382 million from $3.8 billion as of December 31, 2019. We intend to rely on our existing cash, cash equivalents and marketable securities together with cash flows from product sales as our primary source of liquidity.
We may borrow up to $500.0 million pursuant to our revolving credit facility that we entered into in 2019. We may repay and reborrow amounts under the revolving credit agreement without penalty. Subject to certain conditions, we may request that the borrowing capacity under this credit agreement be increased by an additional $500.0 million, up to a total of $1.0 billion.
Other possible sources of future liquidity include commercial debt, public and private offerings of our equity and debt securities, strategic sales of assets or businesses and financial transactions. Negative covenants in our credit agreement may prohibit or limit our ability to access these sources of liquidity.
Future Capital Requirements
We have significant future capital requirements, including:
•
significant expected operating expenses to conduct research and development activities and to operate our organization; and
•
substantial facility and capital lease obligations, including leases for two buildings in Boston, Massachusetts that continue through 2028.
In addition:
•
We have entered into certain collaboration agreements with third parties that include the funding of certain research, development and commercialization efforts with the potential for future milestone and royalty payments by us upon the achievement of pre-established developmental and regulatory targets and/or commercial targets, and we may enter into additional business development transactions, including acquisitions, collaborations and equity investments, that require additional capital.
•
We have reached an agreement with the French government and will repay a portion of the amounts we have collected under the ORKAMBI early access programs in France to the French government in 2020 based on the difference between the invoiced amount and the final amount for ORKAMBI distributed through these programs as reflected in the structure of the agreement with the French government.
•
To the extent we borrow amounts under the credit agreement we entered into in 2019, we would be required to repay any outstanding principal amounts in 2024.
•
As of March 31, 2020, $164.0 million remained available to fund repurchases under our share repurchase program.
We expect that cash flows from our products together with our current cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least the next twelve months and do not expect COVID-19 to have an adverse affect on our liquidity. The adequacy of our available funds to meet our future operating and capital requirements will depend on many factors, including the amounts of future revenues generated by our products, and the potential introduction of one or more of our other drug candidates to the market, the level of our business development activities and the number, breadth, cost and prospects of our research and development programs.
Financing Strategy
We may raise additional capital by borrowing under credit agreements, through public offerings or private placements of our securities or securing new collaborative agreements or other methods of financing. We will continue to manage our capital structure and will consider all financing opportunities, whenever they may occur, that could strengthen our long-term liquidity profile. There can be no assurance that any such financing opportunities will be available on acceptable terms, if at all.


33

CONTRACTUAL COMMITMENTS AND OBLIGATIONS
Our commitments and obligations were reported in our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the Securities and Exchange Commission, or SEC, on February 13, 2020. There have been no material changes from the contractual commitments and obligations previously disclosed in that Annual Report on Form 10-K.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
Our discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements prepared in accordance with generally accepted accounting principles in the United States. The preparation of these financial statements requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reported periods. These items are monitored and analyzed by management for changes in facts and circumstances, and material changes in these estimates could occur in the future. Changes in estimates are reflected in reported results for the period in which the change occurs. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from our estimates if past experience or other assumptions do not turn out to be substantially accurate. During the three months ended March 31, 2020, there were no material changes to our critical accounting policies as reported in our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the SEC on February 13, 2020.
RECENT ACCOUNTING PRONOUNCEMENTS
For a discussion of recent accounting pronouncements, please refer to Note A, “Basis of Presentation and Accounting Policies.”
Item 3.    Quantitative and Qualitative Disclosures About Market Risk
As part of our investment portfolio, we own financial instruments that are sensitive to market risks. The investment portfolio is used to preserve our capital until it is required to fund operations, including our research and development activities. None of these market risk-sensitive instruments are held for trading purposes. We do not have derivative financial instruments in our investment portfolio.
Interest Rate Risk
We invest our cash in a variety of financial instruments, principally securities issued by the U.S. government and its agencies, investment-grade corporate bonds and commercial paper, and money market funds. These investments are denominated in U.S. Dollars. All of our interest-bearing securities are subject to interest rate risk and could decline in value if interest rates fluctuate. Substantially all of our investment portfolio consists of marketable securities with active secondary or resale markets to help ensure portfolio liquidity, and we have implemented guidelines limiting the term-to-maturity of our investment instruments. Due to the conservative nature of these instruments, we do not believe that we have a material exposure to interest rate risk. If interest rates were to increase or decrease by 1%, the fair value of our investment portfolio would increase or decrease by an immaterial amount.
In 2019, we entered into a credit agreement. Loans under the credit agreement bear interest, at our option, at either a base rate or a Eurocurrency rate, in each case plus an applicable margin. The applicable margin on base rate loans ranges from 0.125% to 0.50% and the applicable margin on Eurocurrency loans ranges from 1.125% to 1.50%, in each case, based on our consolidated leverage ratio (the ratio of our total consolidated funded indebtedness to our consolidated EBITDA for the most recently completed four fiscal quarter period). We do not believe that changes in interest rates related to the credit agreement would have a material effect on our financial statements. As of March 31, 2020, we had no principal or interest outstanding. A portion of our “Interest expense” in 2020 will be dependent on whether, and to what extent, we borrow amounts under the existing facility.
Foreign Exchange Market Risk
As a result of our foreign operations, we face exposure to movements in foreign currency exchange rates, primarily the Euro and British Pound against the U.S. Dollar. The current exposures arise primarily from cash, accounts receivable,


34


intercompany receivables and payables, payables and accruals and inventories. Both positive and negative effects to our net revenues from international product sales from movements in exchange rates are partially mitigated by the natural, opposite effect that exchange rates have on our international operating costs and expenses.
We have a foreign currency management program with the objective of reducing the effect of exchange rate fluctuations on our operating results and forecasted revenues and expenses denominated in foreign currencies. We currently have cash flow hedges for the Euro, British Pound, Canadian Dollar and Australian Dollar related to a portion of our forecasted product revenues that qualify for hedge accounting treatment under U.S. GAAP. We do not seek hedge accounting treatment for our foreign currency forward contracts related to monetary assets and liabilities that impact our operating results. As of March 31, 2020, we held foreign exchange forward contracts that were designated as cash flow hedges with notional amounts totaling $827.0 million and had a net fair value of $26.1 million recorded on our condensed consolidated balance sheet.
Although not predictive in nature, we believe a hypothetical 10% threshold reflects a reasonably possible near-term change in exchange rates. Assuming that the March 31, 2020 exchange rates were to change by a hypothetical 10%, the fair value recorded on our condensed consolidated balance sheet related to our foreign exchange forward contracts that were designated as cash flow hedges as of March 31, 2020 would change by approximately $82.7 million. However, since these contracts hedge a specific portion of our forecasted product revenues denominated in certain foreign currencies, any change in the fair value of these contracts is recorded in “Accumulated other comprehensive income (loss) ” on our condensed consolidated balance sheet and is reclassified to earnings in the same periods during which the underlying product revenues affect earnings. Therefore, any change in the fair value of these contracts that would result from a hypothetical 10% change in exchange rates would be entirely offset by the change in value associated with the underlying hedged product revenues resulting in no impact on our future anticipated earnings and cash flows with respect to the hedged portion of our forecasted product revenues.
Item 4.    Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management (under the supervision and with the participation of our chief executive officer and chief financial officer), after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Quarterly Report on Form 10-Q, has concluded that, based on such evaluation, as of March 31, 2020 our disclosure controls and procedures were effective and designed to provide reasonable assurance that the information required to be disclosed is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Changes in Internal Controls Over Financial Reporting
No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended) occurred during the three months ended March 31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
PART II. Other Information
Item 1. Legal Proceedings
We are not currently subject to any material legal proceedings.
Item 1A. Risk Factors
Information regarding risk factors appears in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the SEC on February 13, 2020. There have been no material changes from the risk factors previously disclosed in the Annual Report on Form 10-K, except as noted below.


35

We are subject to risks associated with the spread of the novel strain of coronavirus, or COVID-19.
Our operations expose us to risks associated with the spread of COVID-19, which has affected the regions in which we conduct our operations and distribute medicines to patients.  COVID-19 has broadly affected the global economy, resulted in significant travel and work restrictions in many regions and has put a significant strain on healthcare resources.  COVID-19 is having, and we expect it will continue to have, an impact on our operations and an impact on the operations of our collaborators, third-party contractors and other entities, including governments, governmental agencies and payors, with which we interact.  To date, the most significant effects on our business have been delays in certain research and development activities and the requirement that a majority of our employees work remotely.  In the future, the economic impacts of the COVID-19 outbreak could affect our business directly or indirectly, including potentially affecting the net prices for our products through changes in our payor mix as a result of increased unemployment in the United States or increased pressure on healthcare costs. The effects on our research, development, manufacturing and commercialization activities, will be dependent on, among other things, the severity and duration of the COVID-19 outbreak as well as the impact of the outbreak on our third-party manufacturers, suppliers, distributors, subcontractors and customers. While the ultimate impact of COVID-19 on our business is highly uncertain, any negative impacts that materialize could materially adversely affect our operations, financial performance and stock price.  Any negative impacts of COVID-19, alone or in combination with others, could exacerbate risk factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019. The full extent to which the COVID-19 outbreak will negatively affect our operations, financial performance and stock price will depend on future developments that are highly uncertain and cannot be predicted, including the scope and duration of the outbreak and actions taken by governmental authorities and other third parties in response to the outbreak.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q and, in particular, our Management’s Discussion and Analysis of Financial Condition and Results of Operations set forth in Part I-Item 2, contain or incorporate a number of forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding:
•
our expectations regarding the amount of, timing of and trends with respect to our revenues, costs and expenses and other gains and losses, including those related to net product revenues;
•
our expectations regarding the effect of COVID-19 on, among other things, our financial performance, business and operations;
•
our expectations regarding clinical trials, development timelines and regulatory authority filings and submissions for ivacaftor, lumacaftor, tezacaftor, elexacaftor, and the timelines for regulatory filings for our triple combination regimen;
•
our ability to obtain reimbursement for our medicines in ex-U.S. markets and our ability to otherwise successfully market our medicines or any of our other drug candidates for which we obtain regulatory approval;
•
our expectations regarding the timing and structure of clinical trials of our drugs and drug candidates and the expected timing of our receipt of data from our ongoing and planned clinical trials;
•
the data that will be generated by ongoing and planned clinical trials and the ability to use that data to advance compounds, continue development or support regulatory filings;
•
our beliefs regarding the support provided by clinical trials and preclinical and nonclinical studies of our drug candidates for further investigation, clinical trials or potential use as a treatment;
•
our plan to continue investing in our research and development programs and our strategy to develop our drug candidates, alone or with third party-collaborators;
•
the potential future benefits of our acquisitions and collaborations;
•
the establishment, development and maintenance of collaborative relationships;
•
potential business development activities;


36

•
potential fluctuations in foreign currency exchange rates;
•
our ability to use our research programs to identify and develop new drug candidates to address serious diseases and significant unmet medical needs; and
•
our liquidity and our expectations regarding the possibility of raising additional capital.
Any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many factors mentioned in this Quarterly Report on Form 10-Q will be important in determining future results. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially from expected results. We also provide a cautionary discussion of risks and uncertainties under “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the SEC on February 13, 2020. These are factors and uncertainties that we think could cause our actual results to differ materially from expected results. Other factors and uncertainties besides those listed there could also adversely affect us.
Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “intends,” “expects” and similar expressions are intended to identify forward-looking statements. There are a number of factors and uncertainties that could cause actual events or results to differ materially from those indicated by such forward-looking statements, many of which are beyond our control. In addition, the forward-looking statements contained herein represent our estimate only as of the date of this filing and should not be relied upon as representing our estimate as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements.
Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Repurchases of Equity Securities
In July 2019, we approved a share repurchase program (the “2019 Share Repurchase Program”), pursuant to which we are authorized to repurchase up to $500.0 million of our common stock between August 1, 2019 and December 31, 2020. The table set forth below shows repurchases of securities by us during the three months ended March 31, 2020, including shares repurchased under our 2019 Share Repurchase Program.
Period
 
Total Number
of Shares Purchased
Average Price
Paid per Share
Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs (1)
Approximate Dollar Value of Shares that May Yet be Purchased Under the Plans or Programs (1)
January 1, 2020 to January 31, 2020
—
$—
—
$464,000
February 1, 2020 to February 29, 2020
54,579
$219.86
54,579
$452,001
March 1, 2020 to March 31, 2020
1,349,289
$213.44
1,349,289
$164,002
Total
1,403,868
$213.69
1,403,868
$164,002
(1)Under our 2019 Share Repurchase Program, we are authorized to purchase shares from time to time through open market or privately negotiated transactions. Such purchases may be made pursuant to Rule 10b5-1 plans or other means as determined by our management and in accordance with the requirements of the Securities and Exchange Commission.
Item 5.     Other Information
On April 28, 2020, our board of directors amended and restated our by-laws to permit the holding of virtual meetings of shareholders on an online platform. The foregoing description is qualified by reference to our amended and restated by-laws, which are filed as Exhibit 3.2 to this Quarterly Report on Form 10-Q.
On April 28, 2020, Paul Silva, our Senior Vice President and Corporate Controller and our Principal Accounting Officer, informed us he plans to retire on April 30, 2021.


37

Item 6.    Exhibits
Exhibit Number
Exhibit Description
3.2
10.1
Employment Agreement, dated as of April 1, 2020, between Vertex Pharmaceuticals Incorporated and Dr. Jeffrey M. Leiden  (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on April 1, 2020).*
31.1
31.2
32.1
101.INS
XBRL Instance
101.SCH
XBRL Taxonomy Extension Schema
101.CAL
XBRL Taxonomy Extension Calculation
101.LAB
XBRL Taxonomy Extension Labels
101.PRE
XBRL Taxonomy Extension Presentation
101.DEF
XBRL Taxonomy Extension Definition
 
* Management contract, compensatory plan or agreement.




38

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
Vertex Pharmaceuticals Incorporated
 
 
 
May 1, 2020
By:
/s/ Charles F. Wagner, Jr.
 
 
Charles F. Wagner, Jr.
 
 
Executive Vice President, Chief Financial Officer
(principal financial officer and
duly authorized officer)


39
 EX-3.2 2 a2020q110-qexhibit32.htm EXHIBIT 3.2 Exhibit




AMENDED AND RESTATED
BY-LAWS
of
VERTEX PHARMACEUTICALS INCORPORATED

ARTICLE I

STOCKHOLDERS

Section 1. Annual Meeting. The annual meeting of the stockholders shall be held on the second Monday of May in each year, or on such other date within six months after the end of the fiscal year of the Corporation as the Board of Directors shall fix, at such time as shall be fixed by the Board of Directors in the call of the meeting. Purposes for which an annual meeting is to be held, in addition to those prescribed by law, by the Articles of Organization, or by these By-Laws, may be specified by the Board of Directors in the notice of the meeting.

Section 2. Special Meeting in Lieu of Annual Meeting. If no annual meeting has been held in accordance with the foregoing provisions, a special meeting of the stockholders may be held in lieu thereof. Any action taken at such special meeting shall have the same force and effect as if taken at the annual meeting, and in such case all references in these By-Laws to the annual meeting of the stockholders shall be deemed to refer to such special meeting. Any such special meeting shall be called as provided in Section 3 of this Article 1.

Section 3. Special Meetings. A special meeting of the stockholders may be called at any time by the Chairman of the Board, the President, or by the Board of Directors. A special meeting of the stockholders shall also be called by the Clerk (or, in the case of the death, absence, incapacity, or refusal of the Clerk, by any other officer) upon written application of one or more stockholders who hold at least forty percent in interest of the capital stock entitled to vote at the meeting. Each call of a meeting shall state the place, date, hour, and purposes of the meeting.

Section 4. Place of the Meetings. All meetings of the stockholders shall be held at such place, either within or without The Commonwealth of Massachusetts, within the United States as shall be fixed by the Board of Directors in the notice of the meeting; provided that the meeting may be held without a physical place to the extent permitted by law. Any adjourned session of any meeting of the stockholders shall be held as designated in the vote of adjournment.

Section 5. Notice of Meeting. A written notice of each meeting of stockholders, stating the place, date, hour and purposes of the meeting, shall be given at least seven days before the meeting to each stockholder entitled to vote thereat and to each stockholder who, by law, by the Articles of Organization, or by these By-Laws, is entitled to notice.




Such notice shall be given by the Clerk or an Assistant Clerk or by an officer designated by the Board of Directors. Whenever notice of a meeting is required to be given to a stockholder under any provision of the Business Corporation Law of the Commonwealth of Massachusetts or of the Articles of Organization or these By-Laws, a written waiver thereof, executed before or after the meeting by such stockholder or his attorney thereunto authorized and filed with the records of the meeting, shall be deemed equivalent to such notice.

Section 6. Quorum of Stockholders. At any meeting of the stockholders, a quorum shall consist of a majority in interest of all stock issued and outstanding and entitled to vote at the meeting, except when a larger quorum is required by law, by the Articles of Organization, or by these By-Laws. Stock owned directly or indirectly by the Corporation, if any, shall not be deemed outstanding for this purpose.

Section 7. Adjournment of Meetings. Any meeting of the stockholders may be adjourned (a) prior to the time the meeting has been convened, by the Board of Directors, or (b) after the meeting has been convened, by a majority of the votes properly cast upon the question, whether or not a quorum is present at the meeting, and the meeting may be held as adjourned without further notice.

Section 8. Action by Vote. When a quorum is present at any meeting, (a) upon any question other than an election of a director, a majority of the votes properly cast shall decide the question, except when a larger vote is required by law, by the Articles of Organization, or by these By-Laws, (b) in an uncontested election, votes properly cast in favor of election of a director exceeding the votes properly withheld in such election shall effect the election of a director, and (c) in a contested election, a plurality of the votes properly cast for election shall effect the election of a director. An election of directors shall be considered contested if, as of the record date for the applicable meeting, there are more nominees for election than positions on the board of directors to be filled by election at the meeting. All other elections of directors shall be considered uncontested.

Section 9. Voting. Stockholders entitled to vote shall have one vote for each share of stock held by them of record according to the records of the Corporation, unless otherwise provided by the Articles of Organization. No ballot shall be required for any vote for election to any office unless requested by a stockholder present or represented at the meeting and entitled to vote in such election. The Corporation shall not, directly or indirectly, vote any share of its own stock.

Section 10. Proxies. To the extent permitted by law, stockholders entitled to vote may vote either in person or by written proxy. Unless otherwise specified or limited by their terms, such proxies shall entitle the holders thereof to vote at any adjournment of such meeting but shall not be valid after the final adjournment of such meeting.

Section 11. Action by Consent. Any action required or permitted to be taken at any meeting of the stockholders may be taken without a meeting, but only if all stockholders entitled to vote on the matter consent to the action in




writing and the written consents are filed with the records of meetings of stockholders. Such consents shall be treated for all purposes as a vote taken at a meeting.


ARTICLE II

BOARD OF DIRECTORS

Section 1. Number and Elections. Subject to the rights of the holders of Preferred Stock to elect one or more additional directors under specified circumstances as provided in Article 4 of the Articles of Organization, the Board of Directors shall consist of not less than three nor more than eleven persons, the exact number to be fixed from time to time by the Board of Directors pursuant to a resolution adopted by a majority vote of the directors then in office. The directors shall be elected in the manner provided in the Articles of Organization, by such stockholders as have the right to vote thereon.

Section 2. Nominations. Nominations for the election of directors may be made by the Board of Directors or a committee appointed by the Board of Directors or by any stockholder entitled to vote in the election of directors generally. However, any stockholder entitled to vote in the election of directors generally may nominate one of more persons for election as directors at a meeting only if written notice of such stockholder's intent to make such nomination or nominations has been given, either by personal delivery or by mailing it, postage prepaid, to the Clerk of the Corporation not later than (a) with respect to an election to be held at an annual meeting of stockholders, ninety (90) days prior to the anniversary date of the immediately preceding annual meeting, and (b) with respect to an election to be held at a special meeting of stockholders for the election of directors, the close of business on the tenth day following the date on which notice of such meeting is first given to stockholders. Each such notice shall set forth (i) the name and address of the stockholder who intends to make the nomination and of the person or persons to be nominated; (ii) a representation that the stockholder is a holder of record of stock of the Corporation entitled to vote at such meeting and intends to appear in person or by proxy at the meeting to nominate the person or persons specified in the notice; (iii) a description of all arrangements or understandings between the stockholder and each nominee and any other person or persons (naming such person or persons) pursuant to which the nomination or nominations are to be made by the stockholder; (iv) such other information regarding each nominee proposed by such stockholder as would be required to be included in a proxy statement filed pursuant to the proxy rules of the Securities and Exchange Commission; and (v) the consent of each nominee to serve as a director of the Corporation if so elected. The presiding officer of the meeting may refuse to acknowledge the nomination of any person not made in compliance with the foregoing procedure.

Section 3. Newly Created Directorships and Vacancies. Newly created directorships and vacancies on the Board of Directors shall be filled as provided in the Articles of Organization.





Section 4. Removal of Directors. Directors may be removed from office only as provided in the Articles of Organization.

Section 5. Directors Elected by Holders of Preferred Stock. Whenever the holders of any class or series or Preferred Stock or of any other class or series of shares issued by the Corporation shall have the right, voting separately as a class or series, to elect one or more directors under specified circumstances, the election, term of office, filling of vacancies, and other features of such directorships shall be governed by the terms of the Articles of Organization applicable thereto, and none of the provisions of Sections 1 to 4 of this Article II shall apply with respect to directors so elected.

Section 6. Resignations. Any director, member of a committee, or officer may resign at any time by delivering his resignation in writing to the Chairman of the Board, the President, the Clerk, or to a meeting of the Board of Directors. Such resignation shall be effective upon receipt unless specified to be effective at some other time.

Section 7. Powers. Except as reserved to the stockholders by law, by the Articles of Organization, or by these By-Laws, the business of the Corporation shall be managed by the Board of Directors who shall have and may exercise all the powers of the Corporation.

Section 8. Proxy Access for Director Nominations.
(a)Information to be Included in the Corporation’s Proxy Materials. Whenever the Board of Directors solicits proxies with respect to the election of directors at an annual meeting of stockholders (following the 2016 annual meeting of stockholders), subject to the provisions of this Section 8, the Corporation shall include in its proxy statement for such annual meeting, in addition to any persons nominated for election by the Board of Directors or a committee appointed by the Board of Directors, the name, together with the Required Information (as defined below), of any person to be nominated for election to the Board of Directors by a stockholder pursuant to Section 2 of this Article II (a “Stockholder Nominee”) if (i) the stockholder of record who intends to make the nomination qualifies as, or is acting on behalf of, an Eligible Stockholder (as defined in Section 8(c) of this Article II), (ii) the Eligible Stockholder expressly elects, in a written statement accompanying the notice required by Section 2 of this Article II (a “Nomination Notice”), to have its Stockholder Nominee included in the Corporation’s proxy materials pursuant to this Section 8 and (iii) all of the other requirements set forth in this Section 8 and in Section 2 of this Article II are satisfied. For purposes of this Section 8, the “Required Information” that the Corporation will include in its proxy statement is (A) the information provided to the Clerk of the Corporation concerning the Stockholder Nominee and the Eligible Stockholder that is required to be disclosed in the Corporation’s proxy statement pursuant to Section 14 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations promulgated thereunder, and (B) if the Eligible Stockholder so elects, a Supporting Statement (as defined in Section 8(g) of this Article II). For the avoidance of doubt, nothing in this Section 8 shall limit the Corporation’s ability to solicit against any Stockholder Nominee or include in




its proxy materials the Corporation’s own statements or other information relating to any Eligible Stockholder or Stockholder Nominee, including any information provided to the Corporation pursuant to this Section 8. Subject to the provisions of this Section 8, the name of any Stockholder Nominee included in the Corporation’s proxy statement for an annual meeting of stockholders shall also be set forth on the form of proxy distributed by the Corporation in connection with such annual meeting.
(b)Permitted Number of Stockholder Nominees. The maximum number of Stockholder Nominees that will be included in the Corporation’s proxy materials with respect to an annual meeting of stockholders shall not exceed the greater of (i) two or (ii) 20% of the number of directors in office as of the last day on which a Nomination Notice may be delivered pursuant to Section 2 of this Article II (the “Final Proxy Access Date”) or, if such amount is not a whole number, the closest whole number below 20% (such greater number, as it may be adjusted pursuant to this Section 8(b)), the “Permitted Number”). In the event that one or more vacancies for any reason occurs on the Board of Directors after the Final Proxy Access Date but before the date of the annual meeting and the Board of Directors resolves to reduce the size of the Board of Directors in connection therewith, the Permitted Number shall be calculated based on the number of directors in office as so reduced. In addition, the Permitted Number shall be reduced by (i) the number of individuals who will be included in the Corporation’s proxy materials as nominees recommended by the Board of Directors pursuant to an agreement, arrangement or other understanding with a stockholder or group of stockholders (other than any such agreement, arrangement or understanding entered into in connection with an acquisition of stock from the Corporation by such stockholder or group of stockholders), together with the number of directors in office as of the Final Proxy Access Date who were either elected by the Board of Directors to fill a vacancy pursuant to such an agreement, arrangement or other understanding, or included in the Corporation’s proxy materials as nominees recommended by the Board of Directors pursuant to such an agreement, arrangement or other understanding for any of the two preceding annual meetings of stockholders, and whose remaining terms extend beyond the upcoming annual meeting, and (ii) the number of directors in office as of the Final Proxy Access Date who were included in the Corporation’s proxy materials as Stockholder Nominees for any of the two preceding annual meetings of stockholders (including any persons counted as Stockholder Nominees pursuant to the immediately succeeding sentence) and whose remaining terms extend beyond the upcoming annual meeting. For purposes of determining when the Permitted Number has been reached, any individual requested by an Eligible Stockholder to be included in the Corporation’s proxy materials pursuant to this Section 8 whose nomination is subsequently withdrawn or whom the Board of Directors decides to nominate for election to the Board of Directors shall be counted as one of the Stockholder Nominees. Any Eligible Stockholder requesting that more than one Stockholder Nominee be included in the Corporation’s proxy materials pursuant to this Section 8 shall rank such Stockholder Nominees based on the order in which the Eligible Stockholder desires such Stockholder Nominees to be selected for inclusion in the Corporation’s proxy materials in the event that the total number of Stockholder Nominees requested by Eligible Stockholders to be included in the Corporation’s proxy materials pursuant to this Section 8 exceeds the Permitted Number. In the event that the number of Stockholder Nominees requested by Eligible Stockholders to be included in the Corporation’s proxy materials pursuant to this Section 8 exceeds the Permitted Number, the highest ranking Stockholder Nominee who meets the




requirements of this Section 8 from each Eligible Stockholder will be selected for inclusion in the Corporation’s proxy materials until the Permitted Number is reached, going in order of the amount (largest to smallest) of shares of stock of the Corporation each Eligible Stockholder disclosed as owned in its Nomination Notice. If the Permitted Number is not reached after the highest ranking Stockholder Nominee who meets the requirements of this Section 8 from each Eligible Stockholder has been selected, then the next highest ranking Stockholder Nominee who meets the requirements of this Section 8 from each Eligible Stockholder will be selected for inclusion in the Corporation’s proxy materials, and this process will continue as many times as necessary, following the same order each time, until the Permitted Number is reached. Notwithstanding anything to the contrary contained in this Section 8, the Corporation shall not be required to include any Stockholder Nominees in its proxy materials pursuant to this Section 8 for any meeting of stockholders for which the Corporation receives a Nomination Notice (whether or not subsequently withdrawn) and the stockholder by whom or on whose behalf the nomination is to be made does not expressly elect, in a written statement accompanying the Nomination Notice, to have its Stockholder Nominee included in the Corporation’s proxy materials pursuant to this Section 8.
(c)Eligible Stockholder. An “Eligible Stockholder” is a stockholder or a group of no more than 20 stockholders (counting as one stockholder, for this purpose, any two or more funds that are part of the same Qualifying Fund Group (as defined below)) that (i) has Owned (as defined in Section 8(d) of this Article II) continuously for at least three years (the “Minimum Holding Period”) a number of shares of stock of the Corporation that represents at least three percent of the voting power of the outstanding shares of stock as of the date the Nomination Notice is delivered to or mailed and received by the Clerk of the Corporation in accordance with Section 2 of this Article II (the “Required Shares”) and (ii) continues to Own the Required Shares through the date of the annual meeting. A “Qualifying Fund Group” is any two or more funds that are (A) under common management and investment control, (B) under common management and funded primarily by the same employer or (C) a “group of investment companies” as such term is defined in Section 12(d)(1)(G)(ii) of the Investment Company Act of 1940, as amended. Whenever the Eligible Stockholder consists of a group of stockholders (including a group of funds that are part of the same Qualifying Fund Group), (1) each provision in this Section 8 that requires the Eligible Stockholder to provide any written statements, representations, undertakings, agreements or other instruments or to meet any other conditions shall be deemed to require each stockholder (including each individual fund within a Qualifying Fund Group) that is a member of such group to provide such statements, representations, undertakings, agreements or other instruments and to meet such other conditions (except that the members of such group may aggregate the shares that each member has Owned continuously for the Minimum Holding Period in order to meet the three percent Ownership requirement of the “Required Shares” definition) and (2) a breach of any obligation, agreement or representation under this Section 8 by any member of such group shall be deemed a breach by the Eligible Stockholder. No person may be a member of more than one group of stockholders constituting an Eligible Stockholder with respect to any annual meeting.
(d)Definition of Ownership. For purposes of this Section 8, a stockholder shall be deemed to “Own” only those outstanding shares of stock of the Corporation as to which the stockholder possesses both (i) the full voting and investment rights pertaining to the shares and (ii) the full economic interest in (including the opportunity for profit




from and risk of loss on) such shares; provided that the number of shares calculated in accordance with clauses (i) and (ii) shall not include any shares (A) sold by such stockholder or any of its affiliates in any transaction that has not been settled or closed, (B) borrowed by such stockholder or any of its affiliates for any purposes or purchased by such stockholder or any of its affiliates pursuant to an agreement to resell, or (C) subject to any option, warrant, forward contract, swap, contract of sale, or other derivative or similar instrument or agreement entered into by such stockholder or any of its affiliates, whether any such instrument or agreement is to be settled with shares or with cash based on the notional amount or value of shares of outstanding capital stock of the Corporation, in any such case which instrument or agreement has, or is intended to have, the purpose or effect of (1) reducing in any manner, to any extent or at any time in the future, such stockholder’s or its affiliates’ full right to vote or direct the voting of any such shares or (2) hedging, offsetting or altering to any degree any gain or loss realized or realizable from maintaining the full economic ownership of such shares by such stockholder or affiliate. For purposes of this Section 8, a beneficial owner shall be considered a “stockholder” and shall “Own” shares held in the name of a nominee or other intermediary so long as such person retains the right to instruct how the shares are voted with respect to the election of directors and possesses the full economic interest in the shares. A stockholder’s Ownership of shares shall be deemed to continue during any period in which (i) the stockholder has loaned such shares, provided that the stockholder has the power to recall such loaned shares on five business days’ notice and includes with its Nomination Notice an agreement that it (A) will promptly recall such loaned shares upon being notified that any of its Stockholder Nominees will be included in the Corporation’s proxy materials and (B) will continue to hold such shares through the date of the annual meeting, or (ii) the stockholder has delegated any voting power by means of a proxy, power of attorney or other instrument or arrangement that is revocable at any time by the stockholder. The terms “Owned,” “Owning” and other variations of the word “Own” shall have correlative meanings. Whether outstanding shares of stock of the Corporation are “Owned” for these purposes shall be determined by the Board of Directors. For purposes of this Section 8, the term “affiliate” or “affiliates” shall have the meaning ascribed thereto under the General Rules and Regulations under the Exchange Act.
(e)Information to be Included with a Nomination Notice. In addition to containing the information, representations and other documents required to be set forth in a Nomination Notice pursuant to Section 2 of this Article II, in order for a Stockholder Nominee to be eligible for inclusion in the Corporation’s proxy materials pursuant to this Section 8, the Nomination Notice must also set forth or be accompanied by the following:
(i)    A written statement by the Eligible Stockholder setting forth and certifying as to the number of shares of stock it Owns and has Owned continuously for the Minimum Holding Period;
(ii)    one or more written statements from the record holder of the Required Shares (and from each intermediary through which the Required Shares are or have been held during the Minimum Holding Period) verifying that, as of a date within seven calendar days prior to the date the Nomination Notice is delivered to or mailed and received by the Clerk of the Corporation in accordance with Section 2 of this Article II, the Eligible Stockholder Owns, and has Owned continuously for the Minimum Holding Period, the Required Shares, and the Eligible




Stockholder’s agreement to provide, within five business days following the later of the record date for the determination of stockholders certified to vote at the annual meeting and the date notice of the record date is first publicly disclosed, one or more written statements from the record holder and such intermediaries verifying the Eligible Stockholder’s continuous Ownership of the Required Shares through the record date;
(iii)    a copy of the Schedule 14N that has been or is concurrently being filed with the Securities and Exchange Commission as required by Rule 14a-18 under the Exchange Act;
(iv)    a representation and agreement that the Eligible Stockholder (A) will continue to hold the Required Shares through the date of the annual meeting, (B) acquired the Required Shares in the ordinary course of business and not with the intent to change or influence control of the Corporation, and does not presently have such intent, (C) has not nominated and will not nominate for election to the Board of Directors at the annual meeting any person whom it has not requested be included in the Corporation’s proxy materials pursuant to this Section 8, (D) has not engaged and will not engage in, and has not and will not be a “participant” in another person’s, “solicitation” within the meaning of Rule 14a-1(l) under the Exchange Act in support of the election of any individual as a director at the annual meeting other than its Stockholder Nominee(s) or a nominee of the Board of Directors, (E) has not distributed and will not distribute to any stockholder of the Corporation any form of proxy for the annual meeting other than the form distributed by the Corporation, (F) has complied and will comply with all laws and regulations applicable to solicitations and the use, if any, of soliciting material in connection with the annual meeting and (G) has provided and will provide facts, statements and other information in all communications with the Corporation and its stockholders that are or will be true and correct in all material respects and do not and will not omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which they were made, not misleading;
(v)    an undertaking that the Eligible Stockholder agrees to (A) assume all liability stemming from any legal or regulatory violation arising out of the Eligible Stockholder’s communications with the stockholders of the Corporation or out of the information provided to the Corporation by or on behalf of the Eligible Stockholder, (B) indemnify and hold harmless the Corporation and each of its directors, officers and employees individually against any liability, loss or damages in connection with any threatened or pending action, suit or proceeding, whether legal, administrative or investigative, against the Corporation or any of its directors, officers or employees arising out of any nomination of any person for election to the Board of Directors submitted by or on behalf of the Eligible Stockholder or any solicitation or other activity in connection therewith, and (C) file with the Securities and Exchange Commission any solicitation or other communication with the stockholders of the Corporation relating to the meeting at which its Stockholder Nominee(s) will be nominated, regardless of whether any such filing is required under Regulation 14A of the Exchange Act or whether any exemption from filing is available for such solicitation or other communication under Regulation 14A of the Exchange Act;
(vi)    a written representation and agreement from each Stockholder Nominee that such Stockholder Nominee (A) is not and will not become a party to (1) any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person or entity as to how such Stockholder Nominee, if elected




as a director of the Corporation, will act or vote on any issue or question (a “Voting Commitment”) that has not been disclosed to the Corporation in such representation and agreement or (2) any Voting Commitment that could limit or interfere with such person’s ability to comply, if elected as a director of the Corporation, with such person’s fiduciary duties under applicable law, (B) is not and will not become a party to any agreement, arrangement or understanding with any person or entity other than the Corporation with respect to any direct or indirect compensation, reimbursement or indemnification in connection with such person’s nomination or service or action as a director that has not been disclosed to the Corporation in such representation and agreement, (C) would be in compliance, if elected as a director of the Corporation, and will comply with the Corporation’s code of business conduct and ethics, corporate governance guidelines, stock ownership and trading policies and guidelines and any other policies or guidelines of the Corporation applicable to directors and (D) will make such other acknowledgments, enter into such agreements and provide such information as the Board of Directors requires of all directors, including promptly submitting all completed and signed questionnaires required of the Corporation’s directors;
(vii)    if the Eligible Stockholder consists of a group of stockholders, the designation by all group members of one member of the group that is authorized to receive communications, notices and inquiries from the Corporation and to act on behalf of all members of the group with respect to all matters relating to the request under this Section 8 (including withdrawal of the nomination); and
(viii)    if two or more funds that are part of the same Qualifying Fund Group are intended to be counted as one stockholder for purposes of qualifying as an Eligible Stockholder, documentation reasonably satisfactory to the Corporation that demonstrates that the funds are part of the same Qualifying Fund Group.
(f)Additional Required Information. In addition to the information required pursuant to Section 8(e) of this Article II or any other provision of these By-Laws, the Corporation may require (i) any proposed Stockholder Nominee requested to be included in the Corporation’s proxy materials to furnish any other information (A) that may reasonably be requested by the Corporation to determine whether the Stockholder Nominee would be independent under the Independence Standards (as defined in Section 8(i) of this Article II), (B) that could be material to a reasonable stockholder’s understanding of the independence, or lack thereof, of such Stockholder Nominee or (C) that may reasonably be requested by the Corporation to determine the eligibility of such Stockholder Nominee to be included in the Corporation’s proxy materials pursuant to this Section 8 or to serve as a director of the Corporation, and (ii) any Eligible Stockholder to furnish any other information that may reasonably be requested by the Corporation to verify the Eligible Stockholder’s continuous ownership of the Required Shares for the Minimum Holding Period and through the date of the annual meeting.
(g)Supporting Statement. The Eligible Stockholder may, at its option, provide to the Clerk of the Corporation, at the time the Nomination Notice is provided, a written statement, not to exceed 500 words, in support of its Stockholder Nominee(s)’ candidacy (a “Supporting Statement”). Only one Supporting Statement may be submitted by an Eligible Stockholder (including any group of stockholders together constituting an Eligible Stockholder) in support of its Stockholder Nominee(s). Notwithstanding anything to the contrary contained in this




Section 8, the Corporation may omit from its proxy materials any information or Supporting Statement (or portion thereof) that it, in good faith, believes would violate any applicable law, rule or regulation.
(h)Correction of Defects; Updates and Supplements. In the event that any information or communications provided by or on behalf of an Eligible Stockholder or a Stockholder Nominee to the Corporation or its stockholders ceases to be true and correct in all material respects or omits to state a material fact necessary to make the statements made, in light of the circumstances under which they were made, not misleading, such Eligible Stockholder or Stockholder Nominee, as the case may be, shall promptly notify the Clerk of the Corporation of any such defect and of the information that is required to correct any such defect. Without limiting the forgoing, an Eligible Stockholder must provide immediate notice to the Corporation if the Eligible Stockholder ceases to Own any of the Required Shares prior to the date of the annual meeting. For the avoidance of doubt, no notification, update or supplement provided pursuant to this Section 8(h) shall be deemed to cure any defect in any previously provided information or communications or limit the remedies available to the Corporation relating to any such defect (including the right to omit a Stockholder Nominee from its proxy materials pursuant to this Section 8).
(i)Stockholder Nominee Eligibility. Notwithstanding anything to the contrary contained in this Section 8, the Corporation shall not be required to include in its proxy materials, pursuant to this Section 8, a Stockholder Nominee (i) who would not be an independent director under the rules and listing standards of the United States securities exchanges upon which the capital stock of the Corporation is listed or traded, any applicable rules of the Securities and Exchange Commission, or any publicly disclosed standards used by the Board of Directors in determining and disclosing the independence of the Corporation’s directors (collectively, the “Independence Standards”), (ii) whose election as a member of the Board of Directors would cause the Corporation to be in violation of these By-Laws, the Articles of Organization, the rules and listing standards of the United States securities exchanges upon which the capital stock of the Corporation is listed or traded, or any applicable law, rule or regulation, (iii) who is or has been, within the past three years, an officer or director of a competitor, as defined in Section 8 of the Clayton Antitrust Act of 1914, (iv) who is a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses) or has been convicted in such a criminal proceeding within the past 10 years, (v) who is subject to any order of the type specified in Rule 506(d) of Regulation D promulgated under the Securities Act of 1933, as amended, or (vi) who shall have provided any information to the Corporation or its stockholders that was untrue in any material respect or that omitted to state a material fact necessary to make the statements made, in light of the circumstances in which they were made, not misleading.
(j)Omission and Removal of Stockholder Nominees. Notwithstanding anything to the contrary set forth herein, if (i) a Stockholder Nominee and/or the applicable Eligible Stockholder breaches any of its representations, agreements or undertakings or fails to comply with any of its obligations under this Section 8 or Section 2 of this Article II, or (ii) a Stockholder Nominee otherwise becomes ineligible for inclusion in the Corporation’s proxy materials pursuant to this Section 8 or dies, becomes disabled or otherwise becomes ineligible or unavailable for election at the annual meeting, in each case as determined by the Board of Directors or the presiding officer of the annual meeting,




then (A) the Corporation may omit or, to the extent feasible, remove the information concerning such Stockholder Nominee and the related Supporting Statement from its proxy materials and otherwise communicate to its stockholders that such Stockholder Nominee will not be eligible for election at the annual meeting and, (B) the Corporation shall not be required to include in its proxy materials any successor or replacement nominee proposed by the applicable Eligible Stockholder or any other Eligible Stockholder.
(k)Restrictions on Re-Nominations. Any Stockholder Nominee who is included in the Corporation’s proxy materials for a particular annual meeting of stockholders but either (i) withdraws from or becomes ineligible or unavailable for election at the annual meeting, or (ii) does not receive at least 10% of the votes cast in favor of such Stockholder Nominee’s election, will be ineligible to be included in the Corporation’s proxy materials pursuant to this Section 8 for the next two annual meetings of stockholders.
(l)General. This Section 8 provides the exclusive method for a stockholder to include nominees for election to the Board of Directors in the Corporation’s proxy materials.
Section 9. Other Committees. The Board of Directors may, by vote of a majority of the directors then in office, elect from their number other committees and may delegate to any such committee or committees some or all of the powers of the Board of Directors except those powers which by law, by the Articles of Organization, or by these By-Laws they are prohibited from delegating. Except as the Board of Directors may otherwise determine, each committee may make rules for the conduct of its business, but unless otherwise provided by the Board of Directors or such rules, its business shall be conducted as nearly as may be in the same manner as is provided by these By-Laws for the conduct of business by the Board of Directors. The Board of Directors shall have the power to rescind any vote, resolution, or other action of any committee, provided that the rights of third parties shall not be impaired by such rescission.

Section 10. Regular Meetings. A regular meeting of the Board of Directors shall be held without call or notice immediately after and at the same place as the annual meeting of the stockholders. Other regular meetings of the Board of Directors may be held without call or notice at such places and at such times as the Board of Directors may, from time to time, determine, provided that notice of the first regular meeting following any such determination shall be given to absent directors.

Section 11. Special Meetings. Special meetings of the Board of Directors may be held at any time and at any place designated in the call of the meeting, when called by the Chairman of the Board, the President, or by two or more directors.

Section 12. Notice of the Meetings. It shall be sufficient notice to a director of a meeting of the Board of Directors (i) to send notice by mail at least forty-eight (48) hours before the meeting, addressed to such directors at his usual or last known business or residence address, (ii) to send notice by electronic mail (to the electronic mail address designated by such director) at least twenty-four (24) hours before the meeting, or (iii) to give notice to such director in person




or by telephone at least twenty-four (24) hours before the meeting. A director may waive any notice before or after the date and time of the meeting. The waiver shall be in writing, signed by the director entitled to the notice, or in the form of an electronic transmission by the director to a representative of the Corporation, and filed with the minutes or corporate records. A director's attendance at or participation in a meeting waives any required notice to him or her of the meeting unless the director at the beginning of the meeting, or promptly upon his or her arrival, objects to holding the meeting or transacting business at the meeting and does not thereafter vote for or assent to action taken at the meeting. Neither notice of a meeting nor a waiver of a notice need specify the purposes of the meeting.

Section 13. Quorum of Directors. At any meeting of the Board of Directors, a majority of the directors then in office shall constitute a quorum. Any meeting may be adjourned from time to time by a majority of the votes cast upon the question, whether or not a quorum is present, and the meeting may be held as adjourned without further notice.

Section 14. Action by Vote. When a quorum is present at any meeting, a majority of the directors present may take any action, except when a larger vote is required by law, by the Articles of Organization, or by these By-Laws.

Section 15. Action by Written Consent. Unless the Articles of Organization otherwise provide, any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting if all the directors or members of the committee as the case may be, consent to the action. The action must be evidenced by one or more consents describing the action taken, in writing, signed by each director or delivered to the Corporation by electronic transmission, and included in the minutes or filed with the corporate records reflecting the action taken. Such consents shall be treated for all purposes as a vote taken at a meeting.

Section 16. Participation Through Communications Equipment. Unless otherwise provided by law or the Articles of Organization, members of the Board of Directors or of any committee thereof may participate in a meeting of such Board or committee, as the case may be, through conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other at the same time, and participation by such means shall constitute presence in person at a meeting.

Section 17. Compensation of Directors. The Board of Directors may provide for the payment to any of the directors, other than officers or employees of the Corporation, of a specified amount for services as a director or member of a committee of the Board, or of a specified amount for attendance at each regular or special Board or committee meeting or of both, and all directors shall be reimbursed for expenses of attendance at any such meeting; provided, however, that nothing herein contained shall be construed to preclude any director from serving the Corporation in any other capacity and receiving compensation therefor.






ARTICLE III

OFFICERS AND AGENTS

Section 1. Enumeration; Qualification. The officers of the Corporation shall be a President, a Treasurer, a Secretary, who may also be referred to in these By-Laws as the Clerk, and such other officers, including, without limitation, a Chairman of the Board, one or more Vice Presidents, Assistant Treasurers, and Assistant Clerks as the Board of Directors from time to time may in their discretion elect or appoint. In addition, the Corporation shall have such other agents as may be appointed by management in accordance with these By-Laws. The Chairman of the Board shall be a director. The President need not be a director. Any two or more offices may be held by the same person.

Section 2. Powers. Subject to law, to the Articles of Organization, and to the other provisions of these By-Laws, each officer shall have, in addition to the duties and powers herein set forth, such duties and powers as are commonly incident to his office and such duties and powers as the Board of Directors may from time to time designate.

Section 3. Election. The Chairman of the Board, if any, the President, the Treasurer, and the Clerk shall be elected annually by the Board of Directors at their first meeting following the annual meeting of the stockholders. Other officers, if any, may be elected or appointed by the Board of Directors at said meeting or at any other time.

Section 4. Tenure. Except as otherwise provided by law, by the Articles of Organization, or by these By-Laws, the Chairman of the Board, if any, the President, the Treasurer, and the Clerk shall hold office until the first meeting of the Board of Directors following the next annual meeting of the stockholders and until their respective successors are chosen and qualified, and each other officer shall hold office for such term as may be designated in the vote electing or appointing him, or in each case until such officer sooner dies, resigns, is removed, or becomes disqualified.

Section 5. Chief Executive Officer. The Chief Executive Officer of the Corporation shall be the Chairman of the Board, the President, or such other officer as may from time to time be designated by the Board of Directors. If no such designation is made, the President shall be the Chief Executive Officer. The Chief Executive Officer shall, subject to the control of the Board of Directors, have general charge and supervision of the business of the Corporation and, except as the Board of Directors shall otherwise determine, shall preside at all meetings of the stockholders and of the Executive Committee. Unless otherwise determined by the Board of Directors, the Chief Executive Officer shall have the authority to appoint such agents, in addition to those officers enumerated in Section 2 of this Article III as being elected or appointed by the Board of Directors, as he shall deem appropriate and to define their respective duties and powers.





Section 6. Chairman of the Board. If a Chairman of the Board of Directors is elected, he shall preside at all meetings of the Board of Directors and shall have the duties and powers specified in these By-Laws and such other duties and powers as may be determined by the Board of Directors.

Section 7. President and Vice Presidents. The President shall have the duties and powers specified in these By-Laws and shall have such other duties and powers as may be determined by the Board of Directors.

The Vice Presidents shall have such duties and powers as shall be designated from time to time by the Board of Directors. Unless the Board of Directors otherwise determines, one Vice President shall be designated as the Chief Financial officer of the Corporation and, as such, shall be the chief financial and accounting officer of the Corporation and shall have the duties and powers commonly incident thereto.

Section 8. Treasurer and Assistant Treasurers. The Treasurer shall have general responsibility for the corporate treasury function, shall be in charge of its funds and valuable papers, books of account, and accounting records, and shall have such other duties and powers as may be designated from time to time by the Board of Directors.

Any Assistant Treasurer shall have such duties and powers as shall be designated from time to time by the Board of Directors or the Treasurer.

Section 9. Clerk and Assistant Clerks. The Clerk shall record all proceedings of the stockholders and Board of Directors in a book or series of books to be kept for that purpose, which book or books shall be kept as the principal office of the Corporation and shall be open at all reasonable times to the inspection of any stockholder. In the absence of the Clerk from any meeting of the stockholders or Board of Directors, an Assistant Clerk, or if there be none or he is absent, a temporary clerk chosen at the meeting, shall record the proceedings thereof in the aforesaid book.

Any Assistant Clerks shall have such other duties and powers as shall be designated from time by the Board of Directors or the Clerk.


ARTICLE IV

CAPITAL STOCK

Section 1. Stock Certificates. The Board of Directors may authorize the issue without certificates of some or all of the shares of any or all of the Corporation’s classes or series of stock.  Except to the extent the Board of Directors has determined to issue shares without certificates, a stockholder shall be entitled to a certificate stating the number and the class and the designation of the series, if any, of the shares held by him, in such form as shall, in conformity




to law, be prescribed from time to time by the Board of Directors. Such certificate shall be signed by the President or a Vice President and by the Treasurer or an Assistant Treasurer. Such signatures may be facsimile if the certificate is signed by a transfer agent, or by a registrar, other than a director, officer, or employee of the Corporation. In case any officer who has signed or whose facsimile signature has been placed on such certificate shall have ceased to be such officer before such certificate is issued, it may be issued by the Corporation with the same effect as if he were such officer at the time of its issue.

Every certificate for shares of stock which are subject to any restriction on transfer pursuant to the Articles of Organization, these By-Laws, or any agreement to which the Corporation is a party shall have the existence of the restriction noted conspicuously on the certificate and shall also set forth on the face or back either a summary of the restriction or a statement of the existence of such restriction and a statement that the Corporation will, upon written request, furnish a copy thereof to the holder of such certificate without charge.

Every certificate issued when the Corporation is authorized to issue more that one class or series of stock shall set forth on its face or back either a summary of the preferences, voting powers, qualifications, and special and relative rights of the shares of each class and series authorized to be issued or a statement of the existence of such preferences, powers, qualifications, and rights and a statement that the Corporation will, upon written request, furnish a copy thereof to the holder of such certificate without charge.

Section 2. Lost Certificates. In the case of the alleged loss, destruction, or mutilation of a certificate of stock, a duplicate certificate may be issued in place thereof, upon such conditions as the Board of Directors may prescribe. When authorizing such issue of a new certificate, the Board may in its discretion require the owner of such lost, destroyed, or mutilated certificate, or his legal representative, to give the Corporation a bond, with or without surety, sufficient in the Board's opinion to indemnify the Corporation against any loss or claim that may be made against it with request to the certificate alleged to have been lost, destroyed, or mutilated.

Section 3. Transfer of Shares. Subject to the restrictions, if any, stated or noted on the stock certificates, shares of stock may be transferred on the books of the Corporation by the surrender to the Corporation or its transfer agent of the certificate therefor properly endorsed or accompanied by a written assignment and power of attorney properly executed with necessary transfer stamps affixed, and with such proof of the authenticity of signature as the Board of Directors or the transfer agent of the Corporation may reasonably require. Except as may be otherwise required by law, by the Articles of Organization, or by these By-Laws, the Corporation shall be entitled to treat the record holder of stock as shown on its on its books as the owner of such stock for all purposes, including the payment of dividends and the right to receive notice and to vote with respect thereto, regardless of any transfer, pledge, or other disposition of such stock, until the shares have been transferred on the books of the stock, until the shares have been transferred on the books of the Corporation in accordance with the requirements of these By-Laws.





Section 4. Record Date and Closing Transfer Books. The Board of Directors may fix in advance a time, which shall not be more than sixty (60) days before the date of any meeting of stockholders or the date for the payment of any dividend or making of any distribution to stockholders or the last day on which the consent or dissent of stockholders may be effectively expressed for any purpose, as the record date for determining the stockholders having the right to notice of and to vote at such meeting and any adjournment thereof or the right to receive such dividend or distribution or the right to give such consent or dissent, and in such case only stockholders of record on such record date shall have such right, notwithstanding any transfer of stock on the books of the Corporation after the record date; or without fixing such record date the Board of Directors may for any such purposes close the transfer books for all or any part of such period.

If no record date is fixed and the transfer books are not closed, the record date for determining stockholders having the right to notice of or to vote at a meeting of stockholders shall be at the close of business on the date next preceding the day on which notice is given, and the record date for determining stockholders for any other purpose shall be at the close of business on the date on which the Board of Directors acts with respect thereto.


ARTICLE V

INDEMNIFICATION

Section 1. Directors and Officers. The Corporation shall indemnify, and advance funds to pay for or reimburse the reasonable expenses incurred by, its directors and the officers that have been appointed by the Board of Directors (including persons who serve at its request as directors, officers, or trustees of another organization in which it has any interest, direct or indirect, as a shareholder, creditor, or otherwise or who serve at its request in any capacity with respect to any employee benefit plan) to the fullest extent permitted by law, and may indemnify, and advance funds to pay for or reimburse the reasonable expenses incurred by, such other employees and agents as are identified by the Board of Directors.

The right of indemnification hereby provided shall not be exclusive of or affect any other rights to which any director or officer may be entitled. As used in this section, the terms "director" and "officer" include their respective heirs, executors, and administrators, an "interested" director or officer is one against whom in such capacity the proceedings in question or another proceeding on the same or similar grounds is then pending or threatened, and a "disinterested" director is one against whom no such proceeding is then pending or threatened. Nothing contained in this section shall affect any rights to indemnification to which corporate personnel other than directors and officers may be entitled by contract or otherwise under law.





The Board of Directors may authorize the purchase and maintenance of insurance, in such amounts as the Board of Directors may from time to time deem appropriate, on behalf of any person who is or was a director or officer or agent of the Corporation, or who is or was serving at the request of the Corporation as a director, officer, or agent of another organization in which it has any interest, direct or indirect, as a shareholder, creditor, or otherwise, or with respect to any employee benefit plan, against any liability incurred by him in any such capacity, or arising out of his status as such, whether or not such person is entitled to indemnification by the Corporation pursuant to this Article V or otherwise and whether or not the Corporation would have the power to indemnify him against such liability.

ARTICLE VI

MISCELLANEOUS

Section 1. Corporate Seal. The seal of the Corporation shall be in such form as the Board of Directors may from time to time determine.

Section 2. Fiscal Year. The fiscal year of the Corporation shall be such period as shall from time to time be determined by the Board of Directors.

Section 3. [Intentionally Omitted]

Section 4. Execution of Documents. Except as the Board of Directors may generally or in specific instances authorize the execution thereof in some other manner, all deeds, leases, transfers, contracts, checks, drafts, and other orders for the payment of money out of the funds of the Corporation, and all bonds, notes, debentures, guarantees, and other obligations or evidences or indebtedness of the Corporation shall be executed by the Chairman of the Board, the President, any Vice President, or the Treasurer.

Section 5. Voting of Securities. Except as the Board of Directors may generally or in specific instances direct otherwise, the Chairman of the Board, the President, any Vice President, or the Treasurer shall have the power, in the name and on behalf of the Corporation, to waive notice of, appoint any person or persons to act as proxy or attorney-in-fact of the Corporation (with or without power of substitution) to vote at, or attend and act for the Corporation at, any meeting of holders of shares or other securities of any other organization of which the Corporation holds shares or securities.

Section 6. Appointment of Auditor. The Board of Directors, or a committee thereof, shall each year select independent public accountants to report to the stockholders on the financial statements of the Corporation for such year. The selection of such accountants shall be presented to the stockholders for their approval at the annual meeting




each year; provided, however, that if the shareholders shall not approve the selection made by the Board, the Board shall appoint other independent public accountants for such year.

ARTICLE VII

AMENDMENTS

These By-Laws may be altered, amended, or repealed, and new By-Laws not inconsistent with any provision of the Articles of organization or applicable statute may be made either by the affirmative vote of a majority of the voting power of the then outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, at any annual or special meeting of the stockholders called for the purpose, or (except with respect to any provision hereof which by law, the Articles of Organization, or these By-Laws requires action by the stockholders) by the affirmative vote of a majority of the Board of Directors then in office. Not later that the time of giving notice of the meeting of stockholders next following the making, amending, or repealing by the Board of Directors of any By-Law, notice thereof stating the substance of such change shall be given to all stockholders entitled to vote on amending the By-Laws. Any By-Law made, amended, or repealed by the Board of Directors may be altered, amended, repealed, or reinstated by the stockholders.




 EX-31.1 3 a2020q110-qexhibit311.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
CERTIFICATION
I, Reshma Kewalramani, certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Vertex Pharmaceuticals Incorporated;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
May 1, 2020
/s/ Reshma Kewalramani
 
 
 
 
 
Reshma Kewalramani
 
 
Chief Executive Officer and President




 EX-31.2 4 a2020q110-qexhibit312.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
CERTIFICATION
I, Charles F. Wagner, Jr., certify that:
1.
I have reviewed this Quarterly Report on Form 10-Q of Vertex Pharmaceuticals Incorporated;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:
May 1, 2020
/s/ Charles F. Wagner, Jr.
 
 
 
 
 
Charles F. Wagner, Jr.
 
 
Executive Vice President and Chief Financial Officer



 EX-32.1 5 a2020q110-qexhibit321.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
SECTION 906 CEO/CFO CERTIFICATION
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) each of the undersigned officers of Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (the “Company”), does hereby certify, to such officer’s knowledge, that the Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date:
May 1, 2020
 
 
 
/s/ Reshma Kewalramani
 
 
 
 
 
Reshma Kewalramani
 
 
Chief Executive Officer and President
 
 
 
Date:
May 1, 2020
 
 
 
/s/ Charles F. Wagner, Jr.
 
 
 
 
 
Charles F. Wagner, Jr.
 
 
Executive Vice President and Chief Financial Officer
A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
 





 EX-101.SCH 6 vrtx-20200331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2107100 - Disclosure - Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Additional Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Additional Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Additional Cash Flow Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Basis of Presentation and Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Basis of Presentation and Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Basis of Presentation and Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Collaborative Arrangements link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Collaborative Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2414401 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006000 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 1002001 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Earnings Per Share - Anti-dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Earnings Per Share - Schedule of Computation (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Hedging link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - Hedging - Cash Flow Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2408405 - Disclosure - Hedging - Derivative Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Hedging - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Hedging - Notional Amount (Details) link:presentationLink link:calculationLink link:definitionLink 2408406 - Disclosure - Hedging - Offsetting Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Hedging (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2413401 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Marketable Securities and Equity Investments link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Marketable Securities and Equity Investments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 2406405 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Marketable Securities and Equity Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Revenue Recognition - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Stock Options Outstanding and Exercisable (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 vrtx-20200331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 vrtx-20200331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 vrtx-20200331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Commitments and Contingencies Disclosure [Abstract] Line of Credit Facility [Table] Line of Credit Facility [Table] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Letters of Credit Letter of Credit [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Base Rate Base Rate [Member] Eurodollar Eurodollar [Member] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Line of credit facility additional borrowing capacity Line Of Credit Facility Additional Borrowing Capacity Amount of increased borrowing capacity available in the future. Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Debt covenant, consolidated leverage ratio Debt Covenant, Consolidated Leverage Ratio Consolidated leverage ratio that must be maintained in order to be in compliance with debt covenants. Debt covenant, increase in consolidated leverage ratio Debt Covenant, Increase In Consolidated Leverage Ratio Debt Covenant, Increase In Consolidated Leverage Ratio Debt covenant, interest coverage ratio Debt Covenant, interest Coverage Ratio Debt Covenant, interest Coverage Ratio Indemnification claims Indemnification Claims Amount of indemnification claims currently outstanding Fair Value Disclosures [Abstract] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Balance at December 31, 2019 Business Combination, Contingent Consideration, Liability Increase in fair value of contingent payments Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Balance at March 31, 2020 Investments, Debt and Equity Securities [Abstract] Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table] Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table] Schedule of the cash and cash equivalents and available-for-sale investments held by the entity. Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Corporate equity securities Equity Securities [Member] CRISPR Sale [Member] CRISPR Sale [Member] Sale of CRISPR equity securities Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Other assets Other Assets [Member] Summary of cash, cash equivalents and marketable securities Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Line Items] -- None. No documentation exists for this element. -- Cash Cash Other-than-temporary declines in fair value of available-for-sale debt securities Other than Temporary Impairment Losses, Investments Fair value Equity Securities, FV-NI Unrealized gain (loss) Unrealized Gain (Loss) on Investments Proceeds from Sale and Maturity of Marketable Securities Proceeds from Sale and Maturity of Marketable Securities Equity Securities, Cost Basis Equity Securities, FV-NI, Cost Equity securities without readily determinable fair value, amount Equity Securities without Readily Determinable Fair Value, Amount Share-based Payment Arrangement [Abstract] Stock-based compensation expense by line item Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Unrecognized stock-based compensation expense, net of estimated forfeitures Schedule of Unrecognized Share-based Compensation Expense [Table Text Block] Disclosure as of the latest balance-sheet date presented of the total compensation cost related to outstanding, nonvested share-based compensation awards not yet recognized, net of estimated forfeitures, and the weighted average period over which those unrecognized costs are expected to be reported. Stock options outstanding and exercisable Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Earnings Per Share [Abstract] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] Stock options Share-based Payment Arrangement, Option [Member] Unvested restricted stock and restricted stock units (including PSUs) Restricted Stock [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Net income Net Income (Loss) Attributable to Parent Basic weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Effect of potentially dilutive securities: Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract] Share-based payment arrangements (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Employee stock purchase program (in shares) Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements Diluted weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Basic net income per common share (in dollars per share) Earnings Per Share, Basic Diluted net income per common share (in dollars per share) Earnings Per Share, Diluted Earnings Per Share Earnings Per Share [Text Block] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Accumulated Deficit Retained Earnings [Member] Statement Statement [Line Items] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning balance (shares) Shares, Outstanding Beginning balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Cumulative effect adjustment for adoption of new accounting guidance Cumulative Effect of New Accounting Principle in Period of Adoption Other comprehensive income, net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Repurchases of common stock (in shares) Stock Repurchased During Period, Shares Repurchase of common stock Stock Repurchased During Period, Value Common stock withheld for employee tax obligations (shares) Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Common stock withheld for employee tax obligations Share-based Payment Arrangement, Decrease for Tax Withholding Obligation Issuance of common stock under benefit plans (shares) Stock Issued During Period, Shares, Employee Benefit Plan Issuance of common stock under benefit plans Stock Issued During Period, Value, Employee Benefit Plan Stock-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Ending balance (shares) Ending Balance Organization, Consolidation and Presentation of Financial Statements [Abstract] Collaborative Arrangements Collaborative Arrangement Disclosure [Text Block] Stock-based Compensation Expense and Share Repurchase Programs Share-based Payment Arrangement [Text Block] Equity [Abstract] Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Marketable Securities and Equity Investments Cash, Cash Equivalents, and Marketable Securities [Text Block] Condensed Cash Flow Statement Condensed Cash Flow Statement [Table Text Block] Income Statement [Abstract] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Product revenues, net Product [Member] Collaborative and royalty revenues Collaborative and Royalty [Member] Collaborative and Royalty [Member] Statement [Line Items] Revenues: Revenues [Abstract] Revenues Revenue from Contract with Customer, Excluding Assessed Tax Costs and expenses: Costs and Expenses [Abstract] Cost of sales Cost of Goods and Services Sold Research and development expenses Research and Development Expense Sales, general and administrative expenses Selling, General and Administrative Expense Change in fair value of contingent consideration Total costs and expenses Costs and Expenses Income from operations Operating Income (Loss) Interest income Investment Income, Interest and Dividend Interest expense Interest Income (Expense), Net Other (expense) income, net Other Nonoperating Income (Expense) Income before provision for income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Provision for income taxes Income Tax Expense (Benefit) Net income Net income per common share: Basic (in dollars per share) Diluted (in dollars per share) Shares used in per share calculations: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (in shares) Diluted (in shares) Accounting Policies [Abstract] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Recently Adopted Accounting Standards and Recently Issued Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Derivative Instruments and Hedging Activities Disclosure [Abstract] Hedging Derivative Instruments and Hedging Activities Disclosure [Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangements by Agreement [Axis] Collaborative Arrangements by Agreement [Axis] Significant terms of collaboration arrangements, by individual agreement. Collaborative Arrangement Agreement [Domain] Collaborative Arrangement Agreement [Domain] Listing of significant collaboration agreements. CRISPR Therapeutics CRISPR Therapeutics AG [Member] CRISPR Therapeutics AG CTX001 Co-Co CTX001 Co-Co Agreement [Member] CTX001 Co-Co Agreement [Member] CRISPR DMD/DM1 CRISPR DMD/DM1 [Member] CRISPR Therapeutics DMD/DM1 [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative arrangement, right to exclusively license, number of targets Collaborative Arrangement, Right To License, Number Of Targets Collaborative Arrangement, Right To License, Number Of Targets Collaborative arrangement, development and regulatory potential milestone payments maximum Collaborative Arrangement Development And Regulatory Potential Milestone Payments Maximum Represents the potential milestone amount to be paid by the entity under the collaboration agreement if drug candidates are approved and commercialized. Collaborative arrangement research and development expenses Collaborative Arrangement Research and Development Expenses Collaborative Arrangement Research and Development Expenses Inventory Disclosure [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Work-in-process Inventory, Work in Process, Net of Reserves Finished goods Inventory, Finished Goods, Net of Reserves Total Inventories Inventory, Net Additional Cash Flow Information Additional Financial Information Disclosure [Text Block] Revenue from Contract with Customer [Abstract] Schedule of disaggregation of revenue Disaggregation of Revenue [Table Text Block] Schedule of Inventories by Type Schedule of Inventory, Current [Table Text Block] Fair Value Measurements Fair Value Disclosures [Text Block] Derivative [Table] Derivative [Table] Hedging Relationship [Axis] Hedging Relationship [Axis] Hedging Relationship [Domain] Hedging Relationship [Domain] Cash flow hedging Cash Flow Hedging [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Foreign currency forward contracts Foreign Exchange Forward [Member] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Not designated as hedging instruments Not Designated as Hedging Instrument [Member] Derivative [Line Items] Derivative [Line Items] Derivative term Derivative, Term of Contract Notional amount of foreign currency forward contract Derivative, Notional Amount Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract] Unrealized (losses) gains on foreign currency forward contracts, tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent Designated as hedging instruments Designated as Hedging Instrument [Member] Currency [Axis] Currency [Axis] All Currencies [Domain] All Currencies [Domain] Euro Euro Member Countries, Euro British pound sterling United Kingdom, Pounds Australian dollar Australia, Dollars Canadian dollar Canada, Dollars Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Stock options ESPP share issuances Employee Stock [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Cost of sales Cost of Sales [Member] Research and development expenses Research and Development Expense [Member] Sales, general and administrative expenses Selling, General and Administrative Expenses [Member] Share-based Compensation Arrangement by Share-based Payment Award Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock-based compensation expense: Share-based Compensation Allocation [Abstract] -- None. No documentation exists for this element. -- Total stock-based compensation expense included in costs and expenses Share-based Payment Arrangement, Expense Stock-based compensation expense related to inventories Share-based Payment Arrangement, Amount Capitalized Share-based compensation expense by type of award Share-based Payment Arrangement, Expensed and Capitalized, Amount Income tax effect Share-based Payment Arrangement, Expense, Tax Benefit Total stock-based compensation expense, net of tax Share-based Payment Arrangement, Expense, after Tax Type of award: Share-based Payment Arrangement, Additional Disclosure [Abstract] Unrecognized Expense Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Weighted-average Recognition Period Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] On Foreign Currency Forward Contracts Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Foreign currency forward contracts Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Other (expense) income Share-based Payment Arrangement, Option, Exercise Price Range [Table] Share-based Payment Arrangement, Option, Exercise Price Range [Table] Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Axis] Exercise Price Range [Axis] Exercise Price Range [Domain] Exercise Price Range [Domain] $29.07–$40.00 Exercise Price Range From Dollars 29.07 to Dollars 40.00 [Member] Exercise Price Range From Dollars 29.07 to Dollars 40.00 [Member] $40.01–$60.00 Exercise Price Range from Dollars 40.01 to Dollars 60.00 [Member] Represents the range of exercise prices from $40.01 to $60.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $60.01–$80.00 Exercise Price Range from Dollars 60.01 to Dollars 80.00 [Member] Represents the range of exercise prices from $60.01 to $80.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $80.01–$100.00 Exercise Price Range from Dollars 80.01 to Dollars 100.00 [Member] Represents the range of exercise prices from $80.01 to $100.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $100.01–$120.00 Exercise Price Range from Dollars 100.01 to Dollars 120.00 [Member] Represents the range of exercise prices from $100.01 to $120.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information. $120.01–$140.00 Exercise Price Range From Dollars 120.01 to Dollars 140.0 [Member] Exercise Price Range From Dollars 120.01 to Dollars 140.0 $140.01–$160.00 Exercise Price Range From Dollars 140.01 to Dollars 160.0 [Member] Exercise Price Range From Dollars 140.01 to Dollars 160.0 $160.01–$180.00 Exercise Price Range From Dollars 160.01 to Dollars 180.00 [Member] Exercise Price Range From Dollars 160.01 to Dollars 180.00 [Member] $180.01–$189.38 Exercise Price Range From Dollars 180.01 to Dollars 189.38 [Member] Exercise Price Range From Dollars 180.01 to Dollars 189.38 [Member] Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Exercise price, low end of range (in dollars per share) Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit Exercise price, high end of range (in dollars per share) Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Exercise price range, options outstanding (in shares) Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding Exercise price range, options outstanding, weighted-average remaining contractual life (in years) Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price Exercise price range, options exercisable (in shares) Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price Cash equivalents Cash and Cash Equivalents [Domain] Marketable securities Marketable Securities [Member] Marketable Securities [Member] Money market funds Cash and Money Market Funds [Member] Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time. Government-sponsored enterprise securities US Government-sponsored Enterprises Debt Securities [Member] Commercial paper Commercial Paper [Member] Corporate debt securities Corporate Debt Securities [Member] Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Total marketable debt securities Debt Securities, Available-for-sale [Abstract] Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Fair Value Debt Securities, Available-for-sale Corporate equity securities Equity Securities, FV-NI and without Readily Determinable Fair Value [Abstract] Amortized Cost Gross Unrealized Gains Equity Securities, FV-NI, Unrealized Gain Gross Unrealized Losses Equity Securities, FV-NI, Unrealized Loss Fair Value Amortized Cost Debt and Equity Securities, Cost Debt and Equity Securities, Cost Gross Unrealized Gains Debt and Equity Securities, Unrealized Gain Debt and Equity Securities, Unrealized Gain Gross Unrealized Losses Debt and Equity Securities, Unrealized Loss Debt and Equity Securities, Unrealized Loss Fair Value Debt and Equity Securities, Fair Value Debt and Equity Securities, Fair Value Contract liabilities Contract with Customer, Liability Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Fair Value by Measurement Frequency [Axis] Measurement Frequency [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Recurring basis Fair Value, Recurring [Member] Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Money market funds Money Market Funds [Member] Government-sponsored enterprise securities Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Financial instruments carried at fair value (asset positions): Assets, Fair Value Disclosure [Abstract] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Marketable securities Marketable Securities Derivative asset current Derivative Asset, Current Derivative asset noncurrent Derivative Asset, Noncurrent Total financial assets Assets, Fair Value Disclosure Financial instruments carried at fair value (liability positions): Liabilities, Fair Value Disclosure [Abstract] Derivative liability current Derivative Liability, Current Long-term contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Derivative liability, noncurrent Derivative Liability, Noncurrent Total financial liabilities Financial Liabilities Fair Value Disclosure Schedule of Cash Flow Hedging Instruments Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Schedule of Foreign Exchange Contracts, Condensed Consolidated Statements of Operations Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Schedule of Foreign Exchange Contracts Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block] Offsetting liabilities Offsetting Liabilities [Table Text Block] Offsetting assets Offsetting Assets [Table Text Block] Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Depreciation expense Depreciation, Depletion and Amortization Increase in fair value of contingent consideration Deferred income taxes Increase (Decrease) in Other Deferred Liability Losses (gains) on equity securities Equity Securities, FV-NI, Unrealized Gain (Loss) Other non-cash items, net Other Noncash Income (Expense) Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable, net Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Other liabilities Increase (Decrease) in Other Operating Liabilities Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of available-for-sale debt securities Payments to Acquire Debt Securities, Available-for-sale Maturities of available-for-sale debt securities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale Sale of equity securities Proceeds from Sale and Maturity of Other Investments Expenditures for property and equipment Payments to Acquire Property, Plant, and Equipment Investment in equity securities Payments to Acquire Marketable Securities Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Issuances of common stock under benefit plans Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised Repurchases of common stock Payments for Repurchase of Common Stock Payments in connection with common stock withheld for employee tax obligations Payment, Tax Withholding, Share-based Payment Arrangement Payments on finance leases Finance Lease, Principal Payments Proceeds related to finance leases Proceeds From Finance Leases Proceeds From Finance Leases Advance from collaborator Proceeds From Collaborative Funding Proceeds From Collaborative Funding Repayments of advanced funding Repayments of Collaborative Funding Repayments of Collaborative Funding Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Effect of changes in exchange rates on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, cash equivalents and restricted cash—beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash—end of period Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for income taxes Income Taxes Paid, Net Issuances of common stock from employee benefit plans receivable Employee Benefit Plan Payable (Receivable) Employee Benefit Plan Payable (Receivable) Accrued share repurchase liability Accrued Share Repurchase Liability Accrued Share Repurchase Liability Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Statement of Comprehensive Income [Abstract] Changes in other comprehensive income: Other Comprehensive Income (Loss), Net of Tax [Abstract] Unrealized holding (losses) gains on marketable securities, net Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Unrealized gains (losses) on foreign currency forward contracts, net of tax of $(5.0) million and $1.5 million, respectively Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Total changes in other comprehensive income Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Basis of Presentation and Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Statement of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Marketable securities Marketable Securities, Current Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Inventories Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Goodwill Goodwill Intangible assets Intangible Assets, Net (Excluding Goodwill) Deferred tax assets Deferred Income Tax Assets, Net Other assets Other Assets, Noncurrent Total assets Assets Liabilities and Shareholders’ Equity Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued expenses Accrued Liabilities, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current Long-term finance lease liabilities Finance Lease, Liability, Noncurrent Long-term contingent consideration Other long-term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingencies Commitments and Contingencies Shareholders’ equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Preferred stock, $0.01 par value; 1,000 shares authorized; none issued and outstanding Preferred Stock, Value, Issued Common stock, $0.01 par value; 500,000 shares authorized, 259,079 and 258,993 shares issued and outstanding, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated deficit Retained Earnings (Accumulated Deficit) Total shareholders’ equity Total liabilities and shareholders’ equity Liabilities and Equity Financial assets subject to fair value measurements (excluding VIE cash and cash equivalents, which are recorded as Restricted cash and cash equivalents (VIE)) Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of fair value of our contingent consideration liabilities Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Inventories Inventory Disclosure [Text Block] Matures within one year Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value Matures after one year through five years Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value Total Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Debt securities Revenue Recognition Revenue from Contract with Customer [Text Block] Schedule of earnings per share, basic and diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Potential gross common equivalent shares Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2016-02 Accounting Standards Update 2016-02 [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Number of operating segments Number of Operating Segments Cumulative effect adjustment to accumulated deficit Summary of cash equivalents and marketable securities Cash, Cash Equivalents and Investments [Table Text Block] Cover [Abstract] Document Type Document Type Document Quarterly Report Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Other current liabilities Other Current Liabilities [Member] Other long-term liabilities Other Noncurrent Liabilities [Member] Total assets Derivative Asset, Fair Value, Gross Asset Total liabilities Derivative Liability, Fair Value, Gross Liability Deferred tax assets, valuation allowance Deferred Tax Assets, Valuation Allowance Unrecognized tax benefits Unrecognized Tax Benefits that Would Impact Effective Tax Rate Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] TRIKAFTA TRIKAFTA [Member] TRIKAFTA [Member] SYMDEKO/SYMKEVI SYMDEKO/SYMKEVI [Member] SYMDEKO/SYMKEVI [Member] ORKAMBI ORKAMBI [Member] ORKAMBI [Member] KALYDECO KALYDECO [Member] KALYDECO inventories, net Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] United States UNITED STATES Europe Europe [Member] Other Other, Non U.S. [Member] Other, Non U.S. [Member] Total revenues outside of the United States Non-US [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Equity Components [Axis] Foreign Currency Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] On Available-For-Sale Debt Securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Total Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Other comprehensive (loss) income before reclassifications OCI, before Reclassifications, Net of Tax, Attributable to Parent Amounts reclassified from accumulated other comprehensive income (loss) Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Restrictions on Cash and Cash Equivalents [Table] Restrictions on Cash and Cash Equivalents [Table] Restricted Cash and Cash Equivalents Items [Line Items] Restricted Cash and Cash Equivalents Items [Line Items] Restricted cash and cash equivalents Restricted Cash and Cash Equivalents Cash, cash equivalents and restricted cash per statement of cash flows Measurement Input Type [Axis] Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input Type [Domain] Discount Rate Measurement Input, Discount Rate [Member] Remaining milestone payment Business Combination, Remaining Milestone Payment Business Combination, Remaining Milestone Payment Contingent consideration, measurement input Business Combination, Contingent Consideration, Liability, Measurement Input Class of Treasury Stock [Table] Class of Treasury Stock [Table] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Share Repurchase Program 2018 Share Repurchase Program 2018 [Member] Share Repurchase Program 2018 [Member] Share Repurchase Program 2019 Share Repurchase Program 2019 [Member] Share Repurchase Program [Member] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Number of shares authorized to be repurchased Stock Repurchase Program, Authorized Amount Shares repurchased (in shares) Amount of shares repurchased Cumulative value of shares repurchased Stock Repurchase Program, Cumulative Value Of Shares Repurchased Stock Repurchase Program, Cumulative Value Of Shares Repurchased Stock repurchase program, remaining amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, shares issued Preferred Stock, Shares Issued Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Common stock, shares outstanding Common Stock, Shares, Outstanding Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Offsetting Derivative Assets [Abstract] Offsetting Derivative Assets [Abstract] Gross Amounts Offset Derivative Asset, Fair Value, Gross Liability Gross Amounts Presented Derivative Asset Gross Amounts Not Offset Derivative Asset, Not Offset, Policy Election Deduction Legal Offset Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election Offsetting Derivative Liabilities [Abstract] Offsetting Derivative Liabilities [Abstract] Gross Amounts Recognized Gross Amounts Offset Derivative Liability, Fair Value, Gross Asset Gross Amounts Presented Derivative Liability Gross Amounts Not Offset Derivative Liability, Not Offset, Policy Election Deduction Legal Offset Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election EX-101.PRE 10 vrtx-20200331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 chart-46ee851a54315f11b13.jpg begin 644 chart-46ee851a54315f11b13.jpg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f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chart-c6f6127e7bb55486951.jpg begin 644 chart-c6f6127e7bb55486951.jpg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end XML 13 R54.htm IDEA: XBRL DOCUMENT v3.20.1
Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details) - USD ($)
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Jul. 31, 2019
Jun. 30, 2019
Dec. 31, 2018
Equity, Class of Treasury Stock [Line Items]          
Amount of shares repurchased $ 300,026,000 $ 98,007,000      
Share Repurchase Program 2018          
Equity, Class of Treasury Stock [Line Items]          
Number of shares authorized to be repurchased         $ 500,000,000.0
Shares repurchased (in shares)   537,018      
Amount of shares repurchased   $ 98,000,000.0      
Cumulative value of shares repurchased       $ 500,000,000.0  
Share Repurchase Program 2019          
Equity, Class of Treasury Stock [Line Items]          
Number of shares authorized to be repurchased     $ 500,000,000.0    
Shares repurchased (in shares) 1,403,868        
Amount of shares repurchased $ 300,000,000.0        
Stock repurchase program, remaining amount $ 164,000,000.0        
XML 14 R50.htm IDEA: XBRL DOCUMENT v3.20.1
Hedging - Offsetting Derivatives (Details) - Cash flow hedging - Designated as hedging instruments - Foreign currency forward contracts - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Offsetting Derivative Assets [Abstract]    
Total assets $ 27,232 $ 9,725
Gross Amounts Offset 0 0
Gross Amounts Presented 27,232 9,725
Gross Amounts Not Offset (1,096) (7,354)
Legal Offset 26,136 2,371
Offsetting Derivative Liabilities [Abstract]    
Gross Amounts Recognized (1,096) (7,354)
Gross Amounts Offset 0 0
Gross Amounts Presented (1,096) (7,354)
Gross Amounts Not Offset 1,096 7,354
Legal Offset $ 0 $ 0
JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a2020q110-q.htm": { "axisCustom": 1, "axisStandard": 23, "contextCount": 232, "dts": { "calculationLink": { "local": [ "vrtx-20200331_cal.xml" ] }, "definitionLink": { "local": [ "vrtx-20200331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "a2020q110-q.htm" ] }, "labelLink": { "local": [ "vrtx-20200331_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "vrtx-20200331_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml" ] }, "schema": { "local": [ "vrtx-20200331.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd" ] } }, "elementCount": 444, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 38, "http://xbrl.sec.gov/dei/2019-01-31": 6, "total": 44 }, "keyCustom": 20, "keyStandard": 291, "memberCustom": 23, "memberStandard": 49, "nsprefix": "vrtx", "nsuri": "http://www.vrtx.com/20200331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://www.vrtx.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - Revenue Recognition", "role": "http://www.vrtx.com/role/RevenueRecognition", "shortName": "Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - Collaborative Arrangements", "role": "http://www.vrtx.com/role/CollaborativeArrangements", "shortName": "Collaborative Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - Earnings Per Share", "role": "http://www.vrtx.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - Fair Value Measurements", "role": "http://www.vrtx.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - Marketable Securities and Equity Investments", "role": "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestments", "shortName": "Marketable Securities and Equity Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - Accumulated Other Comprehensive Income (Loss)", "role": "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss", "shortName": "Accumulated Other Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - Hedging", "role": "http://www.vrtx.com/role/Hedging", "shortName": "Hedging", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - Inventories", "role": "http://www.vrtx.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs", "role": "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchasePrograms", "shortName": "Stock-based Compensation Expense and Share Repurchase Programs", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - Income Taxes", "role": "http://www.vrtx.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Condensed Consolidated Statements of Operations", "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - Commitments and Contingencies", "role": "http://www.vrtx.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - Additional Cash Flow Information", "role": "http://www.vrtx.com/role/AdditionalCashFlowInformation", "shortName": "Additional Cash Flow Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - Basis of Presentation and Accounting Policies (Policies)", "role": "http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302301 - Disclosure - Revenue Recognition (Tables)", "role": "http://www.vrtx.com/role/RevenueRecognitionTables", "shortName": "Revenue Recognition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Earnings Per Share (Tables)", "role": "http://www.vrtx.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.vrtx.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Marketable Securities and Equity Investments (Tables)", "role": "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsTables", "shortName": "Marketable Securities and Equity Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)", "role": "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables", "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - Hedging (Tables)", "role": "http://www.vrtx.com/role/HedgingTables", "shortName": "Hedging (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - Inventories (Tables)", "role": "http://www.vrtx.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income", "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "shortName": "Condensed Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312301 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs (Tables)", "role": "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsTables", "shortName": "Stock-based Compensation Expense and Share Repurchase Programs (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315301 - Disclosure - Additional Cash Flow Information (Tables)", "role": "http://www.vrtx.com/role/AdditionalCashFlowInformationTables", "shortName": "Additional Cash Flow Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401402 - Disclosure - Basis of Presentation and Accounting Policies (Details)", "role": "http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesDetails", "shortName": "Basis of Presentation and Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402402 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)", "role": "http://www.vrtx.com/role/RevenueRecognitionDisaggregationOfRevenueDetails", "shortName": "Revenue Recognition - Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD_srt_StatementGeographicalAxis_country_US", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402403 - Disclosure - Revenue Recognition - Narrative (Details)", "role": "http://www.vrtx.com/role/RevenueRecognitionNarrativeDetails", "shortName": "Revenue Recognition - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2019Q4QTD_vrtx_CollaborativeArrangementsByAgreementAxis_vrtx_CRISPRTherapeuticsAGMember", "decimals": "INF", "first": true, "lang": null, "name": "vrtx:CollaborativeArrangementRightToLicenseNumberOfTargets", "reportCount": 1, "unique": true, "unitRef": "target", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403401 - Disclosure - Collaborative Arrangements (Details)", "role": "http://www.vrtx.com/role/CollaborativeArrangementsDetails", "shortName": "Collaborative Arrangements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2019Q4QTD_vrtx_CollaborativeArrangementsByAgreementAxis_vrtx_CRISPRTherapeuticsAGMember", "decimals": "INF", "first": true, "lang": null, "name": "vrtx:CollaborativeArrangementRightToLicenseNumberOfTargets", "reportCount": 1, "unique": true, "unitRef": "target", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - Earnings Per Share - Schedule of Computation (Details)", "role": "http://www.vrtx.com/role/EarningsPerShareScheduleOfComputationDetails", "shortName": "Earnings Per Share - Schedule of Computation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404403 - Disclosure - Earnings Per Share - Anti-dilutive Securities (Details)", "role": "http://www.vrtx.com/role/EarningsPerShareAntiDilutiveSecuritiesDetails", "shortName": "Earnings Per Share - Anti-dilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2020Q1", "decimals": "-8", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details)", "role": "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails", "shortName": "Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember", "decimals": "-3", "lang": null, "name": "us-gaap:DerivativeAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member", "decimals": "-5", "first": true, "lang": null, "name": "vrtx:BusinessCombinationRemainingMilestonePayment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405403 - Disclosure - Fair Value Measurements - Additional Information (Details)", "role": "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member", "decimals": "-5", "first": true, "lang": null, "name": "vrtx:BusinessCombinationRemainingMilestonePayment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1002001 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)", "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405404 - Disclosure - Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details)", "role": "http://www.vrtx.com/role/FairValueMeasurementsFairValueOfContingentConsiderationLiabilitiesDetails", "shortName": "Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2020Q1", "decimals": "-8", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Marketable Securities and Equity Investments - Additional Information (Details)", "role": "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails", "shortName": "Marketable Securities and Equity Investments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "INF", "lang": null, "name": "us-gaap:ImpairmentOfInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details)", "role": "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails", "shortName": "Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "lang": null, "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGain", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406404 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details)", "role": "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAvailableForSaleDebtSecuritiesAtFairValueDetails", "shortName": "Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406405 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details)", "role": "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAvailableForSaleDebtSecuritiesByContractualMaturityDetails", "shortName": "Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)", "role": "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "lang": null, "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - Hedging - Narrative (Details)", "role": "http://www.vrtx.com/role/HedgingNarrativeDetails", "shortName": "Hedging - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeTermOfContract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Hedging - Notional Amount (Details)", "role": "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "shortName": "Hedging - Notional Amount (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408404 - Disclosure - Hedging - Cash Flow Hedging Instruments (Details)", "role": "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "shortName": "Hedging - Cash Flow Hedging Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember", "decimals": "-3", "lang": null, "name": "us-gaap:OtherNonoperatingIncomeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408405 - Disclosure - Hedging - Derivative Fair Value (Details)", "role": "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "shortName": "Hedging - Derivative Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-3", "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "lang": null, "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408406 - Disclosure - Hedging - Offsetting Derivatives (Details)", "role": "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails", "shortName": "Hedging - Offsetting Derivatives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:OffsettingAssetsTableTextBlock", "us-gaap:OffsettingLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeForwardMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-3", "lang": null, "name": "us-gaap:DerivativeAssetFairValueGrossLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - Inventories (Details)", "role": "http://www.vrtx.com/role/InventoriesDetails", "shortName": "Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412402 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details)", "role": "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockBasedCompensationExpenseDetails", "shortName": "Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412403 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Stock Options Outstanding and Exercisable (Details)", "role": "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockOptionsOutstandingAndExercisableDetails", "shortName": "Stock-based Compensation Expense and Share Repurchase Programs - Stock Options Outstanding and Exercisable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockRepurchasedDuringPeriodValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412404 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details)", "role": "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsAdditionalInformationDetails", "shortName": "Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2018Q4_us-gaap_ShareRepurchaseProgramAxis_vrtx_ShareRepurchaseProgram2018Member", "decimals": "INF", "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413401 - Disclosure - Income Taxes (Details)", "role": "http://www.vrtx.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2019Q4", "decimals": "-5", "lang": null, "name": "us-gaap:DeferredTaxAssetsValuationAllowance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2020Q1", "decimals": "INF", "first": true, "lang": null, "name": "vrtx:IndemnificationClaims", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414401 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.vrtx.com/role/CommitmentsAndContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2020Q1", "decimals": "INF", "first": true, "lang": null, "name": "vrtx:IndemnificationClaims", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415402 - Disclosure - Additional Cash Flow Information (Details)", "role": "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails", "shortName": "Additional Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2019Q1", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Condensed Consolidated Statements of Shareholders' Equity", "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquity", "shortName": "Condensed Consolidated Statements of Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006000 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Basis of Presentation and Accounting Policies", "role": "http://www.vrtx.com/role/BasisOfPresentationAndAccountingPolicies", "shortName": "Basis of Presentation and Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "a2020q110-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 78, "tag": { "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "currency_AUD": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Australia, Dollars", "terseLabel": "Australian dollar" } } }, "localname": "AUD", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_CAD": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Canada, Dollars", "terseLabel": "Canadian dollar" } } }, "localname": "CAD", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_EUR": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Euro Member Countries, Euro", "terseLabel": "Euro" } } }, "localname": "EUR", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "currency_GBP": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "United Kingdom, Pounds", "terseLabel": "British pound sterling" } } }, "localname": "GBP", "nsuri": "http://xbrl.sec.gov/currency/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r309" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r310" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r311" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r311" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r311" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r312" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r311" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r311" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r311" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r311" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r307" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r308" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by currency.", "label": "Currency [Axis]", "terseLabel": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "stringItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Continent of Europe.", "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r127", "r177", "r179", "r293", "r294" ], "lang": { "en-US": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfCondensedCashFlowStatementTableTextBlock": { "auth_ref": [ "r315" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations.", "label": "Condensed Cash Flow Statement [Table Text Block]", "terseLabel": "Condensed Cash Flow Statement" } } }, "localname": "ScheduleOfCondensedCashFlowStatementTableTextBlock", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationTables" ], "xbrltype": "textBlockItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r128", "r177", "r180", "r295", "r304", "r305", "r313", "r314" ], "lang": { "en-US": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r262" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Accounting Standards Update 2016-02" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r2", "r16", "r129", "r130", "r178" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r60", "r68", "r225" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "On Foreign Currency Forward Contracts" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r53", "r54", "r55", "r60", "r61" ], "lang": { "en-US": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]", "terseLabel": "On Available-For-Sale Debt Securities" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r57", "r59", "r60" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r56", "r60", "r61", "r226" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "verboseLabel": "Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r52", "r60", "r61", "r226" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation Adjustment" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.", "label": "Additional Financial Information Disclosure [Text Block]", "terseLabel": "Additional Cash Flow Information" } } }, "localname": "AdditionalFinancialInformationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r17" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r100" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Common stock withheld for employee tax obligations" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r185", "r187", "r203", "r204" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r187", "r197", "r202" ], "calculation": { "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockBasedCompensationExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation expense included in costs and expenses" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockBasedCompensationExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, after Tax", "totalLabel": "Total stock-based compensation expense, net of tax" } } }, "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntiDilutiveSecuritiesDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleOfComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r126", "r273", "r285" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r40" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r250" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total financial assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Financial instruments carried at fair value (asset positions):" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r136" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r137" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Gross Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r134", "r149" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetailsCalc2": { "order": 1.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Securities, Available-for-sale [Abstract]", "terseLabel": "Total marketable debt securities" } } }, "localname": "AvailableForSaleSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r138", "r140", "r283" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAvailableForSaleDebtSecuritiesByContractualMaturityDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value", "terseLabel": "Matures after one year through five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAvailableForSaleDebtSecuritiesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r138", "r139", "r282" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAvailableForSaleDebtSecuritiesByContractualMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value", "terseLabel": "Matures within one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAvailableForSaleDebtSecuritiesByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r131", "r135", "r149" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAvailableForSaleDebtSecuritiesByContractualMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Fair Value", "totalLabel": "Total", "verboseLabel": "Debt securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAvailableForSaleDebtSecuritiesAtFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAvailableForSaleDebtSecuritiesByContractualMaturityDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r188", "r200" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleOfComputationDetails", "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAvailableForSaleDebtSecuritiesAtFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r236", "r240" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAvailableForSaleDebtSecuritiesAtFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r89", "r216" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "netLabel": "Increase in fair value of contingent consideration", "terseLabel": "Increase in fair value of contingent payments", "verboseLabel": "Change in fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/FairValueMeasurementsFairValueOfContingentConsiderationLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r212", "r213", "r215" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "periodEndLabel": "Balance at March 31, 2020", "periodStartLabel": "Balance at December 31, 2019" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFairValueOfContingentConsiderationLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "Value of input used to measure contingent consideration liability from business combination.", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "terseLabel": "Contingent consideration, measurement input" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r212", "r214" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails": { "order": 1.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "negatedLabel": "Long-term contingent consideration", "terseLabel": "Long-term contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r28", "r297", "r298" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r0", "r28", "r92" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails", "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "auth_ref": [ "r9", "r141" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).", "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "terseLabel": "Marketable Securities and Equity Investments" } } }, "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r86", "r92", "r94" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash\u2014end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash\u2014beginning of period", "terseLabel": "Cash, cash equivalents and restricted cash per statement of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r86", "r261" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash flow hedging" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r170", "r171", "r172", "r173" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]", "terseLabel": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r217", "r218", "r220" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaborative Arrangements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r167" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "auth_ref": [ "r182", "r256" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.", "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r37", "r165", "r277", "r290" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r164", "r166" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r15", "r168" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r15" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.01 par value; 500,000 shares authorized, 259,079 and 258,993 shares issued and outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r64", "r66", "r67" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r77" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r174", "r175", "r178" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Contract liabilities" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r182", "r184", "r296" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate debt securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r72" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r71" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "netLabel": "Cumulative effect adjustment to accumulated deficit", "terseLabel": "Cumulative effect adjustment for adoption of new accounting guidance" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r141" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAvailableForSaleDebtSecuritiesAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r209" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r208" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "terseLabel": "Deferred tax assets, valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r90", "r124" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetFairValueGrossLiability": { "auth_ref": [ "r42", "r51", "r238" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeAssets", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Asset, Fair Value, Gross Liability", "negatedTerseLabel": "Gross Amounts Offset" } } }, "localname": "DerivativeAssetFairValueGrossLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": { "auth_ref": [ "r45", "r49" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.", "label": "Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election", "totalLabel": "Legal Offset" } } }, "localname": "DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": { "auth_ref": [ "r44", "r49" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative assets.", "label": "Derivative Asset, Not Offset, Policy Election Deduction", "negatedTerseLabel": "Gross Amounts Not Offset" } } }, "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r43", "r48", "r260" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "totalLabel": "Gross Amounts Presented" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsCurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Current", "terseLabel": "Derivative asset current" } } }, "localname": "DerivativeAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset, Noncurrent", "terseLabel": "Derivative asset noncurrent" } } }, "localname": "DerivativeAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r41", "r50", "r238", "r270" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Total assets" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r41", "r50", "r238", "r270" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "negatedLabel": "Total liabilities", "negatedTerseLabel": "Gross Amounts Recognized" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r237", "r239", "r242", "r243" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r249" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Hedging" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/Hedging" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r234", "r237", "r242" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r234", "r237", "r242", "r243", "r244", "r247", "r248" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r43", "r48", "r260" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "negatedTotalLabel": "Gross Amounts Presented" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails": { "order": 2.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Current", "negatedTerseLabel": "Derivative liability current" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails": { "order": 3.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Noncurrent", "negatedTerseLabel": "Derivative liability, noncurrent" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityFairValueGrossAsset": { "auth_ref": [ "r42", "r51", "r238" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Liability, Fair Value, Gross Asset", "terseLabel": "Gross Amounts Offset" } } }, "localname": "DerivativeLiabilityFairValueGrossAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": { "auth_ref": [ "r45", "r49" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.", "label": "Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election", "negatedTotalLabel": "Legal Offset" } } }, "localname": "DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": { "auth_ref": [ "r44", "r49" ], "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative liabilities.", "label": "Derivative Liability, Not Offset, Policy Election Deduction", "terseLabel": "Gross Amounts Not Offset" } } }, "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r230", "r232" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount of foreign currency forward contract" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r98", "r229", "r231", "r232", "r234", "r235", "r241", "r242", "r245", "r246", "r248" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTermOfContract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Derivative, Term of Contract", "terseLabel": "Derivative term" } } }, "localname": "DerivativeTermOfContract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as hedging instruments" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r177" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of disaggregation of revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r205" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-based Compensation Expense and Share Repurchase Programs" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchasePrograms" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net income per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r70", "r101", "r106", "r109", "r110", "r111", "r114", "r280", "r292" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net income per common share (in dollars per share)", "verboseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/EarningsPerShareScheduleOfComputationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r70", "r101", "r106", "r109", "r110", "r111", "r114", "r280", "r292" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net income per common share (in dollars per share)", "verboseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/EarningsPerShareScheduleOfComputationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r115" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r261" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of changes in exchange rates on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement, Additional Disclosure [Abstract]", "terseLabel": "Type of award:" } } }, "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "auth_ref": [ "r198" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost capitalized for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Amount Capitalized", "negatedTerseLabel": "Stock-based compensation expense related to inventories" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r199" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized Expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r199" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average Recognition Period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r197" ], "calculation": { "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockBasedCompensationExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, Tax Benefit", "negatedTerseLabel": "Income tax effect" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "ESPP share issuances" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options", "verboseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntiDilutiveSecuritiesDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleOfComputationDetails", "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r168" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquity", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r259" ], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "vrtx_DebtandEquitySecuritiesFairValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI", "terseLabel": "Fair Value", "verboseLabel": "Fair value" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity Securities, FV-NI and without Readily Determinable Fair Value [Abstract]", "terseLabel": "Corporate equity securities" } } }, "localname": "EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquitySecuritiesFvNiCost": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetailsCalc2": { "order": 2.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.", "label": "Equity Securities, FV-NI, Cost", "terseLabel": "Amortized Cost", "verboseLabel": "Equity Securities, Cost Basis" } } }, "localname": "EquitySecuritiesFvNiCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGain": { "auth_ref": [ "r143" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r143" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "negatedTerseLabel": "Losses (gains) on equity securities" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": { "auth_ref": [ "r143" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Loss", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "EquitySecuritiesFvNiUnrealizedLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r10", "r13", "r141", "r276", "r284", "r303" ], "lang": { "en-US": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Corporate equity securities" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r142" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "verboseLabel": "Equity securities without readily determinable fair value, amount" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EurodollarMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.", "label": "Eurodollar [Member]", "terseLabel": "Eurodollar" } } }, "localname": "EurodollarMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r250", "r251", "r252", "r257" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFairValueOfContingentConsiderationLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r182", "r183", "r184", "r251", "r266" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r250", "r251", "r254", "r255", "r258" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Fair Value by Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r256" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r182", "r183", "r184", "r251", "r267" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r182", "r183", "r184", "r251", "r268" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r182", "r183", "r184", "r251", "r269" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r256", "r258" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r263" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Long-term finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r264", "r265" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedTerseLabel": "Payments on finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r144", "r145", "r146", "r147", "r148", "r150", "r151", "r152", "r153" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "negatedTotalLabel": "Total financial liabilities" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign currency forward contracts", "verboseLabel": "Foreign currency forward contracts" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r158", "r159" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r234", "r244" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfInvestments": { "auth_ref": [ "r133" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.", "label": "Other than Temporary Impairment Losses, Investments", "terseLabel": "Other-than-temporary declines in fair value of available-for-sale debt securities" } } }, "localname": "ImpairmentOfInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r97" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Income before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r163" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "verboseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "verboseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r211" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r95", "r125", "r210" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "verboseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r93" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r89" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r89" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r89" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r89" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherDeferredLiability": { "auth_ref": [ "r89" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in deferred obligations classified as other.", "label": "Increase (Decrease) in Other Deferred Liability", "terseLabel": "Deferred income taxes" } } }, "localname": "IncreaseDecreaseInOtherDeferredLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r89" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r89" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements": { "auth_ref": [ "r107", "r111" ], "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleOfComputationDetails": { "order": 3.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of equity unit purchase agreements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements", "terseLabel": "Employee stock purchase program (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleOfComputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r108", "r113" ], "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleOfComputationDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Share-based payment arrangements (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleOfComputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r160", "r161" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r281" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Interest expense" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r85", "r87", "r93" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r157" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r20", "r156" ], "calculation": { "http://www.vrtx.com/role/InventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r1", "r39", "r155" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.vrtx.com/role/InventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets", "http://www.vrtx.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r22", "r156" ], "calculation": { "http://www.vrtx.com/role/InventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r21", "r156" ], "calculation": { "http://www.vrtx.com/role/InventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/InventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterestAndDividend": { "auth_ref": [ "r74" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Interest and Dividend", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterestAndDividend", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r299", "r300", "r301", "r302" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r299", "r300", "r301", "r302" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letters of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r32" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r19", "r274", "r288" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Shareholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Financial instruments carried at fair value (liability positions):" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r31" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit facility, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r31", "r96" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecurities": { "auth_ref": [ "r278" ], "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in marketable security.", "label": "Marketable Securities", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r3", "r33" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r253" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Discount Rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r253" ], "lang": { "en-US": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r182" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r86" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r86" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r86", "r88", "r91" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r62", "r65", "r69", "r91", "r113", "r279", "r291" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquity", "http://www.vrtx.com/role/EarningsPerShareScheduleOfComputationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r100", "r102" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Standards and Recently Issued Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "Total revenues outside of the United States" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Not designated as hedging instruments" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "auth_ref": [ "r60", "r68" ], "calculation": { "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "terseLabel": "Other comprehensive (loss) income before reclassifications" } } }, "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OffsettingAssetsTableTextBlock": { "auth_ref": [ "r46", "r47" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of derivative and other financial assets that are subject to offsetting, including master netting arrangements.", "label": "Offsetting Assets [Table Text Block]", "terseLabel": "Offsetting assets" } } }, "localname": "OffsettingAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OffsettingDerivativeAssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Offsetting Derivative Assets [Abstract]", "terseLabel": "Offsetting Derivative Assets [Abstract]" } } }, "localname": "OffsettingDerivativeAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingDerivativeLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Offsetting Derivative Liabilities [Abstract]", "terseLabel": "Offsetting Derivative Liabilities [Abstract]" } } }, "localname": "OffsettingDerivativeLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OffsettingLiabilitiesTableTextBlock": { "auth_ref": [ "r46", "r47" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of derivative and other financial liabilities that are subject to offsetting, including master netting arrangements.", "label": "Offsetting Liabilities [Table Text Block]", "terseLabel": "Offsetting liabilities" } } }, "localname": "OffsettingLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r99", "r103", "r123", "r228" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation and Accounting Policies" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/BasisOfPresentationAndAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r236", "r247" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r29" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r223", "r224", "r225" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized holding (losses) gains on marketable securities, net" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r223", "r224", "r225" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r57" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "terseLabel": "Unrealized gains (losses) on foreign currency forward contracts, net of tax of $(5.0) million and $1.5 million, respectively" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent": { "auth_ref": [ "r58" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent", "verboseLabel": "Unrealized (losses) gains on foreign currency forward contracts, tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Changes in other comprehensive income:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r63", "r66", "r223", "r224", "r225" ], "calculation": { "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income, net of tax", "totalLabel": "Total changes in other comprehensive income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome", "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other current liabilities" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r6", "r7", "r34" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r91" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other non-cash items, net" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r75" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other (expense) income, net", "verboseLabel": "Other (expense) income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r84" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Repurchases of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r84" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Payments in connection with common stock withheld for employee tax obligations" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r78", "r81", "r132" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-sale", "negatedLabel": "Purchases of available-for-sale debt securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r132" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedTerseLabel": "Investment in equity securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r82" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Expenditures for property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r14" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $0.01 par value; 1,000 shares authorized; none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r4", "r26", "r27" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r83", "r201" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised", "terseLabel": "Issuances of common stock under benefit plans" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r78", "r79", "r132" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale", "terseLabel": "Maturities of available-for-sale debt securities" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from Sale and Maturity of Marketable Securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": { "auth_ref": [ "r80" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.", "label": "Proceeds from Sale and Maturity of Other Investments", "terseLabel": "Sale of equity securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r179" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product revenues, net" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r11", "r12", "r162", "r289" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r60", "r68" ], "calculation": { "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "negatedTerseLabel": "Amounts reclassified from accumulated other comprehensive income (loss)" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "terseLabel": "Schedule of Foreign Exchange Contracts, Condensed Consolidated Statements of Operations" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r206", "r306" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "verboseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r9", "r92", "r94", "r272", "r286" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash and cash equivalents" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash equivalents" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAvailableForSaleDebtSecuritiesAtFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restricted Cash and Cash Equivalents Items [Line Items]", "terseLabel": "Restricted Cash and Cash Equivalents Items [Line Items]" } } }, "localname": "RestrictedCashAndCashEquivalentsItemsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Unvested restricted stock and restricted stock units (including PSUs)" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntiDilutiveSecuritiesDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleOfComputationDetails", "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r18", "r169", "r287" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r176", "r177" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r181" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/RevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r60" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntiDilutiveSecuritiesDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleOfComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Potential gross common equivalent shares" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAvailableForSaleDebtSecuritiesAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "verboseLabel": "Schedule of fair value of our contingent consideration liabilities" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "terseLabel": "Summary of cash equivalents and marketable securities" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r219" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r113" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of earnings per share, basic and diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r187", "r196", "r202" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Stock-based compensation expense by line item" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r250", "r251" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Financial assets subject to fair value measurements (excluding VIE cash and cash equivalents, which are recorded as Restricted cash and cash equivalents (VIE))" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.", "label": "Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]", "terseLabel": "Schedule of Foreign Exchange Contracts" } } }, "localname": "ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r8", "r23", "r24", "r25" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories by Type" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": { "auth_ref": [ "r230" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.", "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]", "terseLabel": "Schedule of Cash Flow Hedging Instruments" } } }, "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": { "auth_ref": [ "r9", "r94", "r272", "r286" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table]", "terseLabel": "Restrictions on Cash and Cash Equivalents [Table]" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r188", "r200" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "auth_ref": [ "r200" ], "lang": { "en-US": { "role": { "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]", "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r200" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "terseLabel": "Stock options outstanding and exercisable" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r73", "r154" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Sales, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [ "r76" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Sales, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r89" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r186", "r189" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleOfComputationDetails", "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r194" ], "lang": { "en-US": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]", "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Exercise Price Range [Domain]", "terseLabel": "Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]", "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "terseLabel": "Exercise price, low end of range (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r192" ], "lang": { "en-US": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "terseLabel": "Exercise price range, options exercisable (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r190" ], "lang": { "en-US": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding", "terseLabel": "Exercise price range, options outstanding (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "terseLabel": "Exercise price, high end of range (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": { "auth_ref": [ "r196" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount", "terseLabel": "Share-based compensation expense by type of award" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "auth_ref": [ "r191" ], "lang": { "en-US": { "role": { "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercise price range, options exercisable, weighted-average exercise price (in dollars per share)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "auth_ref": [ "r190" ], "lang": { "en-US": { "role": { "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price", "terseLabel": "Exercise price range, options outstanding, weighted-average exercise price (in dollars per share)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r193" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Exercise price range, options outstanding, weighted-average remaining contractual life (in years)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (shares)", "periodStartLabel": "Beginning balance (shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedTerseLabel": "Common stock withheld for employee tax obligations (shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r38", "r168" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]", "verboseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquity", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "verboseLabel": "Statement" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "Stock Issued During Period, Shares, Employee Benefit Plan", "terseLabel": "Issuance of common stock under benefit plans (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "Stock Issued During Period, Value, Employee Benefit Plan", "terseLabel": "Issuance of common stock under benefit plans" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Number of shares authorized to be repurchased" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Stock repurchase program, remaining amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r14", "r15", "r168", "r169" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedLabel": "Repurchases of common stock (in shares)", "terseLabel": "Shares repurchased (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquity", "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r14", "r15", "r168", "r169" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedTerseLabel": "Repurchase of common stock", "verboseLabel": "Amount of shares repurchased" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquity", "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r221", "r222", "r227" ], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets", "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Shareholders\u2019 equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r271" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": { "auth_ref": [ "r182", "r275" ], "lang": { "en-US": { "role": { "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).", "label": "US Government-sponsored Enterprises Debt Securities [Member]", "terseLabel": "Government-sponsored enterprise securities", "verboseLabel": "Government-sponsored enterprise securities" } } }, "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r90" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.", "label": "Unrealized Gain (Loss) on Investments", "terseLabel": "Unrealized gain (loss)" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r207" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r116", "r117", "r118", "r119", "r120", "r121", "r122" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]", "terseLabel": "Effect of potentially dilutive securities:" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleOfComputationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r105", "r111" ], "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleOfComputationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted-average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/EarningsPerShareScheduleOfComputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Shares used in per share calculations:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r104", "r111" ], "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleOfComputationDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic weighted-average common shares outstanding (in shares)", "verboseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations", "http://www.vrtx.com/role/EarningsPerShareScheduleOfComputationDetails" ], "xbrltype": "sharesItemType" }, "vrtx_AccruedShareRepurchaseLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Share Repurchase Liability", "label": "Accrued Share Repurchase Liability", "terseLabel": "Accrued share repurchase liability" } } }, "localname": "AccruedShareRepurchaseLiability", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vrtx_BusinessCombinationRemainingMilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Remaining Milestone Payment", "label": "Business Combination, Remaining Milestone Payment", "terseLabel": "Remaining milestone payment" } } }, "localname": "BusinessCombinationRemainingMilestonePayment", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CRISPRDMDDM1Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "CRISPR Therapeutics DMD/DM1 [Member]", "label": "CRISPR DMD/DM1 [Member]", "terseLabel": "CRISPR DMD/DM1" } } }, "localname": "CRISPRDMDDM1Member", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsDetails" ], "xbrltype": "domainItemType" }, "vrtx_CRISPRSaleMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of CRISPR equity securities", "label": "CRISPR Sale [Member]", "terseLabel": "CRISPR Sale [Member]" } } }, "localname": "CRISPRSaleMember", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_CRISPRTherapeuticsAGMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "CRISPR Therapeutics AG", "label": "CRISPR Therapeutics AG [Member]", "terseLabel": "CRISPR Therapeutics" } } }, "localname": "CRISPRTherapeuticsAGMember", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsDetails" ], "xbrltype": "domainItemType" }, "vrtx_CTX001CoCoAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "CTX001 Co-Co Agreement [Member]", "label": "CTX001 Co-Co Agreement [Member]", "terseLabel": "CTX001 Co-Co" } } }, "localname": "CTX001CoCoAgreementMember", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsDetails" ], "xbrltype": "domainItemType" }, "vrtx_CashAndMoneyMarketFundsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time.", "label": "Cash and Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "CashAndMoneyMarketFundsMember", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "vrtx_CollaborativeArrangementAgreementDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Listing of significant collaboration agreements.", "label": "Collaborative Arrangement Agreement [Domain]", "terseLabel": "Collaborative Arrangement Agreement [Domain]" } } }, "localname": "CollaborativeArrangementAgreementDomain", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsDetails" ], "xbrltype": "domainItemType" }, "vrtx_CollaborativeArrangementDevelopmentAndRegulatoryPotentialMilestonePaymentsMaximum": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the potential milestone amount to be paid by the entity under the collaboration agreement if drug candidates are approved and commercialized.", "label": "Collaborative Arrangement Development And Regulatory Potential Milestone Payments Maximum", "terseLabel": "Collaborative arrangement, development and regulatory potential milestone payments maximum" } } }, "localname": "CollaborativeArrangementDevelopmentAndRegulatoryPotentialMilestonePaymentsMaximum", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CollaborativeArrangementResearchandDevelopmentExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement Research and Development Expenses", "label": "Collaborative Arrangement Research and Development Expenses", "terseLabel": "Collaborative arrangement research and development expenses" } } }, "localname": "CollaborativeArrangementResearchandDevelopmentExpenses", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_CollaborativeArrangementRightToLicenseNumberOfTargets": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Right To License, Number Of Targets", "label": "Collaborative Arrangement, Right To License, Number Of Targets", "terseLabel": "Collaborative arrangement, right to exclusively license, number of targets" } } }, "localname": "CollaborativeArrangementRightToLicenseNumberOfTargets", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsDetails" ], "xbrltype": "integerItemType" }, "vrtx_CollaborativeArrangementsByAgreementAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Significant terms of collaboration arrangements, by individual agreement.", "label": "Collaborative Arrangements by Agreement [Axis]", "terseLabel": "Collaborative Arrangements by Agreement [Axis]" } } }, "localname": "CollaborativeArrangementsByAgreementAxis", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/CollaborativeArrangementsDetails" ], "xbrltype": "stringItemType" }, "vrtx_CollaborativeandRoyaltyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative and Royalty [Member]", "label": "Collaborative and Royalty [Member]", "terseLabel": "Collaborative and royalty revenues" } } }, "localname": "CollaborativeandRoyaltyMember", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "vrtx_DebtCovenantConsolidatedLeverageRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Consolidated leverage ratio that must be maintained in order to be in compliance with debt covenants.", "label": "Debt Covenant, Consolidated Leverage Ratio", "terseLabel": "Debt covenant, consolidated leverage ratio" } } }, "localname": "DebtCovenantConsolidatedLeverageRatio", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "pureItemType" }, "vrtx_DebtCovenantIncreaseInConsolidatedLeverageRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Covenant, Increase In Consolidated Leverage Ratio", "label": "Debt Covenant, Increase In Consolidated Leverage Ratio", "terseLabel": "Debt covenant, increase in consolidated leverage ratio" } } }, "localname": "DebtCovenantIncreaseInConsolidatedLeverageRatio", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "pureItemType" }, "vrtx_DebtCovenantinterestCoverageRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Covenant, interest Coverage Ratio", "label": "Debt Covenant, interest Coverage Ratio", "terseLabel": "Debt covenant, interest coverage ratio" } } }, "localname": "DebtCovenantinterestCoverageRatio", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "pureItemType" }, "vrtx_DebtandEquitySecuritiesCost": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt and Equity Securities, Cost", "label": "Debt and Equity Securities, Cost", "totalLabel": "Amortized Cost" } } }, "localname": "DebtandEquitySecuritiesCost", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DebtandEquitySecuritiesFairValue": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails": { "order": 3.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt and Equity Securities, Fair Value", "label": "Debt and Equity Securities, Fair Value", "totalLabel": "Fair Value" } } }, "localname": "DebtandEquitySecuritiesFairValue", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DebtandEquitySecuritiesUnrealizedGain": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Debt and Equity Securities, Unrealized Gain", "label": "Debt and Equity Securities, Unrealized Gain", "terseLabel": "Gross Unrealized Gains" } } }, "localname": "DebtandEquitySecuritiesUnrealizedGain", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_DebtandEquitySecuritiesUnrealizedLoss": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt and Equity Securities, Unrealized Loss", "label": "Debt and Equity Securities, Unrealized Loss", "negatedLabel": "Gross Unrealized Losses" } } }, "localname": "DebtandEquitySecuritiesUnrealizedLoss", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_EmployeeBenefitPlanPayableReceivable": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Employee Benefit Plan Payable (Receivable)", "label": "Employee Benefit Plan Payable (Receivable)", "terseLabel": "Issuances of common stock from employee benefit plans receivable" } } }, "localname": "EmployeeBenefitPlanPayableReceivable", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vrtx_ExercisePriceRangeFromDollars120.01toDollars140.0Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exercise Price Range From Dollars 120.01 to Dollars 140.0", "label": "Exercise Price Range From Dollars 120.01 to Dollars 140.0 [Member]", "verboseLabel": "$120.01\u2013$140.00" } } }, "localname": "ExercisePriceRangeFromDollars120.01toDollars140.0Member", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "vrtx_ExercisePriceRangeFromDollars140.01toDollars160.0Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exercise Price Range From Dollars 140.01 to Dollars 160.0", "label": "Exercise Price Range From Dollars 140.01 to Dollars 160.0 [Member]", "terseLabel": "$140.01\u2013$160.00" } } }, "localname": "ExercisePriceRangeFromDollars140.01toDollars160.0Member", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "vrtx_ExercisePriceRangeFromDollars160.01toDollars180.00Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exercise Price Range From Dollars 160.01 to Dollars 180.00 [Member]", "label": "Exercise Price Range From Dollars 160.01 to Dollars 180.00 [Member]", "terseLabel": "$160.01\u2013$180.00" } } }, "localname": "ExercisePriceRangeFromDollars160.01toDollars180.00Member", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "vrtx_ExercisePriceRangeFromDollars180.01toDollars189.38Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exercise Price Range From Dollars 180.01 to Dollars 189.38 [Member]", "label": "Exercise Price Range From Dollars 180.01 to Dollars 189.38 [Member]", "terseLabel": "$180.01\u2013$189.38" } } }, "localname": "ExercisePriceRangeFromDollars180.01toDollars189.38Member", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "vrtx_ExercisePriceRangeFromDollars29.07toDollars40.00Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exercise Price Range From Dollars 29.07 to Dollars 40.00 [Member]", "label": "Exercise Price Range From Dollars 29.07 to Dollars 40.00 [Member]", "terseLabel": "$29.07\u2013$40.00" } } }, "localname": "ExercisePriceRangeFromDollars29.07toDollars40.00Member", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "vrtx_ExercisePriceRangefromDollars100.01toDollars120.00Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the range of exercise prices from $100.01 to $120.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information.", "label": "Exercise Price Range from Dollars 100.01 to Dollars 120.00 [Member]", "verboseLabel": "$100.01\u2013$120.00" } } }, "localname": "ExercisePriceRangefromDollars100.01toDollars120.00Member", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "vrtx_ExercisePriceRangefromDollars40.01toDollars60.00Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the range of exercise prices from $40.01 to $60.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information.", "label": "Exercise Price Range from Dollars 40.01 to Dollars 60.00 [Member]", "verboseLabel": "$40.01\u2013$60.00" } } }, "localname": "ExercisePriceRangefromDollars40.01toDollars60.00Member", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "vrtx_ExercisePriceRangefromDollars60.01toDollars80.00Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the range of exercise prices from $60.01 to $80.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information.", "label": "Exercise Price Range from Dollars 60.01 to Dollars 80.00 [Member]", "verboseLabel": "$60.01\u2013$80.00" } } }, "localname": "ExercisePriceRangefromDollars60.01toDollars80.00Member", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "vrtx_ExercisePriceRangefromDollars80.01toDollars100.00Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the range of exercise prices from $80.01 to $100.00 per share for the purpose of disclosing shares potentially issuable under outstanding stock options, as well as other option information.", "label": "Exercise Price Range from Dollars 80.01 to Dollars 100.00 [Member]", "verboseLabel": "$80.01\u2013$100.00" } } }, "localname": "ExercisePriceRangefromDollars80.01toDollars100.00Member", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockOptionsOutstandingAndExercisableDetails" ], "xbrltype": "domainItemType" }, "vrtx_IndemnificationClaims": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of indemnification claims currently outstanding", "label": "Indemnification Claims", "terseLabel": "Indemnification claims" } } }, "localname": "IndemnificationClaims", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_KalydecoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "KALYDECO inventories, net", "label": "KALYDECO [Member]", "terseLabel": "KALYDECO" } } }, "localname": "KalydecoMember", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "vrtx_LineOfCreditFacilityAdditionalBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increased borrowing capacity available in the future.", "label": "Line Of Credit Facility Additional Borrowing Capacity", "terseLabel": "Line of credit facility additional borrowing capacity" } } }, "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_MarketableSecuritiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Marketable Securities [Member]", "label": "Marketable Securities [Member]", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesMember", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAvailableForSaleDebtSecuritiesAtFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "vrtx_ORKAMBIMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ORKAMBI [Member]", "label": "ORKAMBI [Member]", "terseLabel": "ORKAMBI" } } }, "localname": "ORKAMBIMember", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "vrtx_OtherNonU.S.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other, Non U.S. [Member]", "label": "Other, Non U.S. [Member]", "terseLabel": "Other" } } }, "localname": "OtherNonU.S.Member", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "vrtx_ProceedsFromCollaborativeFunding": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds From Collaborative Funding", "label": "Proceeds From Collaborative Funding", "terseLabel": "Advance from collaborator" } } }, "localname": "ProceedsFromCollaborativeFunding", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vrtx_ProceedsFromFinanceLeases": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds From Finance Leases", "label": "Proceeds From Finance Leases", "terseLabel": "Proceeds related to finance leases" } } }, "localname": "ProceedsFromFinanceLeases", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vrtx_RepaymentsofCollaborativeFunding": { "auth_ref": [], "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Repayments of Collaborative Funding", "label": "Repayments of Collaborative Funding", "negatedTerseLabel": "Repayments of advanced funding" } } }, "localname": "RepaymentsofCollaborativeFunding", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "vrtx_SYMDEKOSYMKEVIMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "SYMDEKO/SYMKEVI [Member]", "label": "SYMDEKO/SYMKEVI [Member]", "terseLabel": "SYMDEKO/SYMKEVI" } } }, "localname": "SYMDEKOSYMKEVIMember", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" }, "vrtx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Line Items]", "terseLabel": "Summary of cash, cash equivalents and marketable securities" } } }, "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "vrtx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of the cash and cash equivalents and available-for-sale investments held by the entity.", "label": "Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table]", "terseLabel": "Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "vrtx_ScheduleofUnrecognizedSharebasedCompensationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure as of the latest balance-sheet date presented of the total compensation cost related to outstanding, nonvested share-based compensation awards not yet recognized, net of estimated forfeitures, and the weighted average period over which those unrecognized costs are expected to be reported.", "label": "Schedule of Unrecognized Share-based Compensation Expense [Table Text Block]", "terseLabel": "Unrecognized stock-based compensation expense, net of estimated forfeitures" } } }, "localname": "ScheduleofUnrecognizedSharebasedCompensationExpenseTableTextBlock", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsTables" ], "xbrltype": "textBlockItemType" }, "vrtx_ShareBasedCompensationAllocationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "-- None. No documentation exists for this element. --", "label": "Share-based Compensation Allocation [Abstract]", "terseLabel": "Stock-based compensation expense:" } } }, "localname": "ShareBasedCompensationAllocationAbstract", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "vrtx_ShareRepurchaseProgram2018Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share Repurchase Program 2018 [Member]", "label": "Share Repurchase Program 2018 [Member]", "terseLabel": "Share Repurchase Program 2018" } } }, "localname": "ShareRepurchaseProgram2018Member", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_ShareRepurchaseProgram2019Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share Repurchase Program [Member]", "label": "Share Repurchase Program 2019 [Member]", "terseLabel": "Share Repurchase Program 2019" } } }, "localname": "ShareRepurchaseProgram2019Member", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrtx_StockRepurchaseProgramCumulativeValueOfSharesRepurchased": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Stock Repurchase Program, Cumulative Value Of Shares Repurchased", "label": "Stock Repurchase Program, Cumulative Value Of Shares Repurchased", "terseLabel": "Cumulative value of shares repurchased" } } }, "localname": "StockRepurchaseProgramCumulativeValueOfSharesRepurchased", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrtx_TRIKAFTAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "TRIKAFTA [Member]", "label": "TRIKAFTA [Member]", "terseLabel": "TRIKAFTA" } } }, "localname": "TRIKAFTAMember", "nsuri": "http://www.vrtx.com/20200331", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationOfRevenueDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r103": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1707-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r123": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=SL6284422-111562" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563" }, "r141": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117539-209714" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117546-209714" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r157": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r164": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r166": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r181": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r205": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r211": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686" }, "r228": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r249": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6)(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(2)(i))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12C(1)(a))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r307": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r308": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r309": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r311": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r312": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r313": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r314": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r315": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "i", "Publisher": "SEC", "Section": "3", "Subsection": "10" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(1)(i)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225877-175312" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" } }, "version": "2.1" } XML 16 R16.htm IDEA: XBRL DOCUMENT v3.20.1
Hedging
 3 Months Ended
Mar. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Hedging
Hedging
Foreign currency forward contracts - Designated as hedging instruments
The Company maintains a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of the Company’s forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under GAAP having contractual durations from one to eighteen months. The Company recognizes realized gains and losses for the effective portion of such contracts in “Product revenues, net” in its condensed consolidated statements of operations in the same period that it recognizes the product revenues that were impacted by the hedged foreign exchange rate changes.
The Company formally documents the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as the Company’s risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. The Company also formally assesses, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If the Company were to determine that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, the Company would discontinue hedge accounting treatment prospectively. The Company measures effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of March 31, 2020, all hedges were determined to be highly effective.
The Company considers the impact of its counterparties’ credit risk on the fair value of the foreign currency forward contracts. As of March 31, 2020 and December 31, 2019, credit risk did not change the fair value of the Company’s foreign currency forward contracts.
The following table summarizes the notional amount of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP:
 
As of March 31, 2020
 
As of December 31, 2019
Foreign Currency
(in thousands)
Euro
$
581,764

 
$
501,197

British pound sterling
124,160

 
87,032

Australian dollar
74,643

 
89,705

Canadian dollar
46,390

 
50,452

Total foreign currency forward contracts
$
826,957

 
$
728,386


Foreign currency forward contracts - Not designated as hedging instruments
The Company also enters into foreign currency forward contracts with contractual maturities of less than one month, that are designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities, including intercompany balances. These contracts are not designated as hedging instruments under GAAP. The Company recognizes realized gains and losses for such contracts in “Other (expense) income, net” in its condensed consolidated statements of operations each period. As of March 31, 2020, the notional amount of the Company’s outstanding foreign currency forward contracts where hedge accounting under GAAP is not applied was $522.2 million.
During the three months ended March 31, 2020 and 2019, the Company recognized the following related to foreign currency forward contacts in its condensed consolidated statements of operations:
 
Three Months Ended March 31,
 
2020
 
2019
 
(in thousands)
Designated as hedging instruments - Reclassified from AOCI
 
 
 
Product revenues, net
$
8,922

 
$
6,839

Not designated as hedging instruments
 
 
 
Other (expense) income, net
$
16,229

 
$
3,151

 
 
 
 
Total reported in the Condensed Consolidated Statement of Operations
 
 
 
Product revenues, net
$
1,515,107

 
$
857,253

Other (expense) income, net
$
(61,130
)
 
$
42,610


The following table summarizes the fair value of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on its condensed consolidated balance sheets:
As of March 31, 2020
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid expenses and other current assets
 
$
25,434

 
Other current liabilities
 
$
(459
)
Other assets
 
1,798

 
Other long-term liabilities
 
(637
)
Total assets
 
$
27,232

 
Total liabilities
 
$
(1,096
)
As of December 31, 2019
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid expenses and other current assets
 
$
9,725

 
Other current liabilities
 
$
(5,533
)
Other assets
 
—

 
Other long-term liabilities
 
(1,821
)
Total assets
 
$
9,725

 
Total liabilities
 
$
(7,354
)
As of March 31, 2020, the Company expects the amounts that are related to foreign exchange forward contracts designated as cash flow hedges under GAAP recorded in “Prepaid expenses and other current assets” and “Other current liabilities” to be reclassified to earnings within twelve months.
The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under GAAP on the Company’s condensed consolidated balance sheets:
 
As of March 31, 2020
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
27,232

 
$
—

 
$
27,232

 
$
(1,096
)
 
$
26,136

Total liabilities
(1,096
)
 
—

 
(1,096
)
 
1,096

 
—

 
As of December 31, 2019
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
9,725

 
$
—

 
$
9,725

 
$
(7,354
)
 
$
2,371

Total liabilities
(7,354
)
 
—

 
(7,354
)
 
7,354

 
—
XML 17 R12.htm IDEA: XBRL DOCUMENT v3.20.1
Earnings Per Share
 3 Months Ended
Mar. 31, 2020
Earnings Per Share [Abstract]  
Earnings Per Share
Earnings Per Share
Basic net income per common share is based upon the weighted-average number of common shares outstanding. Diluted net income per common share utilizing the treasury method is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive.
The following table sets forth the computation of basic and diluted net income per common share for the periods ended:
 
Three Months Ended March 31,
 
2020
 
2019
 
(in thousands, except per share amounts)
Net income
$
602,753

 
$
268,631

 
 
 
 
Basic weighted-average common shares outstanding
259,815

 
255,695

Effect of potentially dilutive securities:
 
 
 
Stock options
1,868

 
2,585

Restricted stock and restricted stock units (including PSUs)
1,801

 
1,870

Employee stock purchase program
31

 
25

Diluted weighted-average common shares outstanding
263,515

 
260,175

 
 
 
 
Basic net income per common share
$
2.32

 
$
1.05

Diluted net income per common share
$
2.29

 
$
1.03


The Company did not include the securities in the following table in the computation of the net income per common share because the effect would have been anti-dilutive during each period:
 
Three Months Ended March 31,
 
2020
 
2019
 
(in thousands)
Stock options
879

 
2,837

Unvested restricted stock and restricted stock units (including PSUs)
430

 
6
ZIP 18 0000875320-20-000019-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000875320-20-000019-xbrl.zip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`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

4 M>,*B)PP\%L988706[6RE@] L\N[L*M1MB_\O(_R>3V_VN;721N, OJ)4OCRWY[U M=C=Y;>8)X_$8X-A:%2G#J<'\0"EFM9B(AZE-R#RK7]\;]6O[T%_2HD_'#!X? MD3%-C>(*4@\\JD!PA M",>+D1/Q('2"F7<+V);1^F+'U(BUJO2>C 5-G>#P/ M+$_G@?#HT"I/L&@%3PQD7>I87=*]+PP>G_ECRIV 7]E79 $'82RG424A"**E MI.[IS(+GDRLPVQ$^5KV0_T+NG\SWHK/'W6Q1^"I>VTT4,(>]ID0)+,%@;"@7 M06D'P3M%8<#JU*?!>>#7X19UOGR[S/^=S];W-XJUA1K[ #Y[&Q%*CD M4IBH(8 S03H@KDE=XA'JYEU J9(4:ID?XS@QC5]_+)>W7W^$N;? M=LO;M GDL]_(0#&(ZC*.C%-@D#=.,\&I-T([3*<2A39"3+?-FG' NUW=CRO' MJ-(T&,Z .V>(%''#4P+>(=/H0JYZ,'9A(5F2_8"CKM*Q& M^TMU6GJJC.'&.B^D4!BLY@79",$PL1)0S9E=WFE9C;*OVFF)04;C&Q%EM!)2 M26)T02D3IE;JI W(M.JTK$3]<3@MM93@7*KSZ"SC2&&B<3%GALG$6GRUB)AV M"7MY->@T,"%=7!5B. 21JH&KP_JH5- DN6U$P!E4H6J']#]KT!VO6A2%- Y< M$AD,"0R$H @*2GKA)V(5M(:G+FO056-%_=I@^P/\S]4R_[Z7WN%N>7WF_#PY M*). N?52*1Z$3'TO!&?%S.,I,K&PUV&8ONJ(&[VE_7[X=?4M7R_3XC]\72TW MJ\A1OXSL^KJ>;Y[>^IXU$NJ\+D/"&<\M-P9)035#WA>48=@@-8T3>Q0X[9%/ MO55E6=W>YNM$GG>SK_GZ+$1??#YJQ4H:9HBT**"H$S&O"T(R)FD3 W5$58%& MA<$V&-$?R-9?5^O9-J\H#T^.RPBS,IK?�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end XML 19 R31.htm IDEA: XBRL DOCUMENT v3.20.1
Additional Cash Flow Information (Tables)
 3 Months Ended
Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Condensed Cash Flow Statement
The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in the Company’s condensed consolidated statements of cash flows consisted of the following:
 
Three Months Ended March 31,
 
2020
 
2019
 
Beginning of period
 
End of period
 
Beginning of period
 
End of period
 
(in thousands)
Cash and cash equivalents
$
3,109,322

 
$
3,593,412

 
$
2,650,134

 
$
2,893,885

Prepaid expenses and other current assets
8,004

 
8,552

 
4,910

 
6,250

Other assets
3,355

 
—

 
3,209

 
1,397

Cash, cash equivalents and restricted cash per statement of cash flows
$
3,120,681

 
$
3,601,964

 
$
2,658,253

 
$
2,901,532

XML 20 R35.htm IDEA: XBRL DOCUMENT v3.20.1
Collaborative Arrangements (Details)
 3 Months Ended
Mar. 31, 2020
USD ($)
Dec. 31, 2019
target
Mar. 31, 2019
USD ($)
CRISPR Therapeutics      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Collaborative arrangement, right to exclusively license, number of targets | target   3  
Collaborative arrangement, development and regulatory potential milestone payments maximum $ 410,000,000.0    
CTX001 Co-Co      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Collaborative arrangement research and development expenses 9,300,000   $ 7,000,000.0
CRISPR DMD/DM1      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Collaborative arrangement, development and regulatory potential milestone payments maximum 800,000,000.0    
Collaborative arrangement research and development expenses $ 25,000,000.0    
XML 21 R39.htm IDEA: XBRL DOCUMENT v3.20.1
Fair Value Measurements - Additional Information (Details) - Level 3
$ in Millions
Mar. 31, 2020
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Remaining milestone payment $ 678.3
Minimum | Discount Rate  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Contingent consideration, measurement input 0.018
Maximum | Discount Rate  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Contingent consideration, measurement input 0.031
XML 22 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 23 R28.htm IDEA: XBRL DOCUMENT v3.20.1
Hedging (Tables)
 3 Months Ended
Mar. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Cash Flow Hedging Instruments
The following table summarizes the notional amount of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP:
 
As of March 31, 2020
 
As of December 31, 2019
Foreign Currency
(in thousands)
Euro
$
581,764

 
$
501,197

British pound sterling
124,160

 
87,032

Australian dollar
74,643

 
89,705

Canadian dollar
46,390

 
50,452

Total foreign currency forward contracts
$
826,957

 
$
728,386
Schedule of Foreign Exchange Contracts, Condensed Consolidated Statements of Operations
During the three months ended March 31, 2020 and 2019, the Company recognized the following related to foreign currency forward contacts in its condensed consolidated statements of operations:
 
Three Months Ended March 31,
 
2020
 
2019
 
(in thousands)
Designated as hedging instruments - Reclassified from AOCI
 
 
 
Product revenues, net
$
8,922

 
$
6,839

Not designated as hedging instruments
 
 
 
Other (expense) income, net
$
16,229

 
$
3,151

 
 
 
 
Total reported in the Condensed Consolidated Statement of Operations
 
 
 
Product revenues, net
$
1,515,107

 
$
857,253

Other (expense) income, net
$
(61,130
)
 
$
42,610
Schedule of Foreign Exchange Contracts
The following table summarizes the fair value of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on its condensed consolidated balance sheets:
As of March 31, 2020
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid expenses and other current assets
 
$
25,434

 
Other current liabilities
 
$
(459
)
Other assets
 
1,798

 
Other long-term liabilities
 
(637
)
Total assets
 
$
27,232

 
Total liabilities
 
$
(1,096
)
As of December 31, 2019
Assets
 
Liabilities
Classification
 
Fair Value
 
Classification
 
Fair Value
(in thousands)
Prepaid expenses and other current assets
 
$
9,725

 
Other current liabilities
 
$
(5,533
)
Other assets
 
—

 
Other long-term liabilities
 
(1,821
)
Total assets
 
$
9,725

 
Total liabilities
 
$
(7,354
)
Offsetting liabilities
The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under GAAP on the Company’s condensed consolidated balance sheets:
 
As of March 31, 2020
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
27,232

 
$
—

 
$
27,232

 
$
(1,096
)
 
$
26,136

Total liabilities
(1,096
)
 
—

 
(1,096
)
 
1,096

 
—

 
As of December 31, 2019
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
9,725

 
$
—

 
$
9,725

 
$
(7,354
)
 
$
2,371

Total liabilities
(7,354
)
 
—

 
(7,354
)
 
7,354

 
—
Offsetting assets
The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under GAAP on the Company’s condensed consolidated balance sheets:
 
As of March 31, 2020
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
27,232

 
$
—

 
$
27,232

 
$
(1,096
)
 
$
26,136

Total liabilities
(1,096
)
 
—

 
(1,096
)
 
1,096

 
—

 
As of December 31, 2019
 
Gross Amounts Recognized
 
Gross Amounts Offset
 
Gross Amounts Presented
 
Gross Amounts Not Offset
 
Legal Offset
Foreign currency forward contracts
(in thousands)
Total assets
$
9,725

 
$
—

 
$
9,725

 
$
(7,354
)
 
$
2,371

Total liabilities
(7,354
)
 
—

 
(7,354
)
 
7,354

 
—
XML 24 R24.htm IDEA: XBRL DOCUMENT v3.20.1
Earnings Per Share (Tables)
 3 Months Ended
Mar. 31, 2020
Earnings Per Share [Abstract]  
Schedule of earnings per share, basic and diluted
The following table sets forth the computation of basic and diluted net income per common share for the periods ended:
 
Three Months Ended March 31,
 
2020
 
2019
 
(in thousands, except per share amounts)
Net income
$
602,753

 
$
268,631

 
 
 
 
Basic weighted-average common shares outstanding
259,815

 
255,695

Effect of potentially dilutive securities:
 
 
 
Stock options
1,868

 
2,585

Restricted stock and restricted stock units (including PSUs)
1,801

 
1,870

Employee stock purchase program
31

 
25

Diluted weighted-average common shares outstanding
263,515

 
260,175

 
 
 
 
Basic net income per common share
$
2.32

 
$
1.05

Diluted net income per common share
$
2.29

 
$
1.03
Potential gross common equivalent shares
The Company did not include the securities in the following table in the computation of the net income per common share because the effect would have been anti-dilutive during each period:
 
Three Months Ended March 31,
 
2020
 
2019
 
(in thousands)
Stock options
879

 
2,837

Unvested restricted stock and restricted stock units (including PSUs)
430

 
6
XML 25 R20.htm IDEA: XBRL DOCUMENT v3.20.1
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Commitments and Contingencies
Revolving Credit Facility
In September 2019, the Company and certain of its subsidiaries entered into a Credit Agreement (the “2019 Credit Agreement”) with Bank of America, N.A., as administrative agent and the lenders referred to therein. The 2019 Credit Agreement provides for a $500.0 million unsecured revolving facility, which was not drawn upon at closing. Amounts drawn pursuant to the 2019 Credit Agreement, if any, may be used to finance the Company’s working capital needs, and for general corporate or other lawful purposes. The Company had no borrowings outstanding under the 2019 Credit Agreement as of March 31, 2020 and December 31, 2019. The 2019 Credit Agreement also provides that, subject to satisfaction of certain conditions, the Company may request that the borrowing capacity under the 2019 Credit Agreement be increased by an additional $500.0 million. The 2019 Credit Agreement, which matures on September 17, 2024, supersedes the Company’s credit agreement entered into in 2016 with Bank of America, N.A serving in the same capacity. Additionally, the 2019 Credit Agreement provides a sublimit of $50.0 million for letters of credit.
Direct costs related to the 2019 Credit Agreement, which were not material to the Company’s financial statements, were deferred and will be recorded over the term of the 2019 Credit Agreement.
Any amounts borrowed under the 2019 Credit Agreement will bear interest, at the Company’s option, at either a base rate or a Eurocurrency rate, in each case plus an applicable margin. Under the 2019 Credit Agreement, the applicable margins on base rate loans range from 0.125% to 0.50% and the applicable margins on Eurocurrency loans range from 1.125% to 1.50%, in each case based on the Company’s consolidated leverage ratio (the ratio of the Company’s total consolidated funded indebtedness to the Company’s consolidated EBITDA for the most recently completed four fiscal quarter period).
Any amounts borrowed pursuant to the 2019 Credit Agreement are guaranteed by certain of the Company’s existing and future domestic subsidiaries, subject to certain exceptions.
The 2019 Credit Agreement contains customary representations and warranties and affirmative and negative covenants, including financial covenants to maintain (i) subject to certain limited exceptions, a consolidated leverage ratio of 3.50 to 1.00, subject to an increase to 4.00 to 1.00 following a material acquisition and (ii) a consolidated interest coverage ratio (the ratio of the Company’s consolidated EBITDA to its consolidated interest expenses for the most recently completed four fiscal quarter period) of 2.50 to 1.00, in each case measured on a quarterly basis. The 2019 Credit Agreement also contains customary events of default. In the case of a continuing event of default, the administrative agent would be entitled to exercise various remedies, including the acceleration of amounts due under outstanding loans. As of March 31, 2020, the Company was in compliance with the covenants described above.
Guaranties and Indemnifications
As permitted under Massachusetts law, the Company’s Articles of Organization and By-laws provide that the Company will indemnify certain of its officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that the Company could be required to make under these indemnification provisions is unlimited. However, the Company has purchased directors’ and officers’ liability insurance policies that could reduce its monetary exposure and enable it to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and the Company believes the estimated fair value of these indemnification arrangements is minimal.
The Company customarily agrees in the ordinary course of its business to indemnification provisions in agreements with clinical trial investigators and sites in its drug development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for the Company and its real estate leases. The Company also customarily agrees to certain indemnification provisions in its drug discovery, development and commercialization collaboration agreements. With respect to the Company’s clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of the Company’s contractual obligations arising out of the research or clinical testing of the Company’s compounds or drug candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by the Company, to violations of law by the Company or to certain breaches of the Company’s contractual obligations. The indemnification provisions appearing in the Company’s collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for its collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although the Company believes the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that the Company could be required to make under these provisions is generally unlimited. The Company has purchased insurance policies covering personal injury, property damage and general liability that reduce its exposure for indemnification and would enable it in many cases to recover all or a portion of any future amounts paid. The Company has never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, the Company believes the estimated fair value of these indemnification arrangements is minimal.
Other Contingencies
The Company has certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a reserve for contingent liabilities when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. There were no material contingent liabilities accrued as of March 31, 2020 or December 31, 2019.
XML 26 R41.htm IDEA: XBRL DOCUMENT v3.20.1
Marketable Securities and Equity Investments - Additional Information (Details) - USD ($)
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Summary of cash, cash equivalents and marketable securities      
Cash $ 1,800,000,000   $ 2,300,000,000
Other-than-temporary declines in fair value of available-for-sale debt securities 0 $ 0  
Fair value 165,178,000   282,084,000
Unrealized gain (loss) (39,400,000) $ 43,600,000  
Equity Securities, Cost Basis 87,096,000   113,829,000
Other assets      
Summary of cash, cash equivalents and marketable securities      
Equity securities without readily determinable fair value, amount 46,600,000    
Corporate equity securities      
Summary of cash, cash equivalents and marketable securities      
Fair value 165,200,000   $ 282,100,000
CRISPR Sale [Member]      
Summary of cash, cash equivalents and marketable securities      
Proceeds from Sale and Maturity of Marketable Securities 72,000,000.0    
Equity Securities, Cost Basis $ 26,700,000    
XML 27 R45.htm IDEA: XBRL DOCUMENT v3.20.1
Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance $ 6,085,244 $ 4,435,203
Other comprehensive (loss) income before reclassifications 22,346 10,689
Amounts reclassified from accumulated other comprehensive income (loss) (6,990) (5,348)
Total changes in other comprehensive income 15,356 5,341
Ending Balance 6,461,654 4,723,313
Foreign Currency Translation Adjustment    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (895) (11,227)
Other comprehensive (loss) income before reclassifications (2,662) 4,967
Amounts reclassified from accumulated other comprehensive income (loss) 0 0
Total changes in other comprehensive income (2,662) 4,967
Ending Balance (3,557) (6,260)
On Available-For-Sale Debt Securities    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance 503 (536)
Other comprehensive (loss) income before reclassifications (764) 596
Amounts reclassified from accumulated other comprehensive income (loss) 0 0
Total changes in other comprehensive income (764) 596
Ending Balance (261) 60
On Foreign Currency Forward Contracts    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (1,581) 12,422
Other comprehensive (loss) income before reclassifications 25,772 5,126
Amounts reclassified from accumulated other comprehensive income (loss) (6,990) (5,348)
Total changes in other comprehensive income 18,782 (222)
Ending Balance 17,201 12,200
Total    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (1,973) 659
Total changes in other comprehensive income 15,356 5,341
Ending Balance $ 13,383 $ 6,000
XML 28 R49.htm IDEA: XBRL DOCUMENT v3.20.1
Hedging - Derivative Fair Value (Details) - Designated as hedging instruments - Foreign currency forward contracts - Cash flow hedging - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Derivative [Line Items]    
Total assets $ 27,232 $ 9,725
Total liabilities (1,096) (7,354)
Prepaid expenses and other current assets    
Derivative [Line Items]    
Total assets 25,434 9,725
Other current liabilities    
Derivative [Line Items]    
Total liabilities (459) (5,533)
Other assets    
Derivative [Line Items]    
Total assets 1,798 0
Other long-term liabilities    
Derivative [Line Items]    
Total liabilities $ (637) $ (1,821)
XML 29 R4.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]    
Unrealized (losses) gains on foreign currency forward contracts, tax $ (5.0) $ 1.5
XML 30 R8.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Cash flows from operating activities:    
Net income $ 602,753 $ 268,631
Adjustments to reconcile net income to net cash provided by operating activities:    
Stock-based compensation expense 115,706 93,791
Depreciation expense 26,821 27,140
Increase in fair value of contingent consideration 1,600 0
Deferred income taxes 36,705 43,425
Losses (gains) on equity securities 44,870 (43,551)
Other non-cash items, net 9,668 (2,431)
Changes in operating assets and liabilities:    
Accounts receivable, net (223,672) (30,136)
Inventories (27,450) (13,139)
Prepaid expenses and other assets 2,790 7,941
Accounts payable 14,285 (24,145)
Accrued expenses 153,814 (27,279)
Other liabilities 57,808 24,537
Net cash provided by operating activities 815,698 324,784
Cash flows from investing activities:    
Purchases of available-for-sale debt securities (75,265) (128,215)
Maturities of available-for-sale debt securities 60,145 107,118
Sale of equity securities 72,036 0
Expenditures for property and equipment (19,450) (18,041)
Investment in equity securities (5,800) 0
Net cash provided by (used in) investing activities 31,666 (39,138)
Cash flows from financing activities:    
Issuances of common stock under benefit plans 79,597 63,620
Repurchases of common stock (300,026) (94,007)
Payments in connection with common stock withheld for employee tax obligations (136,167) (5,832)
Payments on finance leases (10,287) (9,385)
Proceeds related to finance leases 5,833 0
Advance from collaborator 2,500 5,000
Repayments of advanced funding (880) (1,385)
Net cash used in financing activities (359,430) (41,989)
Effect of changes in exchange rates on cash (6,651) (378)
Net increase in cash and cash equivalents 481,283 243,279
Cash, cash equivalents and restricted cash—beginning of period 3,120,681 2,658,253
Cash, cash equivalents and restricted cash—end of period 3,601,964 2,901,532
Supplemental disclosure of cash flow information:    
Cash paid for interest 13,771 13,148
Cash paid for income taxes 5,845 1,835
Issuances of common stock from employee benefit plans receivable 817 510
Accrued share repurchase liability $ 0 $ 4,000
XML 31 R25.htm IDEA: XBRL DOCUMENT v3.20.1
Fair Value Measurements (Tables)
 3 Months Ended
Mar. 31, 2020
Fair Value Disclosures [Abstract]  
Financial assets subject to fair value measurements (excluding VIE cash and cash equivalents, which are recorded as Restricted cash and cash equivalents (VIE))
The following tables set forth the Company’s financial assets and liabilities subject to fair value measurements (and does not include $1.8 billion and $2.3 billion of cash as of March 31, 2020 and December 31, 2019, respectively):
 
Fair Value Measurements as of March 31, 2020
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial instruments carried at fair value (asset positions):
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
1,736,913

 
$
1,736,913

 
$
—

 
$
—

Commercial paper
30,700

 
—

 
30,700

 
—

Marketable securities:
 
 
 
 
 
 
 
Corporate equity securities
165,178

 
145,465

 
19,713

 
—

Government-sponsored enterprise securities
7,791

 
7,791

 
—

 
—

Corporate debt securities
305,051

 
—

 
305,051

 
—

Commercial paper
118,964

 
—

 
118,964

 
—

Prepaid expenses and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
25,434

 
—

 
25,434

 
—

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
1,798

 
—

 
1,798

 
—

Total financial assets
$
2,391,829


$
1,890,169

 
$
501,660

 
$
—

Financial instruments carried at fair value (liability positions):
 
 
 
 
 
 
 
Other current liabilities:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(459
)
 
$
—

 
$
(459
)
 
$
—

Long-term contingent consideration
(178,100
)
 
—

 
—

 
(178,100
)
Other long-term liabilities:
 
 
 
 
 
 
 
Foreign currency forward contracts
(637
)
 
—

 
(637
)
 
—

Total financial liabilities
$
(179,196
)
 
$
—

 
$
(1,096
)
 
$
(178,100
)

 
Fair Value Measurements as of December 31, 2019
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial instruments carried at fair value (asset positions):
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
791,039

 
$
791,039

 
$
—

 
$
—

Corporate debt securities
6,070

 
—

 
6,070

 
—

Commercial paper
29,472

 
—

 
29,472

 
—

Marketable securities:
 
 
 
 
 
 
 
Corporate equity securities
282,084

 
261,797

 
20,287

 
—

Government-sponsored enterprise securities
12,733

 
12,733

 
—

 
—

Corporate debt securities
301,799

 
—

 
301,799

 
—

Commercial paper
102,356

 
—

 
102,356

 
—

Prepaid expenses and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
9,725

 
—

 
9,725

 
—

Total financial assets
$
1,535,278

 
$
1,065,569

 
$
469,709

 
$
—

Financial instruments carried at fair value (liability positions):
 
 
 
 
 
 
 
Other current liabilities:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(5,533
)
 
$
—

 
$
(5,533
)
 
$
—

Long-term contingent consideration
(176,500
)
 
—

 
—

 
(176,500
)
Other long-term liabilities:
 
 
 
 
 
 
 
Foreign currency forward contracts
(1,821
)
 
—

 
(1,821
)
 
—

Total financial liabilities
$
(183,854
)
 
$
—

 
$
(7,354
)
 
$
(176,500
)
Schedule of fair value of our contingent consideration liabilities
The following table represents a rollforward of the fair value of the Company’s contingent consideration liabilities:
 
Three Months Ended March 31, 2020
 
(in thousands)
Balance at December 31, 2019
$
176,500

Increase in fair value of contingent payments
1,600

Balance at March 31, 2020
$
178,100
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.20.1
Additional Cash Flow Information
 3 Months Ended
Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Additional Cash Flow Information
Additional Cash Flow Information
The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in the Company’s condensed consolidated statements of cash flows consisted of the following:
 
Three Months Ended March 31,
 
2020
 
2019
 
Beginning of period
 
End of period
 
Beginning of period
 
End of period
 
(in thousands)
Cash and cash equivalents
$
3,109,322

 
$
3,593,412

 
$
2,650,134

 
$
2,893,885

Prepaid expenses and other current assets
8,004

 
8,552

 
4,910

 
6,250

Other assets
3,355

 
—

 
3,209

 
1,397

Cash, cash equivalents and restricted cash per statement of cash flows
$
3,120,681

 
$
3,601,964

 
$
2,658,253

 
$
2,901,532
XML 33 R29.htm IDEA: XBRL DOCUMENT v3.20.1
Inventories (Tables)
 3 Months Ended
Mar. 31, 2020
Inventory Disclosure [Abstract]  
Schedule of Inventories by Type
Inventories consisted of the following:
 
As of March 31, 2020
 
As of December 31, 2019
 
(in thousands)
Raw materials
$
24,835

 
$
26,247

Work-in-process
117,427

 
107,021

Finished goods
44,825

 
34,234

Total
$
187,087

 
$
167,502
XML 34 R48.htm IDEA: XBRL DOCUMENT v3.20.1
Hedging - Cash Flow Hedging Instruments (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]    
Revenues $ 1,515,107 $ 858,435
Other (expense) income (61,130) 42,610
On Foreign Currency Forward Contracts | Reclassification out of Accumulated Other Comprehensive Income | Foreign currency forward contracts | Not designated as hedging instruments    
Derivative Instruments, Gain (Loss) [Line Items]    
Other (expense) income 16,229 3,151
Product revenues, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Revenues 1,515,107 857,253
Product revenues, net | On Foreign Currency Forward Contracts | Reclassification out of Accumulated Other Comprehensive Income | Foreign currency forward contracts | Designated as hedging instruments    
Derivative Instruments, Gain (Loss) [Line Items]    
Revenues $ 8,922 $ 6,839
XML 35 R40.htm IDEA: XBRL DOCUMENT v3.20.1
Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Balance at December 31, 2019 $ 176,500  
Increase in fair value of contingent payments 1,600 $ 0
Balance at March 31, 2020 $ 178,100  
XML 36 R44.htm IDEA: XBRL DOCUMENT v3.20.1
Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Investments, Debt and Equity Securities [Abstract]    
Matures within one year $ 2,157,586 $ 1,137,942
Matures after one year through five years 41,833 105,527
Total $ 2,199,419 $ 1,243,469
XML 37 R9.htm IDEA: XBRL DOCUMENT v3.20.1
Basis of Presentation and Accounting Policies
 3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Basis of Presentation and Accounting Policies
Basis of Presentation and Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex” or the “Company”) in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
The condensed consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. The Company operates in one segment, pharmaceuticals. The Company has reclassified certain items from the prior year’s condensed consolidated financial statements to conform to the current year’s presentation.
Certain information and footnote disclosures normally included in the Company’s 2019 Annual Report on Form 10-K have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended March 31, 2020 and 2019.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2019, which are contained in the Company’s 2019 Annual Report on Form 10-K.
Use of Estimates
The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with (i) determining the transaction price of revenues and (ii) accounting for intangible assets and contingent consideration. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
Recently Adopted Accounting Standards
Leases
On January 1, 2019, the Company adopted Accounting Standards Codification (“ASC”) 842, Leases (“ASC 842”) using the modified-retrospective method, which amended a number of aspects of lease accounting and required the Company to recognize right-of-use assets and liabilities on the balance sheet. As of January 1, 2019, the Company recorded a cumulative effect adjustment to increase its “Accumulated deficit” by $40.3 million, which related to its leases that were accounted for as build-to-suit leases under the previous accounting guidance.
Internal-Use Software
In 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (“ASU 2018-15”), which clarifies the accounting for implementation costs in cloud computing arrangements.  ASU 2018-15 became effective on January 1, 2020. The adoption of ASU 2018-15 resulted in an insignificant amount of additional assets recorded on the Company’s condensed consolidated balance sheet.
Fair Value Measurement
In 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which modifies the disclosure requirements for fair
value measurements. ASU 2018-13 became effective on January 1, 2020. The adoption of ASU 2018-13 resulted in additional disclosures related to the Company’s Level 3 inputs. Please refer to Note E, “Fair Value Measurements,” for further information.
Credit Losses
In 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 became effective on January 1, 2020. The adoption of ASU 2016-13 did not have a significant impact on its condensed consolidated financial statements.
Recently Issued Accounting Standards
Income Taxes
In 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) (“ASU 2019-12”), which simplifies the accounting for income taxes. ASU 2019-12 is effective on January 1, 2021. The Company is evaluating the impact the adoption of ASU 2019-12 may have on its condensed consolidated financial statements.
For a discussion of other recent accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies,” in the Company’s 2019 Annual Report on Form 10-K.
Summary of Significant Accounting Policies
The Company’s significant accounting policies are described in Note A, “Nature of Business and Accounting Policies,” in its 2019 Annual Report on Form 10-K.
XML 38 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Cover Page - shares
 3 Months Ended
Mar. 31, 2020
Apr. 24, 2020
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2020  
Document Transition Report false  
Entity File Number 000-19319  
Entity Registrant Name VERTEX PHARMACEUTICALS INC / MA  
Entity Incorporation, State or Country Code MA  
Entity Tax Identification Number 04-3039129  
Entity Address, Address Line One 50 Northern Avenue  
Entity Address, City or Town Boston  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02210  
City Area Code 617  
Local Phone Number 341-6100  
Title of 12(b) Security Common Stock, $0.01 Par Value Per Share  
Trading Symbol VRTX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   259,276,709
Entity Central Index Key 0000875320  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q1  
Amendment Flag false  
XML 39 R5.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 3,593,412 $ 3,109,322
Marketable securities 596,984 698,972
Accounts receivable, net 845,269 633,518
Inventories 187,087 167,502
Prepaid expenses and other current assets 223,648 213,515
Total current assets 5,446,400 4,822,829
Property and equipment, net 736,303 745,080
Goodwill 1,002,158 1,002,158
Intangible assets 400,000 400,000
Deferred tax assets 1,147,705 1,190,815
Other assets 160,635 157,583
Total assets 8,893,201 8,318,465
Current liabilities:    
Accounts payable 100,703 87,610
Accrued expenses 1,258,271 1,116,912
Other current liabilities 179,776 130,305
Total current liabilities 1,538,750 1,334,827
Long-term finance lease liabilities 532,952 538,576
Long-term contingent consideration 178,100 176,500
Other long-term liabilities 181,745 183,318
Total liabilities 2,431,547 2,233,221
Commitments and contingencies 0 0
Shareholders’ equity:    
Preferred stock, $0.01 par value; 1,000 shares authorized; none issued and outstanding 0 0
Common stock, $0.01 par value; 500,000 shares authorized, 259,079 and 258,993 shares issued and outstanding, respectively 2,591 2,589
Additional paid-in capital 7,695,905 7,937,606
Accumulated other comprehensive income (loss) 13,383 (1,973)
Accumulated deficit (1,250,225) (1,852,978)
Total shareholders’ equity 6,461,654 6,085,244
Total liabilities and shareholders’ equity $ 8,893,201 $ 8,318,465
XML 40 R55.htm IDEA: XBRL DOCUMENT v3.20.1
Income Taxes (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Income Tax Disclosure [Abstract]      
Provision for income taxes $ 54,781 $ 51,534  
Deferred tax assets, valuation allowance     $ 205,200
Unrecognized tax benefits $ 43,000   $ 33,900
XML 41 R51.htm IDEA: XBRL DOCUMENT v3.20.1
Inventories (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Inventory Disclosure [Abstract]    
Raw materials $ 24,835 $ 26,247
Work-in-process 117,427 107,021
Finished goods 44,825 34,234
Total Inventories $ 187,087 $ 167,502
XML 42 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 232 311 1 false 78 0 false 6 false false R1.htm 0001000 - Document - Cover Page Sheet http://www.vrtx.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 2 false false R3.htm 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 3 false false R4.htm 1002001 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical) Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical Condensed Consolidated Statements of Comprehensive Income (Parenthetical) Statements 4 false false R5.htm 1003000 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 5 false false R6.htm 1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 6 false false R7.htm 1004000 - Statement - Condensed Consolidated Statements of Shareholders' Equity Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsOfShareholdersEquity Condensed Consolidated Statements of Shareholders' Equity Statements 7 false false R8.htm 1006000 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 8 false false R9.htm 2101100 - Disclosure - Basis of Presentation and Accounting Policies Sheet http://www.vrtx.com/role/BasisOfPresentationAndAccountingPolicies Basis of Presentation and Accounting Policies Notes 9 false false R10.htm 2102100 - Disclosure - Revenue Recognition Sheet http://www.vrtx.com/role/RevenueRecognition Revenue Recognition Notes 10 false false R11.htm 2103100 - Disclosure - Collaborative Arrangements Sheet http://www.vrtx.com/role/CollaborativeArrangements Collaborative Arrangements Notes 11 false false R12.htm 2104100 - Disclosure - Earnings Per Share Sheet http://www.vrtx.com/role/EarningsPerShare Earnings Per Share Notes 12 false false R13.htm 2105100 - Disclosure - Fair Value Measurements Sheet http://www.vrtx.com/role/FairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 2106100 - Disclosure - Marketable Securities and Equity Investments Sheet http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestments Marketable Securities and Equity Investments Notes 14 false false R15.htm 2107100 - Disclosure - Accumulated Other Comprehensive Income (Loss) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss Accumulated Other Comprehensive Income (Loss) Notes 15 false false R16.htm 2108100 - Disclosure - Hedging Sheet http://www.vrtx.com/role/Hedging Hedging Notes 16 false false R17.htm 2109100 - Disclosure - Inventories Sheet http://www.vrtx.com/role/Inventories Inventories Notes 17 false false R18.htm 2112100 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs Sheet http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchasePrograms Stock-based Compensation Expense and Share Repurchase Programs Notes 18 false false R19.htm 2113100 - Disclosure - Income Taxes Sheet http://www.vrtx.com/role/IncomeTaxes Income Taxes Notes 19 false false R20.htm 2114100 - Disclosure - Commitments and Contingencies Sheet http://www.vrtx.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 20 false false R21.htm 2115100 - Disclosure - Additional Cash Flow Information Sheet http://www.vrtx.com/role/AdditionalCashFlowInformation Additional Cash Flow Information Notes 21 false false R22.htm 2201201 - Disclosure - Basis of Presentation and Accounting Policies (Policies) Sheet http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesPolicies Basis of Presentation and Accounting Policies (Policies) Policies http://www.vrtx.com/role/BasisOfPresentationAndAccountingPolicies 22 false false R23.htm 2302301 - Disclosure - Revenue Recognition (Tables) Sheet http://www.vrtx.com/role/RevenueRecognitionTables Revenue Recognition (Tables) Tables http://www.vrtx.com/role/RevenueRecognition 23 false false R24.htm 2304301 - Disclosure - Earnings Per Share (Tables) Sheet http://www.vrtx.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.vrtx.com/role/EarningsPerShare 24 false false R25.htm 2305301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.vrtx.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.vrtx.com/role/FairValueMeasurements 25 false false R26.htm 2306301 - Disclosure - Marketable Securities and Equity Investments (Tables) Sheet http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsTables Marketable Securities and Equity Investments (Tables) Tables http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestments 26 false false R27.htm 2307301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss 27 false false R28.htm 2308301 - Disclosure - Hedging (Tables) Sheet http://www.vrtx.com/role/HedgingTables Hedging (Tables) Tables http://www.vrtx.com/role/Hedging 28 false false R29.htm 2309301 - Disclosure - Inventories (Tables) Sheet http://www.vrtx.com/role/InventoriesTables Inventories (Tables) Tables http://www.vrtx.com/role/Inventories 29 false false R30.htm 2312301 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs (Tables) Sheet http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsTables Stock-based Compensation Expense and Share Repurchase Programs (Tables) Tables http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchasePrograms 30 false false R31.htm 2315301 - Disclosure - Additional Cash Flow Information (Tables) Sheet http://www.vrtx.com/role/AdditionalCashFlowInformationTables Additional Cash Flow Information (Tables) Tables http://www.vrtx.com/role/AdditionalCashFlowInformation 31 false false R32.htm 2401402 - Disclosure - Basis of Presentation and Accounting Policies (Details) Sheet http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesDetails Basis of Presentation and Accounting Policies (Details) Details http://www.vrtx.com/role/BasisOfPresentationAndAccountingPoliciesPolicies 32 false false R33.htm 2402402 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details) Sheet http://www.vrtx.com/role/RevenueRecognitionDisaggregationOfRevenueDetails Revenue Recognition - Disaggregation of Revenue (Details) Details 33 false false R34.htm 2402403 - Disclosure - Revenue Recognition - Narrative (Details) Sheet http://www.vrtx.com/role/RevenueRecognitionNarrativeDetails Revenue Recognition - Narrative (Details) Details 34 false false R35.htm 2403401 - Disclosure - Collaborative Arrangements (Details) Sheet http://www.vrtx.com/role/CollaborativeArrangementsDetails Collaborative Arrangements (Details) Details http://www.vrtx.com/role/CollaborativeArrangements 35 false false R36.htm 2404402 - Disclosure - Earnings Per Share - Schedule of Computation (Details) Sheet http://www.vrtx.com/role/EarningsPerShareScheduleOfComputationDetails Earnings Per Share - Schedule of Computation (Details) Details 36 false false R37.htm 2404403 - Disclosure - Earnings Per Share - Anti-dilutive Securities (Details) Sheet http://www.vrtx.com/role/EarningsPerShareAntiDilutiveSecuritiesDetails Earnings Per Share - Anti-dilutive Securities (Details) Details 37 false false R38.htm 2405402 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsAndLiabilitiesSubjectToFairValueMeasurementsDetails Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) Details 38 false false R39.htm 2405403 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 39 false false R40.htm 2405404 - Disclosure - Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsFairValueOfContingentConsiderationLiabilitiesDetails Fair Value Measurements - Fair Value of Contingent Consideration Liabilities (Details) Details 40 false false R41.htm 2406402 - Disclosure - Marketable Securities and Equity Investments - Additional Information (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAdditionalInformationDetails Marketable Securities and Equity Investments - Additional Information (Details) Details 41 false false R42.htm 2406403 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsSummaryOfCashEquivalentsAndMarketableSecuritiesDetails Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) Details 42 false false R43.htm 2406404 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAvailableForSaleDebtSecuritiesAtFairValueDetails Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) Details 43 false false R44.htm 2406405 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesAndEquityInvestmentsAvailableForSaleDebtSecuritiesByContractualMaturityDetails Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) Details 44 false false R45.htm 2407402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails Accumulated Other Comprehensive Income (Loss) (Details) Details http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables 45 false false R46.htm 2408402 - Disclosure - Hedging - Narrative (Details) Sheet http://www.vrtx.com/role/HedgingNarrativeDetails Hedging - Narrative (Details) Details 46 false false R47.htm 2408403 - Disclosure - Hedging - Notional Amount (Details) Sheet http://www.vrtx.com/role/HedgingNotionalAmountDetails Hedging - Notional Amount (Details) Details 47 false false R48.htm 2408404 - Disclosure - Hedging - Cash Flow Hedging Instruments (Details) Sheet http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails Hedging - Cash Flow Hedging Instruments (Details) Details 48 false false R49.htm 2408405 - Disclosure - Hedging - Derivative Fair Value (Details) Sheet http://www.vrtx.com/role/HedgingDerivativeFairValueDetails Hedging - Derivative Fair Value (Details) Details 49 false false R50.htm 2408406 - Disclosure - Hedging - Offsetting Derivatives (Details) Sheet http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails Hedging - Offsetting Derivatives (Details) Details 50 false false R51.htm 2409402 - Disclosure - Inventories (Details) Sheet http://www.vrtx.com/role/InventoriesDetails Inventories (Details) Details http://www.vrtx.com/role/InventoriesTables 51 false false R52.htm 2412402 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details) Sheet http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockBasedCompensationExpenseDetails Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details) Details 52 false false R53.htm 2412403 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Stock Options Outstanding and Exercisable (Details) Sheet http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsStockOptionsOutstandingAndExercisableDetails Stock-based Compensation Expense and Share Repurchase Programs - Stock Options Outstanding and Exercisable (Details) Details 53 false false R54.htm 2412404 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details) Sheet http://www.vrtx.com/role/StockBasedCompensationExpenseAndShareRepurchaseProgramsAdditionalInformationDetails Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details) Details 54 false false R55.htm 2413401 - Disclosure - Income Taxes (Details) Sheet http://www.vrtx.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.vrtx.com/role/IncomeTaxes 55 false false R56.htm 2414401 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.vrtx.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.vrtx.com/role/CommitmentsAndContingencies 56 false false R57.htm 2415402 - Disclosure - Additional Cash Flow Information (Details) Sheet http://www.vrtx.com/role/AdditionalCashFlowInformationDetails Additional Cash Flow Information (Details) Details http://www.vrtx.com/role/AdditionalCashFlowInformationTables 57 false false All Reports Book All Reports a2020q110-q.htm a2020q110-qexhibit311.htm a2020q110-qexhibit312.htm a2020q110-qexhibit32.htm a2020q110-qexhibit321.htm vrtx-20200331.xsd vrtx-20200331_cal.xml vrtx-20200331_def.xml vrtx-20200331_lab.xml vrtx-20200331_pre.xml chart-46ee851a54315f11b13.jpg chart-c6f6127e7bb55486951.jpg http://xbrl.sec.gov/currency/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true XML 43 R17.htm IDEA: XBRL DOCUMENT v3.20.1
Inventories
 3 Months Ended
Mar. 31, 2020
Inventory Disclosure [Abstract]  
Inventories
Inventories
Inventories consisted of the following:
 
As of March 31, 2020
 
As of December 31, 2019
 
(in thousands)
Raw materials
$
24,835

 
$
26,247

Work-in-process
117,427

 
107,021

Finished goods
44,825

 
34,234

Total
$
187,087

 
$
167,502
XML 44 R13.htm IDEA: XBRL DOCUMENT v3.20.1
Fair Value Measurements
 3 Months Ended
Mar. 31, 2020
Fair Value Disclosures [Abstract]  
Fair Value Measurements
Fair Value Measurements
The fair value of the Company’s financial assets and liabilities reflects the Company’s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market
participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:
Level 1:
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable inputs based on the Company’s assessment of the assumptions that market participants would use in pricing the asset or liability.
The Company’s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit quality standards outlined in the Company’s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument. The Company maintains strategic investments separately from the investment policy that governs its other cash, cash equivalents and marketable securities as described in “Note F, “Marketable Securities and Equity Investments.” As of March 31, 2020, the Company’s investments were in money market funds, corporate debt securities, commercial paper, government-sponsored enterprise securities and corporate equity securities. Additionally, the Company utilizes foreign currency forward contracts intended to mitigate the effect of changes in foreign exchange rates on its condensed consolidated statement of operations.
As of March 31, 2020, the Company’s financial assets and liabilities that were subject to fair value measurements were valued using both observable and unobservable inputs. The Company’s financial assets valued based on Level 1 inputs consisted of money market funds, government-sponsored enterprise securities and corporate equity securities. The Company’s financial assets and liabilities valued based on Level 2 inputs consisted of certain corporate equity securities as described below, corporate debt securities, commercial paper, which consisted of investments in highly-rated investment-grade corporations, and foreign currency forward contracts with reputable and creditworthy counterparties. As discussed further below, the Company’s financial liabilities valued based on Level 3 inputs consisted of acquisition-related contingent milestones. During the three months ended March 31, 2020 and 2019, the Company did not record any other-than-temporary impairment charges related to its financial assets.
The following tables set forth the Company’s financial assets and liabilities subject to fair value measurements (and does not include $1.8 billion and $2.3 billion of cash as of March 31, 2020 and December 31, 2019, respectively):
 
Fair Value Measurements as of March 31, 2020
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial instruments carried at fair value (asset positions):
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
1,736,913

 
$
1,736,913

 
$
—

 
$
—

Commercial paper
30,700

 
—

 
30,700

 
—

Marketable securities:
 
 
 
 
 
 
 
Corporate equity securities
165,178

 
145,465

 
19,713

 
—

Government-sponsored enterprise securities
7,791

 
7,791

 
—

 
—

Corporate debt securities
305,051

 
—

 
305,051

 
—

Commercial paper
118,964

 
—

 
118,964

 
—

Prepaid expenses and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
25,434

 
—

 
25,434

 
—

Other assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
1,798

 
—

 
1,798

 
—

Total financial assets
$
2,391,829


$
1,890,169

 
$
501,660

 
$
—

Financial instruments carried at fair value (liability positions):
 
 
 
 
 
 
 
Other current liabilities:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(459
)
 
$
—

 
$
(459
)
 
$
—

Long-term contingent consideration
(178,100
)
 
—

 
—

 
(178,100
)
Other long-term liabilities:
 
 
 
 
 
 
 
Foreign currency forward contracts
(637
)
 
—

 
(637
)
 
—

Total financial liabilities
$
(179,196
)
 
$
—

 
$
(1,096
)
 
$
(178,100
)

 
Fair Value Measurements as of December 31, 2019
 
 
 
Fair Value Hierarchy
 
Total
 
Level 1
 
Level 2
 
Level 3
 
(in thousands)
Financial instruments carried at fair value (asset positions):
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
791,039

 
$
791,039

 
$
—

 
$
—

Corporate debt securities
6,070

 
—

 
6,070

 
—

Commercial paper
29,472

 
—

 
29,472

 
—

Marketable securities:
 
 
 
 
 
 
 
Corporate equity securities
282,084

 
261,797

 
20,287

 
—

Government-sponsored enterprise securities
12,733

 
12,733

 
—

 
—

Corporate debt securities
301,799

 
—

 
301,799

 
—

Commercial paper
102,356

 
—

 
102,356

 
—

Prepaid expenses and other current assets:
 
 
 
 
 
 
 
Foreign currency forward contracts
9,725

 
—

 
9,725

 
—

Total financial assets
$
1,535,278

 
$
1,065,569

 
$
469,709

 
$
—

Financial instruments carried at fair value (liability positions):
 
 
 
 
 
 
 
Other current liabilities:
 
 
 
 
 
 
 
Foreign currency forward contracts
$
(5,533
)
 
$
—

 
$
(5,533
)
 
$
—

Long-term contingent consideration
(176,500
)
 
—

 
—

 
(176,500
)
Other long-term liabilities:
 
 
 
 
 
 
 
Foreign currency forward contracts
(1,821
)
 
—

 
(1,821
)
 
—

Total financial liabilities
$
(183,854
)
 
$
—

 
$
(7,354
)
 
$
(176,500
)

Please refer to Note F, “Marketable Securities and Equity Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.
Fair Value of Corporate Equity Securities
The Company maintains strategic investments in corporate equity securities separately from the investment policy that governs its other cash, cash equivalents and marketable securities. The Company classifies its investments in publicly traded companies as “Marketable securities” on its condensed consolidated balance sheets. Generally, the Company’s investments in the common stock of these publicly traded companies are valued based on Level 1 inputs because they have readily determinable fair values. However, certain of the Company’s investments in publicly traded companies have been or continue to be valued based on Level 2 inputs due to transfer restrictions associated with these investments. Please refer to Note F, “Marketable Securities and Equity Investments,” for further information on these investments.
Fair Value of Contingent Consideration
The Company’s contingent consideration liabilities, which are related to $678.3 million of development and regulatory milestones potentially payable to Exonics’ former equity holders, are classified as Level 3 within the valuation hierarchy. The Company bases its estimates of the probability of achieving the milestones relevant to the fair value of contingent payments on industry data attributable to rare diseases. The discount rates used in the valuation model for contingent payments, which were between 1.8% and 3.1%, represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Due to the uncertainties associated with development and commercialization of a drug candidate in the pharmaceutical industry, the Company's estimates regarding the fair value of contingent consideration will change in the future, resulting in adjustments to the fair value of the Company’s contingent consideration liabilities, and the effect of any such adjustments could be material.
The following table represents a rollforward of the fair value of the Company’s contingent consideration liabilities:
 
Three Months Ended March 31, 2020
 
(in thousands)
Balance at December 31, 2019
$
176,500

Increase in fair value of contingent payments
1,600

Balance at March 31, 2020
$
178,100


The “Increase in fair value of contingent payments” in the table above was due to changes in market interest rates and the time value of money.
XML 45 R38.htm IDEA: XBRL DOCUMENT v3.20.1
Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Fair Value Disclosures [Abstract]    
Cash $ 1,800,000 $ 2,300,000
Financial instruments carried at fair value (liability positions):    
Long-term contingent consideration (178,100) (176,500)
Recurring basis    
Financial instruments carried at fair value (asset positions):    
Derivative asset current 25,434 9,725
Derivative asset noncurrent 1,798  
Total financial assets 2,391,829 1,535,278
Financial instruments carried at fair value (liability positions):    
Derivative liability current (459) (5,533)
Long-term contingent consideration (178,100) (176,500)
Derivative liability, noncurrent (637) (1,821)
Total financial liabilities (179,196) (183,854)
Recurring basis | Level 1    
Financial instruments carried at fair value (asset positions):    
Derivative asset current 0 0
Derivative asset noncurrent 0  
Total financial assets 1,890,169 1,065,569
Financial instruments carried at fair value (liability positions):    
Derivative liability current 0 0
Long-term contingent consideration 0 0
Derivative liability, noncurrent 0 0
Total financial liabilities 0 0
Recurring basis | Level 2    
Financial instruments carried at fair value (asset positions):    
Derivative asset current 25,434 9,725
Derivative asset noncurrent 1,798  
Total financial assets 501,660 469,709
Financial instruments carried at fair value (liability positions):    
Derivative liability current (459) (5,533)
Long-term contingent consideration 0 0
Derivative liability, noncurrent (637) (1,821)
Total financial liabilities (1,096) (7,354)
Recurring basis | Level 3    
Financial instruments carried at fair value (asset positions):    
Derivative asset current 0 0
Derivative asset noncurrent 0  
Total financial assets 0 0
Financial instruments carried at fair value (liability positions):    
Derivative liability current 0 0
Long-term contingent consideration (178,100) (176,500)
Derivative liability, noncurrent 0 0
Total financial liabilities (178,100) (176,500)
Recurring basis | Money market funds    
Financial instruments carried at fair value (asset positions):    
Cash and cash equivalents 1,736,913 791,039
Recurring basis | Money market funds | Level 1    
Financial instruments carried at fair value (asset positions):    
Cash and cash equivalents 1,736,913 791,039
Recurring basis | Money market funds | Level 2    
Financial instruments carried at fair value (asset positions):    
Cash and cash equivalents 0 0
Recurring basis | Money market funds | Level 3    
Financial instruments carried at fair value (asset positions):    
Cash and cash equivalents 0 0
Recurring basis | Government-sponsored enterprise securities    
Financial instruments carried at fair value (asset positions):    
Cash and cash equivalents   6,070
Marketable securities 7,791 12,733
Recurring basis | Government-sponsored enterprise securities | Level 1    
Financial instruments carried at fair value (asset positions):    
Cash and cash equivalents   0
Marketable securities 7,791 12,733
Recurring basis | Government-sponsored enterprise securities | Level 2    
Financial instruments carried at fair value (asset positions):    
Cash and cash equivalents   6,070
Marketable securities 0 0
Recurring basis | Government-sponsored enterprise securities | Level 3    
Financial instruments carried at fair value (asset positions):    
Cash and cash equivalents   0
Marketable securities 0 0
Recurring basis | Commercial paper    
Financial instruments carried at fair value (asset positions):    
Cash and cash equivalents 30,700 29,472
Marketable securities 118,964 102,356
Recurring basis | Commercial paper | Level 1    
Financial instruments carried at fair value (asset positions):    
Cash and cash equivalents 0 0
Marketable securities 0 0
Recurring basis | Commercial paper | Level 2    
Financial instruments carried at fair value (asset positions):    
Cash and cash equivalents 30,700 29,472
Marketable securities 118,964 102,356
Recurring basis | Commercial paper | Level 3    
Financial instruments carried at fair value (asset positions):    
Cash and cash equivalents 0 0
Marketable securities 0 0
Recurring basis | Corporate equity securities    
Financial instruments carried at fair value (asset positions):    
Marketable securities 165,178 282,084
Recurring basis | Corporate equity securities | Level 1    
Financial instruments carried at fair value (asset positions):    
Marketable securities 145,465 261,797
Recurring basis | Corporate equity securities | Level 2    
Financial instruments carried at fair value (asset positions):    
Marketable securities 19,713 20,287
Recurring basis | Corporate equity securities | Level 3    
Financial instruments carried at fair value (asset positions):    
Marketable securities 0 0
Recurring basis | Corporate debt securities    
Financial instruments carried at fair value (asset positions):    
Marketable securities 305,051 301,799
Recurring basis | Corporate debt securities | Level 1    
Financial instruments carried at fair value (asset positions):    
Marketable securities 0 0
Recurring basis | Corporate debt securities | Level 2    
Financial instruments carried at fair value (asset positions):    
Marketable securities 305,051 301,799
Recurring basis | Corporate debt securities | Level 3    
Financial instruments carried at fair value (asset positions):    
Marketable securities $ 0 $ 0
XML 46 R30.htm IDEA: XBRL DOCUMENT v3.20.1
Stock-based Compensation Expense and Share Repurchase Programs (Tables)
 3 Months Ended
Mar. 31, 2020
Share-based Payment Arrangement [Abstract]  
Stock-based compensation expense by line item
During the three months ended March 31, 2020 and 2019, the Company recognized the following stock-based compensation expense:
 
Three Months Ended March 31,
 
2020
 
2019
 
(in thousands)
Stock-based compensation expense by type of award:
 
 
 
Restricted stock and restricted stock units (including PSUs)
$
97,149

 
$
63,510

Stock options
17,266

 
28,156

ESPP share issuances
2,485

 
2,577

Stock-based compensation expense related to inventories
(1,194
)
 
(452
)
Total stock-based compensation expense included in costs and expenses
$
115,706

 
$
93,791

 
 
 


Stock-based compensation expense by line item:
 
 


Cost of sales
$
1,361

 
$
1,338

Research and development expenses
72,687

 
59,715

Sales, general and administrative expenses
41,658

 
32,738

Total stock-based compensation expense included in costs and expenses
115,706

 
93,791

Income tax effect
(64,246
)
 
(39,524
)
Total stock-based compensation expense, net of tax
$
51,460

 
$
54,267
Unrecognized stock-based compensation expense, net of estimated forfeitures
The following table sets forth the Company’s unrecognized stock-based compensation expense as of March 31, 2020, by type of award and the weighted-average period over which that expense is expected to be recognized:
 
As of March 31, 2020
 
Unrecognized Expense
 
Weighted-average
Recognition Period
 
(in thousands)
 
(in years)
Type of award:
 
 
 
Restricted stock and restricted stock units (including PSUs)
$
550,095

 
2.27
Stock options
$
109,086

 
2.33
ESPP share issuances
$
2,238

 
0.40
Stock options outstanding and exercisable
The following table summarizes information about stock options outstanding and exercisable as of March 31, 2020:
 
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
 
Number
Outstanding
 
Weighted-average
Remaining
Contractual Life
 
Weighted-average
Exercise Price
 
Number
Exercisable
 
Weighted-average
Exercise Price
 
 
(in thousands)
 
(in years)
 
(per share)
 
(in thousands)
 
(per share)
$29.07–$40.00
 
81

 
1.47
 
$
37.70

 
81

 
$
37.70

$40.01–$60.00
 
224

 
2.41
 
$
49.15

 
224

 
$
49.15

$60.01–$80.00
 
116

 
4.03
 
$
74.89

 
112

 
$
74.89

$80.01–$100.00
 
1,393

 
5.99
 
$
89.44

 
1,085

 
$
90.01

$100.01–$120.00
 
182

 
4.88
 
$
109.25

 
180

 
$
109.18

$120.01–$140.00
 
402

 
5.44
 
$
129.59

 
400

 
$
129.61

$140.01–$160.00
 
954

 
7.86
 
$
155.50

 
436

 
$
155.41

$160.01–$180.00
 
669

 
8.24
 
$
168.21

 
245

 
$
165.11

$180.01–$189.38
 
1,498

 
8.65
 
$
185.44

 
440

 
$
185.31

Total
 
5,519

 
6.98
 
$
137.34

 
3,203

 
$
119.05
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.20.1
Revenue Recognition - Narrative (Details) - USD ($)
$ in Millions
Mar. 31, 2020
Dec. 31, 2019
Revenue from Contract with Customer [Abstract]    
Contract liabilities $ 76.3 $ 62.3
XML 48 R27.htm IDEA: XBRL DOCUMENT v3.20.1
Accumulated Other Comprehensive Income (Loss) (Tables)
 3 Months Ended
Mar. 31, 2020
Equity [Abstract]  
Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss) by component:
 
 
 
Unrealized Holding Gains (Losses), Net of Tax
 
 
 
Foreign Currency Translation Adjustment
 
On Available-For-Sale Debt Securities
 
On Foreign Currency Forward Contracts
 
Total
 
(in thousands)
Balance at December 31, 2019
$
(895
)
 
$
503

 
$
(1,581
)
 
$
(1,973
)
Other comprehensive (loss) income before reclassifications
(2,662
)
 
(764
)
 
25,772

 
22,346

Amounts reclassified from accumulated other comprehensive income (loss)
—

 
—

 
(6,990
)
 
(6,990
)
Net current period other comprehensive (loss) income
(2,662
)
 
(764
)
 
18,782

 
15,356

Balance at March 31, 2020
$
(3,557
)
 
$
(261
)
 
$
17,201

 
$
13,383

 
 
 
 
 
 
 
 
Balance at December 31, 2018
$
(11,227
)
 
$
(536
)
 
$
12,422

 
$
659

Other comprehensive income before reclassifications
4,967

 
596

 
5,126

 
10,689

Amounts reclassified from accumulated other comprehensive income
—

 
—

 
(5,348
)
 
(5,348
)
Net current period other comprehensive income (loss)
4,967

 
596

 
(222
)
 
5,341

Balance at March 31, 2019
$
(6,260
)
 
$
60

 
$
12,200

 
$
6,000
XML 49 R23.htm IDEA: XBRL DOCUMENT v3.20.1
Revenue Recognition (Tables)
 3 Months Ended
Mar. 31, 2020
Revenue from Contract with Customer [Abstract]  
Schedule of disaggregation of revenue
Product revenues, net consisted of the following:
 
Three Months Ended March 31,
 
2020
 
2019
 
(in thousands)
TRIKAFTA
$
895,233

 
$
—

SYMDEKO/SYMKEVI
173,159

 
320,275

ORKAMBI
234,138

 
293,007

KALYDECO
212,577

 
243,971

Total product revenues, net*
$
1,515,107

 
$
857,253


* The preceding table does not include collaborative and royalty revenues.
Total revenues from external customers and collaborators by geographic region consisted of the following:
 
Three Months Ended March 31,
 
2020
 
2019
 
(in thousands)
United States
$
1,187,588

 
$
641,104

Outside of the United States
 
 
 
Europe
257,391

 
167,751

Other
70,128

 
49,580

Total revenues outside of the United States
327,519

 
217,331

Total revenues
$
1,515,107

 
$
858,435
XML 51 R3.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Statement of Comprehensive Income [Abstract]    
Net income $ 602,753 $ 268,631
Changes in other comprehensive income:    
Unrealized holding (losses) gains on marketable securities, net (764) 596
Unrealized gains (losses) on foreign currency forward contracts, net of tax of $(5.0) million and $1.5 million, respectively 18,782 (222)
Foreign currency translation adjustment (2,662) 4,967
Total changes in other comprehensive income 15,356 5,341
Comprehensive income $ 618,109 $ 273,972
XML 52 R7.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Shareholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning balance (shares) at Dec. 31, 2018   255,172      
Beginning balance at Dec. 31, 2018 $ 4,435,203 $ 2,546 $ 7,421,476 $ 659 $ (2,989,478)
Increase (Decrease) in Stockholders' Equity          
Other comprehensive income, net of tax 5,341     5,341  
Net income 268,631       268,631
Repurchases of common stock (in shares)   (537)      
Repurchase of common stock (98,007) $ (6) (98,001)    
Common stock withheld for employee tax obligations (shares)   (27)      
Common stock withheld for employee tax obligations (5,832)   (5,832)    
Issuance of common stock under benefit plans (shares)   1,743      
Issuance of common stock under benefit plans 64,044 $ 21 64,023    
Stock-based compensation expense 94,243   94,243    
Ending balance (shares) at Mar. 31, 2019   256,351      
Ending Balance at Mar. 31, 2019 4,723,313 $ 2,561 7,475,909 6,000 (2,761,157)
Beginning balance (shares) at Dec. 31, 2019   258,993      
Beginning balance at Dec. 31, 2019 6,085,244 $ 2,589 7,937,606 (1,973) (1,852,978)
Increase (Decrease) in Stockholders' Equity          
Other comprehensive income, net of tax 15,356     15,356  
Net income 602,753       602,753
Repurchases of common stock (in shares)   (1,404)      
Repurchase of common stock (300,026) $ (14) (300,012)    
Common stock withheld for employee tax obligations (shares)   (575)      
Common stock withheld for employee tax obligations (136,167) $ (6) (136,161)    
Issuance of common stock under benefit plans (shares)   2,065      
Issuance of common stock under benefit plans 77,594 $ 22 77,572    
Stock-based compensation expense 116,900   116,900    
Ending balance (shares) at Mar. 31, 2020   259,079      
Ending Balance at Mar. 31, 2020 $ 6,461,654 $ 2,591 $ 7,695,905 $ 13,383 $ (1,250,225)
XML 53 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 54 R42.htm IDEA: XBRL DOCUMENT v3.20.1
Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Total marketable debt securities    
Fair Value $ 2,199,419 $ 1,243,469
Corporate equity securities    
Amortized Cost 87,096 113,829
Gross Unrealized Gains 78,082 168,255
Gross Unrealized Losses 0 0
Fair Value 165,178 282,084
Amortized Cost 519,163 530,216
Gross Unrealized Gains 78,837 168,811
Gross Unrealized Losses (1,016) (55)
Fair Value 596,984 698,972
Cash equivalents    
Total marketable debt securities    
Amortized Cost 1,767,613 826,579
Gross Unrealized Gains 4 3
Gross Unrealized Losses (4) (1)
Fair Value 1,767,613 826,581
Cash equivalents | Money market funds    
Total marketable debt securities    
Amortized Cost 1,736,913 791,039
Gross Unrealized Gains 0 0
Gross Unrealized Losses 0 0
Fair Value 1,736,913 791,039
Cash equivalents | Commercial paper    
Total marketable debt securities    
Amortized Cost 30,700 29,470
Gross Unrealized Gains 4 3
Gross Unrealized Losses (4) (1)
Fair Value 30,700 29,472
Cash equivalents | Corporate debt securities    
Total marketable debt securities    
Amortized Cost   6,070
Gross Unrealized Gains   0
Gross Unrealized Losses   0
Fair Value   6,070
Marketable securities    
Total marketable debt securities    
Amortized Cost 432,067 416,387
Gross Unrealized Gains 755 556
Gross Unrealized Losses (1,016) (55)
Fair Value 431,806 416,888
Marketable securities | Government-sponsored enterprise securities    
Total marketable debt securities    
Amortized Cost 7,717 12,689
Gross Unrealized Gains 74 44
Gross Unrealized Losses 0 0
Fair Value 7,791 12,733
Marketable securities | Corporate debt securities    
Total marketable debt securities    
Amortized Cost 305,808 301,458
Gross Unrealized Gains 255 391
Gross Unrealized Losses (1,012) (50)
Fair Value 305,051 301,799
Marketable securities | Commercial paper    
Total marketable debt securities    
Amortized Cost 118,542 102,240
Gross Unrealized Gains 426 121
Gross Unrealized Losses (4) (5)
Fair Value $ 118,964 $ 102,356
XML 55 R46.htm IDEA: XBRL DOCUMENT v3.20.1
Hedging - Narrative (Details) - Foreign currency forward contracts
$ in Millions
 3 Months Ended
Mar. 31, 2020
USD ($)
Not designated as hedging instruments  
Derivative [Line Items]  
Derivative term 1 month
Cash flow hedging | Not designated as hedging instruments  
Derivative [Line Items]  
Notional amount of foreign currency forward contract $ 522.2
Cash flow hedging | Minimum  
Derivative [Line Items]  
Derivative term 1 month
Cash flow hedging | Maximum  
Derivative [Line Items]  
Derivative term 18 months
XML 56 R57.htm IDEA: XBRL DOCUMENT v3.20.1
Additional Cash Flow Information (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Mar. 31, 2019
Dec. 31, 2018
Restricted Cash and Cash Equivalents Items [Line Items]        
Cash and cash equivalents $ 3,593,412 $ 3,109,322 $ 2,893,885 $ 2,650,134
Cash, cash equivalents and restricted cash per statement of cash flows 3,601,964 3,120,681 2,901,532 2,658,253
Prepaid expenses and other current assets        
Restricted Cash and Cash Equivalents Items [Line Items]        
Restricted cash and cash equivalents 8,552 8,004 6,250 4,910
Other assets        
Restricted Cash and Cash Equivalents Items [Line Items]        
Restricted cash and cash equivalents $ 0 $ 3,355 $ 1,397 $ 3,209
XML 57 R53.htm IDEA: XBRL DOCUMENT v3.20.1
Stock-based Compensation Expense and Share Repurchase Programs - Stock Options Outstanding and Exercisable (Details)
shares in Thousands
 3 Months Ended
Mar. 31, 2020
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]  
Exercise price range, options outstanding (in shares) | shares 5,519
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 6 years 11 months 23 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 137.34
Exercise price range, options exercisable (in shares) | shares 3,203
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 119.05
$29.07–$40.00  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]  
Exercise price, low end of range (in dollars per share) 29.07
Exercise price, high end of range (in dollars per share) $ 40
Exercise price range, options outstanding (in shares) | shares 81
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 1 year 5 months 19 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 37.70
Exercise price range, options exercisable (in shares) | shares 81
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 37.70
$40.01–$60.00  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]  
Exercise price, low end of range (in dollars per share) 40.01
Exercise price, high end of range (in dollars per share) $ 60
Exercise price range, options outstanding (in shares) | shares 224
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 2 years 4 months 28 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 49.15
Exercise price range, options exercisable (in shares) | shares 224
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 49.15
$60.01–$80.00  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]  
Exercise price, low end of range (in dollars per share) 60.01
Exercise price, high end of range (in dollars per share) $ 80
Exercise price range, options outstanding (in shares) | shares 116
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 4 years 10 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 74.89
Exercise price range, options exercisable (in shares) | shares 112
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 74.89
$80.01–$100.00  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]  
Exercise price, low end of range (in dollars per share) 80.01
Exercise price, high end of range (in dollars per share) $ 100
Exercise price range, options outstanding (in shares) | shares 1,393
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 5 years 11 months 26 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 89.44
Exercise price range, options exercisable (in shares) | shares 1,085
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 90.01
$100.01–$120.00  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]  
Exercise price, low end of range (in dollars per share) 100.01
Exercise price, high end of range (in dollars per share) $ 120
Exercise price range, options outstanding (in shares) | shares 182
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 4 years 10 months 17 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 109.25
Exercise price range, options exercisable (in shares) | shares 180
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 109.18
$120.01–$140.00  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]  
Exercise price, low end of range (in dollars per share) 120.01
Exercise price, high end of range (in dollars per share) $ 140.00
Exercise price range, options outstanding (in shares) | shares 402
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 5 years 5 months 8 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 129.59
Exercise price range, options exercisable (in shares) | shares 400
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 129.61
$140.01–$160.00  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]  
Exercise price, low end of range (in dollars per share) 140.01
Exercise price, high end of range (in dollars per share) $ 160.00
Exercise price range, options outstanding (in shares) | shares 954
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 7 years 10 months 9 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 155.50
Exercise price range, options exercisable (in shares) | shares 436
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 155.41
$160.01–$180.00  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]  
Exercise price, low end of range (in dollars per share) 160.01
Exercise price, high end of range (in dollars per share) $ 180.00
Exercise price range, options outstanding (in shares) | shares 669
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 8 years 2 months 26 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 168.21
Exercise price range, options exercisable (in shares) | shares 245
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 165.11
$180.01–$189.38  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]  
Exercise price, low end of range (in dollars per share) 180.01
Exercise price, high end of range (in dollars per share) $ 189.38
Exercise price range, options outstanding (in shares) | shares 1,498
Exercise price range, options outstanding, weighted-average remaining contractual life (in years) 8 years 7 months 24 days
Exercise price range, options outstanding, weighted-average exercise price (in dollars per share) $ 185.44
Exercise price range, options exercisable (in shares) | shares 440
Exercise price range, options exercisable, weighted-average exercise price (in dollars per share) $ 185.31
XML 58 R32.htm IDEA: XBRL DOCUMENT v3.20.1
Basis of Presentation and Accounting Policies (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2020
segment
Jan. 01, 2019
USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Number of operating segments | segment 1  
Cumulative effect adjustment to accumulated deficit   $ (40,310)
Accumulated Deficit    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Cumulative effect adjustment to accumulated deficit   (40,310)
Accounting Standards Update 2016-02 | Accumulated Deficit    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Cumulative effect adjustment to accumulated deficit   $ (40,300)
EXCEL 59 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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htm IDEA: XBRL DOCUMENT v3.20.1
Earnings Per Share - Schedule of Computation (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share    
Net income $ 602,753 $ 268,631
Basic weighted-average common shares outstanding (in shares) 259,815 255,695
Effect of potentially dilutive securities:    
Employee stock purchase program (in shares) 31 25
Diluted weighted-average common shares outstanding (in shares) 263,515 260,175
Basic net income per common share (in dollars per share) $ 2.32 $ 1.05
Diluted net income per common share (in dollars per share) $ 2.29 $ 1.03
Stock options    
Effect of potentially dilutive securities:    
Share-based payment arrangements (in shares) 1,868 2,585
Unvested restricted stock and restricted stock units (including PSUs)    
Effect of potentially dilutive securities:    
Share-based payment arrangements (in shares) 1,801 1,870
XML 62 R19.htm IDEA: XBRL DOCUMENT v3.20.1
Income Taxes
 3 Months Ended
Mar. 31, 2020
Income Tax Disclosure [Abstract]  
Income Taxes
Income Taxes
The Company is subject to U.S. federal, state, and foreign income taxes. For the three months ended March 31, 2020 and 2019, the Company recorded provisions for income taxes of $54.8 million and $51.5 million, respectively. The Company’s effective tax rate for the three months ended March 31, 2020 was lower than the U.S. statutory rate primarily due to a discrete benefit related to the write-off of a long-term intercompany receivable and excess tax benefits related to stock-based compensation. The Company’s effective tax rate for the three months ended March 31, 2019 was lower than the U.S. statutory rate primarily due to excess tax benefits related to stock-based compensation.
The Company released its valuation allowance on the majority of its net operating losses and other deferred tax assets as of December 31, 2018. Starting in 2019, the Company began recording a provision for income taxes on its pre-tax income using an effective tax rate approximating statutory rates. Due to the Company's ability to offset its pre-tax income against
previously benefited net operating losses, it expects a portion of its tax provision to represent a non-cash expense until its net operating losses have been fully utilized.
The Company maintained a valuation allowance of $205.2 million related primarily to U.S. state and foreign tax attributes as of December 31, 2019. On a periodic basis, the Company reassesses any valuation allowances that it maintains on its deferred tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets.  
In March 2020, the Coronavirus Aid, Relief and Economic Security Act (“the CARES Act”) was signed into law. The CARES Act includes provisions relating to several aspects of corporate income taxes. The Company does not currently expect the CARES Act to have a significant impact on its provision for income taxes; however, it will continue to monitor the provisions of the CARES Act in relation to its operations.
The Company has reviewed the tax positions taken, or to be taken, in its tax returns for all tax years currently open to examination by a taxing authority. Unrecognized tax benefits represent the aggregate tax effect of differences between tax return positions and the benefits recognized in the financial statements. As of March 31, 2020 and December 31, 2019, the Company had $43.0 million and $33.9 million, respectively, of gross unrecognized tax benefits, which would affect the Company’s tax rate if recognized. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company accrues interest and penalties related to unrecognized tax benefits as a component of its provision for income taxes. As of March 31, 2020, no significant interest or penalties were accrued. The Company did not recognize any material interest or penalties related to uncertain tax positions during the three months ended March 31, 2020 and 2019.
As of March 31, 2020, foreign earnings, which were not significant, have been retained by foreign subsidiaries for indefinite reinvestment. Upon repatriation of those earnings, in the form of dividends or otherwise, the Company could be subject to withholding taxes payable to the various foreign countries.
The Company files U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. The Company is no longer subject to any tax assessment from an income tax examination in the United States or any other major taxing jurisdiction for years before 2011, except where the Company has net operating losses or tax credit carryforwards that originate before 2011. The Company has various income tax audits ongoing at any time throughout the world. No significant adjustments have been reported for any jurisdiction under audit.
XML 63 R15.htm IDEA: XBRL DOCUMENT v3.20.1
Accumulated Other Comprehensive Income (Loss)
 3 Months Ended
Mar. 31, 2020
Equity [Abstract]  
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss) by component:
 
 
 
Unrealized Holding Gains (Losses), Net of Tax
 
 
 
Foreign Currency Translation Adjustment
 
On Available-For-Sale Debt Securities
 
On Foreign Currency Forward Contracts
 
Total
 
(in thousands)
Balance at December 31, 2019
$
(895
)
 
$
503

 
$
(1,581
)
 
$
(1,973
)
Other comprehensive (loss) income before reclassifications
(2,662
)
 
(764
)
 
25,772

 
22,346

Amounts reclassified from accumulated other comprehensive income (loss)
—

 
—

 
(6,990
)
 
(6,990
)
Net current period other comprehensive (loss) income
(2,662
)
 
(764
)
 
18,782

 
15,356

Balance at March 31, 2020
$
(3,557
)
 
$
(261
)
 
$
17,201

 
$
13,383

 
 
 
 
 
 
 
 
Balance at December 31, 2018
$
(11,227
)
 
$
(536
)
 
$
12,422

 
$
659

Other comprehensive income before reclassifications
4,967

 
596

 
5,126

 
10,689

Amounts reclassified from accumulated other comprehensive income
—

 
—

 
(5,348
)
 
(5,348
)
Net current period other comprehensive income (loss)
4,967

 
596

 
(222
)
 
5,341

Balance at March 31, 2019
$
(6,260
)
 
$
60

 
$
12,200

 
$
6,000
XML 64 R11.htm IDEA: XBRL DOCUMENT v3.20.1
Collaborative Arrangements
 3 Months Ended
Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Collaborative Arrangements
Collaborative Arrangements
The Company has entered into numerous agreements pursuant to which it collaborates with third parties on research, development and commercialization programs, including in-license and out-license agreements.
The Company’s in-license and out-license agreements that had a significant impact on its financial statements for the three months ended March 31, 2020 and 2019, or were new during the three months ended March 31, 2020, are described below. Additional in-license and out-license agreements were described in Note B, “Collaborative Arrangements,” of the Company’s 2019 Annual Report on Form 10-K.
In-license Agreements
The Company has entered into a number of license agreements in order to advance and obtain access to technologies and services related to its research and early-development activities. The Company is generally required to make an upfront payment upon execution of the license agreement; development, regulatory and commercialization milestones payments upon the achievement of certain product research, development and commercialization objectives; and royalty payments on future sales, if any, of commercial products resulting from the collaboration.
Pursuant to the terms of its in-license agreements, the Company’s collaborators typically lead the discovery efforts and the Company leads all preclinical, development and commercialization activities associated with the advancement of any drug candidates and funds all expenses.
The Company typically can terminate its in-license agreements by providing advance notice to its collaborators; the required length of notice is dependent on whether any product developed under the license agreement has received marketing approval. The Company’s license agreements may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, these license agreements generally remain in effect until the date on which the royalty term and all payment obligations with respect to all products in all countries have expired.
CRISPR Therapeutics AG
In 2015, the Company entered into a strategic collaboration, option and license agreement (the “CRISPR Agreement”) with CRISPR Therapeutics AG and its affiliates (“CRISPR”) to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene-editing technology. The Company had the exclusive right to license certain CRISPR-Cas9-based targets. In the fourth quarter of 2019, the Company elected to exclusively license three CRISPR-Cas9-based targets, including cystic fibrosis, pursuant to the CRISPR Agreement. For each of the three targets that the Company elected to license, CRISPR has the potential to receive up to an additional $410.0 million in development, regulatory and commercial milestones as well as royalties on net product sales.
In 2017, the Company entered into a co-development and co-commercialization agreement with CRISPR pursuant to the terms of the CRISPR Agreement, under which the Company and CRISPR are co-developing and will co-commercialize CTX001 (the “CTX001 Co-Co Agreement”) for the treatment of hemoglobinopathies, including treatments for sickle cell disease and beta thalassemia. As part of the collaboration, the Company and CRISPR share equally all development costs and potential worldwide revenues related to potential hemoglobinopathy treatments. The Company concluded that the CTX001 Co-Co Agreement is a cost-sharing arrangement, which results in the net impact of the arrangement being recorded in “Research and development expenses” in its condensed consolidated statements of operations. During the three months ended March 31, 2020 and 2019, the net expense related to the CTX001 Co-Co Agreement was $9.3 million and $7.0 million, respectively.
In July 2019, the Company entered into a separate strategic collaboration and license agreement (the “CRISPR DMD/DM1 Agreement”) with CRISPR. Pursuant to this agreement, the Company received an exclusive worldwide license to CRISPR’s existing and future intellectual property for duchenne muscular dystrophy (“DMD”) and myotonic dystrophy type 1 (“DM1”). In the first quarter of 2020, the Company recorded $25.0 million to “Research and development expenses” related to a pre-clinical milestone earned by CRISPR under the CRISPR DMD/DM1 Agreement. CRISPR has the potential to receive up to an additional $800.0 million in research, development, regulatory and commercial milestones for the DMD and DM1 programs as well as royalties on net product sales. CRISPR has the option to co-develop and co-commercialize all DM1 products globally and forego the milestones and royalties associated with the DM1 program. The Company funds all expenses associated with the collaboration except for research costs for specified guide RNA research conducted by CRISPR, which the Company and CRISPR share equally.
Please refer to Note F, “Marketable Securities and Equity Investments,” for further information regarding the Company’s investment in CRISPR’s common stock.
Out-license Agreements
The Company has entered into licensing agreements pursuant to which it has out-licensed rights to certain drug candidates to third-party collaborators. Pursuant to these out-license agreements, the Company’s collaborators become responsible for all costs related to the continued development of such drug candidates and obtain development and commercialization rights to these drug candidates. Depending on the terms of the agreements, the Company’s collaborators may be required to make upfront payments, milestone payments upon the achievement of certain product research and development objectives and may also be required to pay royalties on future sales, if any, of commercial products resulting from the collaboration. The termination provisions associated with these collaborations are generally the same as those described above related to the Company’s in-license agreements. None of the Company’s out-license agreements had a significant impact on the Company’s condensed consolidated statement of operations during the three months ended March 31, 2020 and 2019.
Cystic Fibrosis Foundation
The Company has a research, development and commercialization agreement that was originally entered into in 2004 with Cystic Fibrosis Foundation (“CFF”), as successor in interest to the Cystic Fibrosis Foundation Therapeutics, Inc. This agreement was most recently amended in 2016. Pursuant to the agreement, as amended, the Company agreed to pay royalties ranging from low-single digits to mid-single digits on potential sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016, including elexacaftor, and tiered royalties ranging from single digits to sub-teens on covered compounds first synthesized and/or tested during a research term on or before February 28, 2014, including KALYDECO (ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor). For combination products, such as ORKAMBI, SYMDEKO/SYMKEVI and TRIKAFTA (elexacaftor, tezacaftor, and ivacaftor), sales are allocated equally to each of the active pharmaceutical ingredients in the combination product.
XML 65 a2020q110-q_htm.xml IDEA: XBRL DOCUMENT 0000875320 2020-01-01 2020-03-31 0000875320 2020-04-24 0000875320 2019-01-01 2019-03-31 0000875320 us-gaap:ProductMember 2019-01-01 2019-03-31 0000875320 vrtx:CollaborativeandRoyaltyMember 2019-01-01 2019-03-31 0000875320 vrtx:CollaborativeandRoyaltyMember 2020-01-01 2020-03-31 0000875320 us-gaap:ProductMember 2020-01-01 2020-03-31 0000875320 2019-12-31 0000875320 2020-03-31 0000875320 us-gaap:CommonStockMember 2019-03-31 0000875320 us-gaap:CommonStockMember 2020-03-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000875320 us-gaap:RetainedEarningsMember 2019-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000875320 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000875320 2018-12-31 0000875320 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000875320 us-gaap:CommonStockMember 2018-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000875320 us-gaap:RetainedEarningsMember 2019-03-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000875320 us-gaap:CommonStockMember 2019-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000875320 2019-01-01 0000875320 us-gaap:RetainedEarningsMember 2020-03-31 0000875320 us-gaap:RetainedEarningsMember 2018-12-31 0000875320 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000875320 2019-03-31 0000875320 us-gaap:RetainedEarningsMember 2019-01-01 0000875320 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000875320 us-gaap:AccountingStandardsUpdate201602Member us-gaap:RetainedEarningsMember 2019-01-01 0000875320 vrtx:ORKAMBIMember 2020-01-01 2020-03-31 0000875320 vrtx:TRIKAFTAMember 2019-01-01 2019-03-31 0000875320 vrtx:ORKAMBIMember 2019-01-01 2019-03-31 0000875320 vrtx:TRIKAFTAMember 2020-01-01 2020-03-31 0000875320 vrtx:KalydecoMember 2020-01-01 2020-03-31 0000875320 vrtx:SYMDEKOSYMKEVIMember 2019-01-01 2019-03-31 0000875320 vrtx:KalydecoMember 2019-01-01 2019-03-31 0000875320 vrtx:SYMDEKOSYMKEVIMember 2020-01-01 2020-03-31 0000875320 srt:EuropeMember 2019-01-01 2019-03-31 0000875320 us-gaap:NonUsMember 2019-01-01 2019-03-31 0000875320 us-gaap:NonUsMember 2020-01-01 2020-03-31 0000875320 country:US 2020-01-01 2020-03-31 0000875320 vrtx:OtherNonU.S.Member 2019-01-01 2019-03-31 0000875320 srt:EuropeMember 2020-01-01 2020-03-31 0000875320 vrtx:OtherNonU.S.Member 2020-01-01 2020-03-31 0000875320 country:US 2019-01-01 2019-03-31 0000875320 vrtx:CTX001CoCoAgreementMember 2019-01-01 2019-03-31 0000875320 vrtx:CRISPRTherapeuticsAGMember 2020-01-01 2020-03-31 0000875320 vrtx:CRISPRTherapeuticsAGMember 2019-10-01 2019-12-31 0000875320 vrtx:CRISPRDMDDM1Member 2020-01-01 2020-03-31 0000875320 vrtx:CTX001CoCoAgreementMember 2020-01-01 2020-03-31 0000875320 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0000875320 us-gaap:RestrictedStockMember 2020-01-01 2020-03-31 0000875320 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0000875320 us-gaap:RestrictedStockMember 2019-01-01 2019-03-31 0000875320 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0000875320 us-gaap:RestrictedStockMember 2019-01-01 2019-03-31 0000875320 us-gaap:RestrictedStockMember 2020-01-01 2020-03-31 0000875320 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0000875320 us-gaap:FairValueInputsLevel3Member 2020-03-31 0000875320 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember 2020-03-31 0000875320 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2020-03-31 0000875320 us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember us-gaap:CommercialPaperMember 2019-12-31 0000875320 us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember 2019-12-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2020-03-31 0000875320 us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember us-gaap:CommercialPaperMember 2020-03-31 0000875320 vrtx:MarketableSecuritiesMember 2020-03-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2019-12-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2019-12-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2020-03-31 0000875320 vrtx:MarketableSecuritiesMember 2019-12-31 0000875320 us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember vrtx:CashAndMoneyMarketFundsMember 2020-03-31 0000875320 us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember vrtx:CashAndMoneyMarketFundsMember 2019-12-31 0000875320 us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember 2020-03-31 0000875320 2019-01-01 2019-12-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000875320 us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000875320 vrtx:MarketableSecuritiesMember us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0000875320 us-gaap:OtherAssetsMember 2020-03-31 0000875320 us-gaap:EquitySecuritiesMember 2019-12-31 0000875320 us-gaap:EquitySecuritiesMember 2020-03-31 0000875320 vrtx:CRISPRSaleMember 2020-03-31 0000875320 vrtx:CRISPRSaleMember 2020-01-01 2020-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2020-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-03-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-03-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2019-03-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-01-01 2020-03-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-03-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-03-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-03-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000875320 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000875320 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 currency:CAD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000875320 currency:CAD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:NondesignatedMember 2020-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2020-01-01 2020-03-31 0000875320 srt:MaximumMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2020-01-01 2020-03-31 0000875320 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0000875320 us-gaap:ProductMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0000875320 srt:MinimumMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2020-01-01 2020-03-31 0000875320 vrtx:ExercisePriceRangeFromDollars120.01toDollars140.0Member 2020-01-01 2020-03-31 0000875320 vrtx:ExercisePriceRangeFromDollars160.01toDollars180.00Member 2020-03-31 0000875320 vrtx:ExercisePriceRangeFromDollars120.01toDollars140.0Member 2020-03-31 0000875320 vrtx:ExercisePriceRangeFromDollars160.01toDollars180.00Member 2020-01-01 2020-03-31 0000875320 vrtx:ExercisePriceRangeFromDollars140.01toDollars160.0Member 2020-03-31 0000875320 vrtx:ExercisePriceRangefromDollars100.01toDollars120.00Member 2020-03-31 0000875320 vrtx:ExercisePriceRangefromDollars100.01toDollars120.00Member 2020-01-01 2020-03-31 0000875320 vrtx:ExercisePriceRangefromDollars80.01toDollars100.00Member 2020-03-31 0000875320 vrtx:ExercisePriceRangefromDollars40.01toDollars60.00Member 2020-01-01 2020-03-31 0000875320 vrtx:ExercisePriceRangefromDollars60.01toDollars80.00Member 2020-03-31 0000875320 vrtx:ExercisePriceRangefromDollars40.01toDollars60.00Member 2020-03-31 0000875320 vrtx:ExercisePriceRangeFromDollars140.01toDollars160.0Member 2020-01-01 2020-03-31 0000875320 vrtx:ExercisePriceRangeFromDollars29.07toDollars40.00Member 2020-01-01 2020-03-31 0000875320 vrtx:ExercisePriceRangeFromDollars180.01toDollars189.38Member 2020-01-01 2020-03-31 0000875320 vrtx:ExercisePriceRangefromDollars80.01toDollars100.00Member 2020-01-01 2020-03-31 0000875320 vrtx:ExercisePriceRangeFromDollars29.07toDollars40.00Member 2020-03-31 0000875320 vrtx:ExercisePriceRangefromDollars60.01toDollars80.00Member 2020-01-01 2020-03-31 0000875320 vrtx:ExercisePriceRangeFromDollars180.01toDollars189.38Member 2020-03-31 0000875320 vrtx:ShareRepurchaseProgram2019Member 2020-03-31 0000875320 vrtx:ShareRepurchaseProgram2018Member 2019-01-01 2019-03-31 0000875320 vrtx:ShareRepurchaseProgram2018Member 2019-06-30 0000875320 vrtx:ShareRepurchaseProgram2018Member 2018-12-31 0000875320 vrtx:ShareRepurchaseProgram2019Member 2020-01-01 2020-03-31 0000875320 vrtx:ShareRepurchaseProgram2019Member 2019-07-31 0000875320 us-gaap:EmployeeStockMember 2020-03-31 0000875320 us-gaap:EmployeeStockMember 2020-01-01 2020-03-31 0000875320 us-gaap:EmployeeStockOptionMember 2020-03-31 0000875320 us-gaap:RestrictedStockMember 2020-03-31 0000875320 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-03-31 0000875320 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-03-31 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0000875320 us-gaap:CostOfSalesMember 2019-01-01 2019-03-31 0000875320 us-gaap:EmployeeStockMember 2019-01-01 2019-03-31 0000875320 us-gaap:CostOfSalesMember 2020-01-01 2020-03-31 0000875320 us-gaap:RevolvingCreditFacilityMember 2020-01-01 2020-03-31 0000875320 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:EurodollarMember 2020-01-01 2020-03-31 0000875320 us-gaap:RevolvingCreditFacilityMember 2019-09-30 0000875320 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2020-01-01 2020-03-31 0000875320 us-gaap:LetterOfCreditMember 2019-09-30 0000875320 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:EurodollarMember 2020-01-01 2020-03-31 0000875320 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2020-01-01 2020-03-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2019-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2020-03-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2019-03-31 0000875320 us-gaap:OtherAssetsMember 2018-12-31 0000875320 us-gaap:OtherAssetsMember 2019-12-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2018-12-31 0000875320 us-gaap:OtherAssetsMember 2019-03-31 shares iso4217:USD shares vrtx:segment vrtx:target pure iso4217:USD false --12-31 Q1 2020 0000875320 VERTEX PHARMACEUTICALS INC / MA 0.01 0.01 500000000 500000000 258993000 259079000 258993000 259079000 P1M 0 1500000 -5000000 0.01 0.01 1000000 1000000 0 0 0 0 120.01 140.01 160.01 180.01 29.07 100.01 40.01 60.01 80.01 140.00 160.00 180.00 189.38 40 120 60 80 100 10-Q true 2020-03-31 false 000-19319 MA 50 Northern Avenue Boston MA 04-3039129 02210 617 341-6100 Common Stock, $0.01 Par Value Per Share VRTX NASDAQ Yes Yes Large Accelerated Filer false false false 259276709 1515107000 857253000 0 1182000 1515107000 858435000 162497000 95092000 448528000 339490000 182258000 147045000 1600000 0 794883000 581627000 720224000 276808000 12576000 15615000 -14136000 -14868000 -61130000 42610000 657534000 320165000 54781000 51534000 602753000 268631000 2.32 1.05 2.29 1.03 259815000 255695000 263515000 260175000 602753000 268631000 -764000 596000 18782000 -222000 -2662000 4967000 15356000 5341000 618109000 273972000 3593412000 3109322000 596984000 698972000 845269000 633518000 187087000 167502000 223648000 213515000 5446400000 4822829000 736303000 745080000 1002158000 1002158000 400000000 400000000 1147705000 1190815000 160635000 157583000 8893201000 8318465000 100703000 87610000 1258271000 1116912000 179776000 130305000 1538750000 1334827000 532952000 538576000 178100000 176500000 181745000 183318000 2431547000 2233221000 0 0 0 0 2591000 2589000 7695905000 7937606000 13383000 -1973000 -1250225000 -1852978000 6461654000 6085244000 8893201000 8318465000 255172000 2546000 7421476000 659000 -2989478000 4435203000 -40310000 -40310000 5341000 5341000 268631000 268631000 537000 6000 98001000 98007000 27000 5832000 5832000 1743000 21000 64023000 64044000 94243000 94243000 256351000 2561000 7475909000 6000000 -2761157000 4723313000 258993000 2589000 7937606000 -1973000 -1852978000 6085244000 15356000 15356000 602753000 602753000 1404000 14000 300012000 300026000 575000 6000 136161000 136167000 2065000 22000 77572000 77594000 116900000 116900000 259079000 2591000 7695905000 13383000 -1250225000 6461654000 602753000 268631000 115706000 93791000 26821000 27140000 1600000 0 36705000 43425000 -44870000 43551000 -9668000 2431000 223672000 30136000 27450000 13139000 -2790000 -7941000 14285000 -24145000 153814000 -27279000 57808000 24537000 815698000 324784000 75265000 128215000 60145000 107118000 72036000 0 19450000 18041000 5800000 0 31666000 -39138000 79597000 63620000 300026000 94007000 136167000 5832000 10287000 9385000 5833000 0 2500000 5000000 880000 1385000 -359430000 -41989000 -6651000 -378000 481283000 243279000 3120681000 2658253000 3601964000 2901532000 13771000 13148000 5845000 1835000 817000 510000 0 4000000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Basis of Presentation and Accounting Policies</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex” or the “Company”) in accordance with accounting principles generally accepted in the United States of America (“GAAP”). </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The condensed consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. The Company operates in </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>one</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> segment, pharmaceuticals. The Company has reclassified certain items from the prior year’s condensed consolidated financial statements to conform to the current year’s presentation.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certain information and footnote disclosures normally included in the Company’s </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> Annual Report on Form 10-K have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which are contained in the Company’s </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> Annual Report on Form 10-K. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Use of Estimates </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with (i) determining the transaction price of revenues and (ii) accounting for intangible assets and contingent consideration. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Recently Adopted Accounting Standards</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:underline;">Leases</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">On January 1, 2019, the Company adopted Accounting Standards Codification (“ASC”) 842, </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">(“ASC 842”) using the modified-retrospective method, which amended a number of aspects of lease accounting and required the Company to recognize right-of-use assets and liabilities on the balance sheet. As of January 1, 2019, the Company recorded a cumulative effect adjustment to increase its “</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;">Accumulated deficit</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">” by </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$40.3 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which related to its leases that were accounted for as build-to-suit leases under the previous accounting guidance. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:underline;">Internal-Use Software</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-15, </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">(“ASU 2018-15”), which clarifies the accounting for implementation costs in cloud computing arrangements.  ASU 2018-15 became effective on January 1, 2020. The adoption of ASU 2018-15 resulted in an insignificant amount of additional assets recorded on the Company’s condensed consolidated balance sheet.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:underline;">Fair Value Measurement</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2018, the FASB issued ASU 2018-13, </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (“ASU 2018-13”), which modifies the disclosure requirements for fair </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">value measurements. ASU 2018-13 became effective on January 1, 2020. The adoption of ASU 2018-13 resulted in additional disclosures related to the Company’s Level 3 inputs. Please refer to </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note E, “Fair Value Measurements,”</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for further information.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:underline;">Credit Losses</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2016, the FASB issued ASU 2016-13, </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (“ASU 2016-13”), which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 became effective on January 1, 2020. The adoption of ASU 2016-13 did not have a significant impact on its condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Recently Issued Accounting Standards </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:underline;">Income Taxes</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2019, the FASB issued </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">ASU 2019-12</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Income Taxes (Topic 740)</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">ASU 2019-12</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">”), which simplifies the accounting for income taxes. </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">ASU 2019-12</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> is effective on January 1, 2021. </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company is evaluating the impact the adoption of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">ASU 2019-12</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> may have on its condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">For a discussion of other recent accounting pronouncements please refer to </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note A, “Nature of Business and Accounting Policies,”</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in the Company’s </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> Annual Report on Form 10-K. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Summary of Significant Accounting Policies</span></div><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company’s significant accounting policies are described in </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note A, “Nature of Business and Accounting Policies,”</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in its </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span> Annual Report on Form 10-K. <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex” or the “Company”) in accordance with accounting principles generally accepted in the United States of America (“GAAP”). </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The condensed consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. The Company operates in </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>one</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> segment, pharmaceuticals. The Company has reclassified certain items from the prior year’s condensed consolidated financial statements to conform to the current year’s presentation.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certain information and footnote disclosures normally included in the Company’s </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> Annual Report on Form 10-K have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which are contained in the Company’s </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> Annual Report on Form 10-K. </span></div> 1 <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Use of Estimates </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with (i) determining the transaction price of revenues and (ii) accounting for intangible assets and contingent consideration. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div> <div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Recently Adopted Accounting Standards</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:underline;">Leases</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">On January 1, 2019, the Company adopted Accounting Standards Codification (“ASC”) 842, </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">(“ASC 842”) using the modified-retrospective method, which amended a number of aspects of lease accounting and required the Company to recognize right-of-use assets and liabilities on the balance sheet. As of January 1, 2019, the Company recorded a cumulative effect adjustment to increase its “</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;">Accumulated deficit</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">” by </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$40.3 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which related to its leases that were accounted for as build-to-suit leases under the previous accounting guidance. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:underline;">Internal-Use Software</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-15, </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">(“ASU 2018-15”), which clarifies the accounting for implementation costs in cloud computing arrangements.  ASU 2018-15 became effective on January 1, 2020. The adoption of ASU 2018-15 resulted in an insignificant amount of additional assets recorded on the Company’s condensed consolidated balance sheet.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:underline;">Fair Value Measurement</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2018, the FASB issued ASU 2018-13, </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (“ASU 2018-13”), which modifies the disclosure requirements for fair </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">value measurements. ASU 2018-13 became effective on January 1, 2020. The adoption of ASU 2018-13 resulted in additional disclosures related to the Company’s Level 3 inputs. Please refer to </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note E, “Fair Value Measurements,”</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for further information.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:underline;">Credit Losses</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2016, the FASB issued ASU 2016-13, </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (“ASU 2016-13”), which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 became effective on January 1, 2020. The adoption of ASU 2016-13 did not have a significant impact on its condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Recently Issued Accounting Standards </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:underline;">Income Taxes</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2019, the FASB issued </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">ASU 2019-12</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Income Taxes (Topic 740)</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (“</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">ASU 2019-12</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">”), which simplifies the accounting for income taxes. </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">ASU 2019-12</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> is effective on January 1, 2021. </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company is evaluating the impact the adoption of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">ASU 2019-12</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> may have on its condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">For a discussion of other recent accounting pronouncements please refer to </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note A, “Nature of Business and Accounting Policies,”</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in the Company’s </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> Annual Report on Form 10-K. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Summary of Significant Accounting Policies</span></div><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company’s significant accounting policies are described in </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note A, “Nature of Business and Accounting Policies,”</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in its </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span> Annual Report on Form 10-K. -40300000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Revenue Recognition </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Disaggregation of Revenue</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:underline;">Revenues by Product</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Product revenues, net consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.46031746031747%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">TRIKAFTA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>895,233</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">SYMDEKO/SYMKEVI</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>173,159</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>320,275</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">ORKAMBI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>234,138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>293,007</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">KALYDECO</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>212,577</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>243,971</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total product revenues, net</span><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">*</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,515,107</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>857,253</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">* </sup></span><span style="font-family:inherit;font-size:8pt;">The preceding table does not include collaborative and royalty revenues.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:underline;">Revenues by Geographic Location</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Net product revenues are attributed to countries based on the location of the customer. Collaborative and royalty revenues are attributed to countries based on the location of the Company’s subsidiary associated with the collaborative arrangement related to such revenues. Total revenues from external customers and collaborators by geographic region consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.46031746031747%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,187,588</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>641,104</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Outside of the United States</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>257,391</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>167,751</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>70,128</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>49,580</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total revenues outside of the United States</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>327,519</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>217,331</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,515,107</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>858,435</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Contract Liabilities </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company recorded contract liabilities of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$76.3 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$62.3 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> as of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement the Company can receive. Upon exceeding the annual reimbursement amount, products are provided free of charge, which is a material right. These contracts include upfront payments and fees.  The Company defers a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;">Other current liabilities</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">.” The deferred amount is recognized as revenue when the free products are shipped. The Company’s product revenue contracts include performance obligations that are one year or less.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company’s contract liabilities at the end of each fiscal year relate to contracts with annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as the Company’s fiscal year. In these markets, the Company recognizes revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year.</span></div> <div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Product revenues, net consisted of the following:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.46031746031747%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">TRIKAFTA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>895,233</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">SYMDEKO/SYMKEVI</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>173,159</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>320,275</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">ORKAMBI</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>234,138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>293,007</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">KALYDECO</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>212,577</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>243,971</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total product revenues, net</span><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">*</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,515,107</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>857,253</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-left:24px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">* </sup></span><span style="font-family:inherit;font-size:8pt;">The preceding table does not include collaborative and royalty revenues.</span></div>Total revenues from external customers and collaborators by geographic region consisted of the following:<div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.46031746031747%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,187,588</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>641,104</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Outside of the United States</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>257,391</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>167,751</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>70,128</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>49,580</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total revenues outside of the United States</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>327,519</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>217,331</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,515,107</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>858,435</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div> 895233000 0 173159000 320275000 234138000 293007000 212577000 243971000 1515107000 857253000 1187588000 641104000 257391000 167751000 70128000 49580000 327519000 217331000 1515107000 858435000 76300000 62300000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has entered into numerous agreements pursuant to which it collaborates with third parties on research, development and commercialization programs, including in-license and out-license agreements. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company’s in-license and out-license agreements that had a significant impact on its financial statements for </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">the three months ended March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, or were new during </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">the three months ended March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, are described below. Additional in-license and out-license agreements were described in </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note B, “Collaborative Arrangements,”</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of the Company’s </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> Annual Report on Form 10-K.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">In-license Agreements</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has entered into a number of license agreements in order to advance and obtain access to technologies and services related to its research and early-development activities. The Company is generally required to make an upfront payment upon execution of the license agreement; development, regulatory and commercialization milestones payments upon the achievement of certain product research, development and commercialization objectives; and royalty payments on future sales, if any, of commercial products resulting from the collaboration.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the terms of its in-license agreements, the Company’s collaborators typically lead the discovery efforts and the Company leads all preclinical, development and commercialization activities associated with the advancement of any drug candidates and funds all expenses.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company typically can terminate its in-license agreements by providing advance notice to its collaborators; the required length of notice is dependent on whether any product developed under the license agreement has received marketing approval. The Company’s license agreements may be terminated by either party for a material breach by the other, subject to notice and cure provisions. Unless earlier terminated, these license agreements generally remain in effect until the date on which the royalty term and all payment obligations with respect to all products in all countries have expired.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:normal;text-decoration:underline;">CRISPR Therapeutics AG</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2015, the Company entered into a strategic collaboration, option and license agreement (the “CRISPR Agreement”) with CRISPR Therapeutics AG and its affiliates (“CRISPR”) to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene-editing technology. The Company had the exclusive right to license certain CRISPR-Cas9-based targets. In the fourth quarter of 2019, the Company elected to exclusively license </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>three</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> CRISPR-Cas9-based targets, including cystic fibrosis, pursuant to the CRISPR Agreement. For each of the </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>three</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> targets that the Company elected to license, CRISPR has the potential to receive up to an additional </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$410.0 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in development, regulatory and commercial milestones as well as royalties on net product sales. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2017, the Company entered into a co-development and co-commercialization agreement with CRISPR pursuant to the terms of the CRISPR Agreement, under which the Company and CRISPR are co-developing and will co-commercialize CTX001 (the “CTX001 Co-Co Agreement”) for the treatment of hemoglobinopathies, including treatments for sickle cell disease and beta thalassemia. As part of the collaboration, the Company and CRISPR share equally all development costs and potential worldwide revenues related to potential hemoglobinopathy treatments. The Company concluded that the CTX001 Co-Co Agreement is a cost-sharing arrangement, which results in the net impact of the arrangement being recorded in “</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Research and development expenses</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">” in its condensed consolidated statements of operations. During </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">the three months ended March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the net expense related to the CTX001 Co-Co Agreement was </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$9.3 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$7.0 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">In July 2019, the Company entered into a separate strategic collaboration and license agreement (the “CRISPR DMD/DM1 Agreement”) with CRISPR. Pursuant to this agreement, the Company received an exclusive worldwide license to CRISPR’s existing and future intellectual property for duchenne muscular dystrophy (“DMD”) and myotonic dystrophy type 1 (“DM1”). In the first quarter of 2020, the Company recorded </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$25.0 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> to “</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Research and development expenses</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">” related to a pre-clinical milestone earned by CRISPR under the CRISPR DMD/DM1 Agreement. CRISPR has the potential to receive up to an additional </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$800.0 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in research, development, regulatory and commercial milestones for the DMD and DM1 programs as well as royalties on net product sales. CRISPR has the option to co-develop and co-commercialize all DM1 products globally and forego the milestones and royalties associated with the DM1 program. The Company funds all expenses associated with the collaboration except for research costs for specified guide RNA research conducted by CRISPR, which the Company and CRISPR share equally. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Please refer to </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note F, “Marketable Securities and Equity Investments,”</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for further information regarding the Company’s investment in CRISPR’s common stock.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Out-license Agreements</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has entered into licensing agreements pursuant to which it has out-licensed rights to certain drug candidates to third-party collaborators. Pursuant to these out-license agreements, the Company’s collaborators become responsible for all costs related to the continued development of such drug candidates and obtain development and commercialization rights to these drug candidates. Depending on the terms of the agreements, the Company’s collaborators may be required to make upfront payments, milestone payments upon the achievement of certain product research and development objectives and may also be required to pay royalties on future sales, if any, of commercial products resulting from the collaboration. The termination provisions associated with these collaborations are generally the same as those described above related to the Company’s in-license agreements. None of the Company’s out-license agreements had a significant impact on the Company’s condensed consolidated statement of operations during </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">the three months ended March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Cystic Fibrosis Foundation</span></div>The Company has a research, development and commercialization agreement that was originally entered into in 2004 with Cystic Fibrosis Foundation (“CFF”), as successor in interest to the Cystic Fibrosis Foundation Therapeutics, Inc. This agreement was most recently amended in 2016. Pursuant to the agreement, as amended, the Company agreed to pay royalties ranging from low-single digits to mid-single digits on potential sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016, including elexacaftor, and tiered royalties ranging from single digits to sub-teens on covered compounds first synthesized and/or tested during a research term on or before February 28, 2014, including KALYDECO (ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor). For combination products, such as ORKAMBI, SYMDEKO/SYMKEVI and TRIKAFTA (elexacaftor, tezacaftor, and ivacaftor), sales are allocated equally to each of the active pharmaceutical ingredients in the combination product. 3 3 410000000.0 9300000 7000000.0 25000000.0 800000000.0 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Earnings Per Share</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Basic net income per common share</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> is based upon the weighted-average number of common shares outstanding. </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Diluted net income per common share</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> utilizing the treasury method is based upon the weighted-average number of common shares outstanding during the period plus additional weighted-average common equivalent shares outstanding during the period when the effect is dilutive. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table sets forth the computation of basic and diluted net income per common share for the periods ended:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.46031746031747%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands, except per share amounts)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>602,753</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>268,631</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Basic weighted-average common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>259,815</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>255,695</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Effect of potentially dilutive securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock options</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,868</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,585</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Restricted stock and restricted stock units (including PSUs)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,801</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,870</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Employee stock purchase program</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>31</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Diluted weighted-average common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>263,515</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>260,175</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Basic net income per common share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.32</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1.05</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Diluted net income per common share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1.03</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company did not include the securities in the following table in the computation of the net income per common share because the effect would have been anti-dilutive during each period:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.46031746031747%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>879</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,837</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Unvested restricted stock and restricted stock units (including PSUs)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>430</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table sets forth the computation of basic and diluted net income per common share for the periods ended:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.46031746031747%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands, except per share amounts)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>602,753</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>268,631</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Basic weighted-average common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>259,815</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>255,695</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Effect of potentially dilutive securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock options</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,868</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,585</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Restricted stock and restricted stock units (including PSUs)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,801</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,870</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Employee stock purchase program</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>31</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Diluted weighted-average common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>263,515</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>260,175</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Basic net income per common share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.32</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1.05</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Diluted net income per common share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1.03</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div> 602753000 268631000 259815000 255695000 1868000 2585000 1801000 1870000 31000 25000 263515000 260175000 2.32 1.05 2.29 1.03 <div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company did not include the securities in the following table in the computation of the net income per common share because the effect would have been anti-dilutive during each period:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.46031746031747%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>879</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,837</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Unvested restricted stock and restricted stock units (including PSUs)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>430</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div> 879000 2837000 430000 6000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Fair Value Measurements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value of the Company’s financial assets and liabilities reflects the Company’s estimate of amounts that it would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.4920634920635%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"/></tr><tr><td style="width:12%;"/><td style="width:88%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Level 1:</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Level 2:</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Level 3:</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Unobservable inputs based on the Company’s assessment of the assumptions that market participants would use in pricing the asset or liability.</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company’s investment strategy is focused on capital preservation. The Company invests in instruments that meet the credit quality standards outlined in the Company’s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument. The Company maintains strategic investments separately from the investment policy that governs its other cash, cash equivalents and marketable securities as described in “</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note F, “Marketable Securities and Equity Investments.”</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> As of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company’s investments were in money market funds, corporate debt securities, commercial paper, government-sponsored enterprise securities and corporate equity securities. Additionally, the Company utilizes foreign currency forward contracts intended to mitigate the effect of changes in foreign exchange rates on its condensed consolidated statement of operations. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company’s financial assets and liabilities that were subject to fair value measurements were valued using both observable and unobservable inputs. The Company’s financial assets valued based on Level 1 inputs consisted of money market funds, government-sponsored enterprise securities and corporate equity securities. The Company’s financial assets and liabilities valued based on Level 2 inputs consisted of certain corporate equity securities as described below, corporate debt securities, commercial paper, which consisted of investments in highly-rated investment-grade corporations, and foreign currency forward contracts with reputable and creditworthy counterparties. As discussed further below, the Company’s financial liabilities valued based on Level 3 inputs consisted of acquisition-related contingent milestones. During </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">the three months ended March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company did not record any other-than-temporary impairment charges related to its financial assets.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following tables set forth the Company’s financial assets and liabilities subject to fair value measurements (and does not include </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$1.8 billion</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and $</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>2.3 billion</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of cash as of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively):</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Fair Value Measurements as of March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value Hierarchy</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Financial instruments carried at fair value (asset positions):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,736,913</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,736,913</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>30,700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>30,700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Marketable securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>165,178</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>145,465</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>19,713</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,791</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,791</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>305,051</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>305,051</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>118,964</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>118,964</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Prepaid expenses and other current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>25,434</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>25,434</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,798</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,798</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total financial assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,391,829</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,890,169</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>501,660</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Financial instruments carried at fair value (liability positions):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(459</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(459</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Long-term contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(178,100</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(178,100</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other long-term liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(637</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(637</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total financial liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(179,196</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,096</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(178,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value Measurements as of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value Hierarchy</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Financial instruments carried at fair value (asset positions):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>791,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>791,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,070</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,070</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>29,472</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>29,472</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Marketable securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>282,084</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>261,797</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>20,287</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>301,799</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>301,799</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>102,356</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>102,356</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Prepaid expenses and other current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total financial assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,535,278</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,065,569</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>469,709</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Financial instruments carried at fair value (liability positions):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(5,533</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(5,533</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Long-term contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(176,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(176,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other long-term liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,821</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,821</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total financial liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(183,854</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,354</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(176,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Please refer to </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note F, “Marketable Securities and Equity Investments,”</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for the carrying amount and related unrealized gains (losses) by type of investment.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Fair Value of Corporate Equity Securities</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company maintains strategic investments in corporate equity securities separately from the investment policy that governs its other cash, cash equivalents and marketable securities. The Company classifies its investments in publicly traded companies as “</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;">Marketable securities</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">” on its condensed consolidated balance sheets. Generally, the Company’s investments in the common stock of these publicly traded companies are valued based on Level 1 inputs because they have readily determinable fair values. However, certain of the Company’s investments in publicly traded companies have been or continue to be valued based on Level 2 inputs due to transfer restrictions associated with these investments. Please refer to </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note F, “Marketable Securities and Equity Investments,”</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for further information on these investments.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Fair Value of Contingent Consideration</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company’s contingent consideration liabilities, which are related to </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$678.3 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of development and regulatory milestones potentially payable to Exonics’ former equity holders, are classified as Level 3 within the valuation hierarchy. The Company bases its estimates of the probability of achieving the milestones relevant to the fair value of contingent payments on industry data attributable to rare diseases. The discount rates used in the valuation model for contingent payments, which were between </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>1.8%</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>3.1%</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period. Due to the uncertainties associated with development and commercialization of a drug candidate in the pharmaceutical industry, the Company's estimates regarding the fair value of contingent consideration will change in the future, resulting in adjustments to the fair value of the Company’s contingent consideration liabilities, and the effect of any such adjustments could be material.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table represents a rollforward of the fair value of the Company’s contingent consideration liabilities:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:61.50793650793651%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Three Months Ended March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>176,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Increase in fair value of contingent payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,600</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Balance at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>178,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The “</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Increase in fair value of contingent payments</span>” in the table above was due to changes in market interest rates and the time value of money. <div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following tables set forth the Company’s financial assets and liabilities subject to fair value measurements (and does not include </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$1.8 billion</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and $</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>2.3 billion</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of cash as of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively):</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:1px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Fair Value Measurements as of March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value Hierarchy</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Financial instruments carried at fair value (asset positions):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,736,913</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,736,913</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>30,700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>30,700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Marketable securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>165,178</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>145,465</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>19,713</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,791</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,791</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>305,051</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>305,051</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>118,964</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>118,964</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Prepaid expenses and other current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>25,434</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>25,434</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,798</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,798</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total financial assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,391,829</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,890,169</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>501,660</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Financial instruments carried at fair value (liability positions):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(459</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(459</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Long-term contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(178,100</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(178,100</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other long-term liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(637</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(637</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total financial liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(179,196</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,096</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(178,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value Measurements as of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value Hierarchy</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Financial instruments carried at fair value (asset positions):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>791,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>791,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,070</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,070</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>29,472</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>29,472</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Marketable securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>282,084</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>261,797</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>20,287</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>301,799</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>301,799</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>102,356</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>102,356</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Prepaid expenses and other current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total financial assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,535,278</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,065,569</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>469,709</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Financial instruments carried at fair value (liability positions):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(5,533</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(5,533</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Long-term contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(176,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(176,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other long-term liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:40px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Foreign currency forward contracts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,821</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,821</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total financial liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(183,854</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,354</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(176,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div> 1800000000 2300000000 1736913000 1736913000 0 0 30700000 0 30700000 0 165178000 145465000 19713000 0 7791000 7791000 0 0 305051000 0 305051000 0 118964000 0 118964000 0 25434000 0 25434000 0 1798000 0 1798000 0 2391829000 1890169000 501660000 0 459000 0 459000 0 178100000 0 0 178100000 637000 0 637000 0 179196000 0 1096000 178100000 791039000 791039000 0 0 6070000 0 6070000 0 29472000 0 29472000 0 282084000 261797000 20287000 0 12733000 12733000 0 0 301799000 0 301799000 0 102356000 0 102356000 0 9725000 0 9725000 0 1535278000 1065569000 469709000 0 5533000 0 5533000 0 176500000 0 0 176500000 1821000 0 1821000 0 183854000 0 7354000 176500000 678300000 0.018 0.031 <div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table represents a rollforward of the fair value of the Company’s contingent consideration liabilities:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:61.50793650793651%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Three Months Ended March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>176,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Increase in fair value of contingent payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,600</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Balance at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>178,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div> 176500000 1600000 178100000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Marketable Securities and Equity Investments</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the Company’s cash equivalents and marketable securities, which are recorded at fair value (and do not include </span><span style="font-family:inherit;font-size:10pt;"><span>$1.8 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and $</span><span style="font-family:inherit;font-size:10pt;"><span>2.3 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of cash as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively), is shown below:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross <br/>Unrealized <br/>Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross <br/>Unrealized <br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of March 31, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,736,913</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,736,913</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>30,700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>30,700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,767,613</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,767,613</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Marketable securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,717</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>74</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,791</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>305,808</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>255</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,012</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>305,051</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>118,542</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>426</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>118,964</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total marketable debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>432,067</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>755</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,016</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>431,806</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate equity securities </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>87,096</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>78,082</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>165,178</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>519,163</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>78,837</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,016</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>596,984</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>791,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>791,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,070</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,070</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>29,470</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>29,472</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>826,579</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>826,581</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Marketable securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,689</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>301,458</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>391</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>301,799</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>102,240</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>121</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>102,356</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total marketable debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>416,387</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>556</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>416,888</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate equity securities </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>113,829</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>168,255</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>282,084</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>530,216</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>168,811</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>698,972</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Available-for-sale debt securities were classified on the Company's condensed consolidated balance sheets at fair value as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,767,613</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>826,581</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>431,806</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>416,888</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,199,419</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,243,469</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Available-for-sale debt securities by contractual maturity were as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Matures within one year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,157,586</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,137,942</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Matures after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>41,833</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>105,527</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,199,419</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,243,469</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has a limited number of available-for-sale debt securities in insignificant loss positions as of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which it does not intend to sell and has concluded it will not be required to sell before recovery of the amortized costs for the investments at maturity. The Company did </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>no</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">t record any charges for other-than-temporary declines in the fair value of available-for-sale debt securities or gross realized gains or losses in </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">the three months ended March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the total fair value of the Company’s strategic investments in the common stock of publicly traded companies, which was primarily related to its investment in CRISPR, was </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$165.2 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$282.1 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, and was classified as “</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;">Marketable securities</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">” on its condensed consolidated balance sheets. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company records changes in the fair value of its investments in corporate equity securities, which are primarily attributable to its investment in CRISPR, to “</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;">Other (expense) income, net</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">” on its condensed consolidated statements of operations. During </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">the three months ended March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company recorded a net unrealized loss of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$39.4 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and a net unrealized gain of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$43.6 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, on corporate equity securities held at the conclusion of each period. During </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">the three months ended March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company received proceeds of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$72.0 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> related to sales of CRISPR’s common stock, which had an original weighted-average cost basis of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$26.7 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">. There were no sales of CRISPR’s common stock during </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">the three months ended March 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the carrying value of the Company’s equity investments without readily determinable fair values, which are recorded in “</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;">Other assets</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">” on its condensed consolidated balance sheets, was </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$46.6 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</span></div> <div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the Company’s cash equivalents and marketable securities, which are recorded at fair value (and do not include </span><span style="font-family:inherit;font-size:10pt;"><span>$1.8 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and $</span><span style="font-family:inherit;font-size:10pt;"><span>2.3 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of cash as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively), is shown below:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross <br/>Unrealized <br/>Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross <br/>Unrealized <br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of March 31, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,736,913</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,736,913</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>30,700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>30,700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,767,613</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,767,613</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Marketable securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,717</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>74</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,791</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>305,808</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>255</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,012</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>305,051</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>118,542</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>426</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>118,964</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total marketable debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>432,067</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>755</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,016</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>431,806</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate equity securities </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>87,096</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>78,082</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>165,178</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>519,163</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>78,837</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,016</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>596,984</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>791,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>791,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,070</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,070</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>29,470</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>29,472</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>826,579</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>826,581</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Marketable securities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Government-sponsored enterprise securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,689</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>301,458</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>391</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>301,799</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>102,240</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>121</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>102,356</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total marketable debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>416,387</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>556</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>416,888</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Corporate equity securities </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>113,829</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>168,255</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>282,084</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>530,216</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>168,811</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>698,972</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Available-for-sale debt securities were classified on the Company's condensed consolidated balance sheets at fair value as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,767,613</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>826,581</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>431,806</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>416,888</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,199,419</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,243,469</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Available-for-sale debt securities by contractual maturity were as follows:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Matures within one year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,157,586</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,137,942</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Matures after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>41,833</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>105,527</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,199,419</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,243,469</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div> 1800000000 2300000000 1736913000 0 0 1736913000 30700000 4000 4000 30700000 1767613000 4000 4000 1767613000 7717000 74000 0 7791000 305808000 255000 1012000 305051000 118542000 426000 4000 118964000 432067000 755000 1016000 431806000 87096000 78082000 0 165178000 519163000 78837000 1016000 596984000 791039000 0 0 791039000 6070000 0 0 6070000 29470000 3000 1000 29472000 826579000 3000 1000 826581000 12689000 44000 0 12733000 301458000 391000 50000 301799000 102240000 121000 5000 102356000 416387000 556000 55000 416888000 113829000 168255000 0 282084000 530216000 168811000 55000 698972000 1767613000 826581000 431806000 416888000 2199419000 1243469000 2157586000 1137942000 41833000 105527000 2199419000 1243469000 0 165200000 282100000 -39400000 43600000 72000000.0 26700000 46600000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes the changes in accumulated other comprehensive income (loss) by component: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Unrealized Holding Gains (Losses), Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Foreign Currency Translation Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">On Available-For-Sale Debt Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">On Foreign Currency Forward Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(895</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>503</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,581</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,973</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other comprehensive (loss) income before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(2,662</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(764</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>25,772</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>22,346</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(6,990</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(6,990</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net current period other comprehensive (loss) income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(2,662</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(764</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>18,782</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>15,356</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Balance at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(3,557</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(261</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>17,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>13,383</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(11,227</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(536</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,422</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>659</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other comprehensive income before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,967</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>596</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,689</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Amounts reclassified from accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(5,348</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(5,348</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net current period other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,967</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>596</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(222</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,341</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Balance at March 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(6,260</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>60</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,200</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes the changes in accumulated other comprehensive income (loss) by component: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Unrealized Holding Gains (Losses), Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Foreign Currency Translation Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">On Available-For-Sale Debt Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">On Foreign Currency Forward Contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(895</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>503</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,581</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,973</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other comprehensive (loss) income before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(2,662</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(764</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>25,772</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>22,346</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Amounts reclassified from accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(6,990</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(6,990</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net current period other comprehensive (loss) income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(2,662</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(764</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>18,782</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>15,356</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Balance at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(3,557</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(261</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>17,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>13,383</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(11,227</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(536</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,422</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>659</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other comprehensive income before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,967</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>596</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>10,689</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Amounts reclassified from accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(5,348</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(5,348</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Net current period other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,967</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>596</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(222</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,341</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Balance at March 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(6,260</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>60</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>12,200</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div> -895000 503000 -1581000 -1973000 -2662000 -764000 25772000 22346000 0 0 6990000 6990000 -2662000 -764000 18782000 15356000 -3557000 -261000 17201000 13383000 -11227000 -536000 12422000 659000 4967000 596000 5126000 10689000 0 0 5348000 5348000 4967000 596000 -222000 5341000 -6260000 60000 12200000 6000000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Hedging </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Foreign currency forward contracts - Designated as hedging instruments</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company maintains a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of the Company’s forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under GAAP having contractual durations from </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> to </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>eighteen months</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The Company recognizes realized gains and losses for the effective portion of such contracts in “</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Product revenues, net</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">” in its condensed consolidated statements of operations in the same period that it recognizes the product revenues that were impacted by the hedged foreign exchange rate changes. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company formally documents the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as the Company’s risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. The Company also formally assesses, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If the Company were to determine that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, the Company would discontinue hedge accounting treatment prospectively. The Company measures effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, all hedges were determined to be highly effective.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company considers the impact of its counterparties’ credit risk on the fair value of the foreign currency forward contracts. As of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, credit risk did not change the fair value of the Company’s foreign currency forward contracts.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes the notional amount of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Foreign Currency</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Euro</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>581,764</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>501,197</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">British pound sterling</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>124,160</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>87,032</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Australian dollar</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>74,643</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>89,705</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Canadian dollar</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>46,390</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>50,452</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>826,957</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>728,386</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Foreign currency forward contracts - Not designated as hedging instruments</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company also enters into foreign currency forward contracts with contractual maturities of less than </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>one month</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, that are designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities, including intercompany balances. These contracts are not designated as hedging instruments under GAAP. The Company recognizes realized gains and losses for such contracts in “</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;">Other (expense) income, net</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">” in its condensed consolidated statements of operations each period. As of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the notional amount of the Company’s outstanding foreign currency forward contracts where hedge accounting under GAAP is not applied was </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$522.2 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">During </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">the three months ended March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company recognized the following related to foreign currency forward contacts in its condensed consolidated statements of operations:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.46031746031747%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-style:italic;">Designated as hedging instruments - Reclassified from AOCI</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,922</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,839</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-style:italic;">Not designated as hedging instruments</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other (expense) income, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>16,229</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,151</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-style:italic;">Total reported in the Condensed Consolidated Statement of Operations</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,515,107</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>857,253</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other (expense) income, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(61,130</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>42,610</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes the fair value of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on its condensed consolidated balance sheets: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.85714285714286%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:35%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of March 31, 2020</span></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Liabilities</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Classification</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Classification</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Fair Value</span></div></td></tr><tr><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>25,434</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(459</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,798</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(637</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>27,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,096</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.85714285714286%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:35%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Liabilities</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Classification</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Classification</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value</span></div></td></tr><tr><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(5,533</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,821</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,354</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company expects the amounts that are related to foreign exchange forward contracts designated as cash flow hedges under GAAP recorded in “</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;">Prepaid expenses and other current assets</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">” and “</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;">Other current liabilities</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">” to be reclassified to earnings within twelve months.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under GAAP on the Company’s condensed consolidated balance sheets:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.85714285714286%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Offset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Presented</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Not Offset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Legal Offset</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Foreign currency forward contracts</span></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>27,232</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>27,232</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,096</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>26,136</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,096</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,096</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,096</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.85714285714286%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Offset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Presented</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Not Offset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Legal Offset</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Foreign currency forward contracts</span></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,354</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,371</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,354</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,354</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,354</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div> P18M <div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes the notional amount of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Foreign Currency</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Euro</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>581,764</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>501,197</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">British pound sterling</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>124,160</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>87,032</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Australian dollar</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>74,643</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>89,705</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Canadian dollar</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>46,390</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>50,452</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total foreign currency forward contracts</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>826,957</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>728,386</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div> 581764000 501197000 124160000 87032000 74643000 89705000 46390000 50452000 826957000 728386000 P1M 522200000 <div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">During </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">the three months ended March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company recognized the following related to foreign currency forward contacts in its condensed consolidated statements of operations:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.46031746031747%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-style:italic;">Designated as hedging instruments - Reclassified from AOCI</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,922</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,839</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-style:italic;">Not designated as hedging instruments</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other (expense) income, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>16,229</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,151</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-style:italic;">Total reported in the Condensed Consolidated Statement of Operations</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Product revenues, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,515,107</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>857,253</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other (expense) income, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(61,130</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>42,610</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div> 8922000 6839000 16229000 3151000 1515107000 857253000 -61130000 42610000 <div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes the fair value of the Company’s outstanding foreign currency forward contracts designated as cash flow hedges under GAAP included on its condensed consolidated balance sheets: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.85714285714286%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:35%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of March 31, 2020</span></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Liabilities</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Classification</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Classification</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Fair Value</span></div></td></tr><tr><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>25,434</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(459</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,798</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(637</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>27,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,096</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.85714285714286%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:35%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Liabilities</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Classification</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Classification</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Fair Value</span></div></td></tr><tr><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(5,533</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,821</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,354</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr></table></div></div> 25434000 459000 1798000 637000 27232000 1096000 9725000 5533000 0 1821000 9725000 7354000 <div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under GAAP on the Company’s condensed consolidated balance sheets:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.85714285714286%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Offset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Presented</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Not Offset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Legal Offset</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Foreign currency forward contracts</span></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>27,232</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>27,232</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,096</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>26,136</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,096</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,096</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,096</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.85714285714286%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Offset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Presented</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Not Offset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Legal Offset</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Foreign currency forward contracts</span></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,354</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,371</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,354</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,354</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,354</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under GAAP on the Company’s condensed consolidated balance sheets:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.85714285714286%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Offset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Presented</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Not Offset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Legal Offset</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Foreign currency forward contracts</span></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>27,232</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>27,232</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,096</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>26,136</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,096</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,096</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,096</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.85714285714286%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Offset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Presented</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Gross Amounts Not Offset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Legal Offset</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Foreign currency forward contracts</span></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,354</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,371</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,354</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(7,354</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7,354</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div> 27232000 0 27232000 1096000 26136000 1096000 0 1096000 1096000 0 9725000 0 9725000 7354000 2371000 7354000 0 7354000 7354000 0 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Inventories</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Inventories consisted of the following: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>24,835</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>26,247</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>117,427</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>107,021</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>44,825</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>34,234</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>187,087</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>167,502</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Inventories consisted of the following: </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.52380952380952%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:24%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>24,835</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>26,247</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>117,427</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>107,021</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>44,825</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>34,234</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>187,087</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>167,502</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div> 24835000 26247000 117427000 107021000 44825000 34234000 187087000 167502000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Stock-based Compensation Expense and Share Repurchase Programs</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Stock-based compensation expense </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">During </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">the three months ended March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company recognized the following stock-based compensation expense:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.46031746031747%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock-based compensation expense by type of award:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Restricted stock and restricted stock units (including PSUs)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>97,149</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>63,510</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock options</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>17,266</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>28,156</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">ESPP share issuances</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,485</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,577</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock-based compensation expense related to inventories</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,194</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(452</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total stock-based compensation expense included in costs and expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>115,706</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>93,791</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock-based compensation expense by line item:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,361</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,338</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Research and development expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>72,687</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>59,715</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Sales, general and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>41,658</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>32,738</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total stock-based compensation expense included in costs and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>115,706</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>93,791</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Income tax effect</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(64,246</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(39,524</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total stock-based compensation expense, net of tax</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>51,460</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>54,267</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table sets forth the Company’s unrecognized stock-based compensation expense as of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, by type of award and the weighted-average period over which that expense is expected to be recognized:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Unrecognized Expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Weighted-average <br/>Recognition Period</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in years)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Type of award:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Restricted stock and restricted stock units (including PSUs)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>550,095</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.27</span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>109,086</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.33</span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">ESPP share issuances</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,238</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.40</span></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes information about stock options outstanding and exercisable as of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.28571428571429%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Options Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Options Exercisable</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Range of Exercise Prices</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Number <br/>Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Weighted-average <br/>Remaining <br/>Contractual Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Weighted-average <br/>Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Number <br/>Exercisable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Weighted-average <br/>Exercise Price</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(per share)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(per share)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$29.07–$40.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1.47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>37.70</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>37.70</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$40.01–$60.00</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.41</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>49.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>49.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$60.01–$80.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>116</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4.03</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>74.89</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>112</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>74.89</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$80.01–$100.00</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,393</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5.99</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>89.44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,085</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>90.01</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$100.01–$120.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>182</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4.88</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>109.25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>180</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>109.18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$120.01–$140.00</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>402</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5.44</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>129.59</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>400</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>129.61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$140.01–$160.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>954</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7.86</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>155.50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>436</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>155.41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$160.01–$180.00</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>669</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8.24</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>168.21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>245</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>165.11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$180.01–$189.38</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,498</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8.65</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>185.44</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>440</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>185.31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,519</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6.98</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>137.34</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,203</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>119.05</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Share repurchase programs</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">During 2018, the Company’s Board of Directors approved a share repurchase program (the “2018 Share Repurchase Program”), pursuant to which the Company repurchased </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$500.0 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of its common stock in 2018 and 2019. During </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">the three months ended March 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company repurchased </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>537,018</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of its common stock under the share repurchase program for an aggregate of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$98.0 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> including commissions and fees. As of June 30, 2019, the Company had repurchased the entire </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$500.0 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> it was authorized to repurchase of its common stock under the 2018 Share Repurchase Program. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">During 2019, the Company’s Board of Directors approved a new share repurchase program (the “2019 Share Repurchase Program”), pursuant to which the Company is authorized to repurchase up to </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$500.0 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of its common stock between August 1, 2019 and December 31, 2020. The Company expects to fund further repurchases of its common stock through a combination of cash on hand and cash generated by operations. During </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">the three months ended March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company repurchased </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>1,403,868</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of its common stock under the 2019 Share Repurchase Program for an aggregate of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$300.0 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> including commissions and fees. As of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, there was a total of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$164.0 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> remaining for repurchases under the 2019 Share Repurchase Program. </span></div>Under the 2019 Share Repurchase Programs, the Company is authorized to purchase shares from time to time through open market or privately negotiated transactions. Such purchases are made pursuant to Rule 10b5-1 plans or other means as determined by the Company’s management and in accordance with the requirements of the SEC. <div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">During </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">the three months ended March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company recognized the following stock-based compensation expense:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.46031746031747%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock-based compensation expense by type of award:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Restricted stock and restricted stock units (including PSUs)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>97,149</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>63,510</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock options</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>17,266</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>28,156</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">ESPP share issuances</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,485</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,577</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:1px;padding-right:2px;"><div style="padding-bottom:1px;text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock-based compensation expense related to inventories</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(1,194</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(452</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total stock-based compensation expense included in costs and expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>115,706</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>93,791</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock-based compensation expense by line item:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,361</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,338</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Research and development expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>72,687</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>59,715</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Sales, general and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>41,658</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>32,738</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total stock-based compensation expense included in costs and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>115,706</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>93,791</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Income tax effect</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(64,246</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>(39,524</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total stock-based compensation expense, net of tax</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>51,460</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>54,267</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div> 97149000 63510000 17266000 28156000 2485000 2577000 1194000 452000 115706000 93791000 1361000 1338000 72687000 59715000 41658000 32738000 115706000 93791000 64246000 39524000 51460000 54267000 <div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table sets forth the Company’s unrecognized stock-based compensation expense as of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, by type of award and the weighted-average period over which that expense is expected to be recognized:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">As of March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Unrecognized Expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Weighted-average <br/>Recognition Period</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in years)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Type of award:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Restricted stock and restricted stock units (including PSUs)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>550,095</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.27</span></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>109,086</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.33</span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:26px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">ESPP share issuances</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,238</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>0.40</span></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div> 550095000 P2Y3M7D 109086000 P2Y3M29D 2238000 P0M12D <div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes information about stock options outstanding and exercisable as of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">:</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.28571428571429%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;font-weight:bold;color:#000000;">Options Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Options Exercisable</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Range of Exercise Prices</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Number <br/>Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Weighted-average <br/>Remaining <br/>Contractual Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Weighted-average <br/>Exercise Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Number <br/>Exercisable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Weighted-average <br/>Exercise Price</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(per share)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(per share)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$29.07–$40.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1.47</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>37.70</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>37.70</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$40.01–$60.00</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2.41</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>49.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>224</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>49.15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$60.01–$80.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>116</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4.03</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>74.89</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>112</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>74.89</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$80.01–$100.00</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,393</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5.99</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>89.44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,085</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>90.01</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$100.01–$120.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>182</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4.88</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>109.25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>180</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>109.18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$120.01–$140.00</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>402</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5.44</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>129.59</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>400</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>129.61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$140.01–$160.00</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>954</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>7.86</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>155.50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>436</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>155.41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$160.01–$180.00</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>669</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8.24</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>168.21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>245</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>165.11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$180.01–$189.38</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,498</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8.65</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>185.44</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>440</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>185.31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>5,519</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6.98</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>137.34</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,203</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>119.05</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div> 81000 P1Y5M19D 37.70 81000 37.70 224000 P2Y4M28D 49.15 224000 49.15 116000 P4Y10D 74.89 112000 74.89 1393000 P5Y11M26D 89.44 1085000 90.01 182000 P4Y10M17D 109.25 180000 109.18 402000 P5Y5M8D 129.59 400000 129.61 954000 P7Y10M9D 155.50 436000 155.41 669000 P8Y2M26D 168.21 245000 165.11 1498000 P8Y7M24D 185.44 440000 185.31 5519000 P6Y11M23D 137.34 3203000 119.05 500000000.0 537018 98000000.0 500000000.0 500000000.0 1403868 300000000.0 164000000.0 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company is subject to U.S. federal, state, and foreign income taxes. For </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">the three months ended March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company recorded provisions for income taxes of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$54.8 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$51.5 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. The Company’s effective tax rate for </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">the three months ended March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> was lower than the U.S. statutory rate primarily due to a discrete benefit related to the write-off of a long-term intercompany receivable and excess tax benefits related to stock-based compensation. The Company’s effective tax rate for </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">the three months ended March 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> was lower than the U.S. statutory rate primarily due to excess tax benefits related to stock-based compensation. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company released its valuation allowance on the majority of its net operating losses and other deferred tax assets as of December 31, 2018. Starting in 2019, the Company began recording a provision for income taxes on its pre-tax income using an effective tax rate approximating statutory rates. Due to the Company's ability to offset its pre-tax income against </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">previously benefited net operating losses, it expects a portion of its tax provision to represent a non-cash expense until its net operating losses have been fully utilized. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company maintained a valuation allowance of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$205.2 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> related primarily to U.S. state and foreign tax attributes as of December 31, 2019. On a periodic basis, the Company reassesses any valuation allowances that it maintains on its deferred tax assets, weighing positive and negative evidence to assess the recoverability of the deferred tax assets.  </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">In March 2020, the Coronavirus Aid, Relief and Economic Security Act (“the CARES Act”) was signed into law. The CARES Act includes provisions relating to several aspects of corporate income taxes. The Company does not currently expect the CARES Act to have a significant impact on its provision for income taxes; however, it will continue to monitor the provisions of the CARES Act in relation to its operations.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has reviewed the tax positions taken, or to be taken, in its tax returns for all tax years currently open to examination by a taxing authority. Unrecognized tax benefits represent the aggregate tax effect of differences between tax return positions and the benefits recognized in the financial statements. As of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company had </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$43.0 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$33.9 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, of gross unrecognized tax benefits, which would affect the Company’s tax rate if recognized. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company accrues interest and penalties related to unrecognized tax benefits as a component of its provision for income taxes. </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> significant interest or penalties were accrued. The Company did not recognize any material interest or penalties related to uncertain tax positions during </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">the three months ended March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, foreign earnings, which were not significant, have been retained by foreign subsidiaries for indefinite reinvestment. Upon repatriation of those earnings, in the form of dividends or otherwise, the Company could be subject to withholding taxes payable to the various foreign countries.</span></div>The Company files U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. The Company is no longer subject to any tax assessment from an income tax examination in the United States or any other major taxing jurisdiction for years before 2011, except where the Company has net operating losses or tax credit carryforwards that originate before 2011. The Company has various income tax audits ongoing at any time throughout the world. No significant adjustments have been reported for any jurisdiction under audit. 54800000 51500000 205200000 43000000.0 33900000 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Commitments and Contingencies</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Revolving Credit Facility</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">In September 2019, the Company and certain of its subsidiaries entered into a Credit Agreement (the “2019 Credit Agreement”) with Bank of America, N.A., as administrative agent and the lenders referred to therein. The 2019 Credit Agreement provides for a </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$500.0 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> unsecured revolving facility, which was not drawn upon at closing. Amounts drawn pursuant to the 2019 Credit Agreement, if any, may be used to finance the Company’s working capital needs, and for general corporate or other lawful purposes. The Company had no borrowings outstanding under the 2019 Credit Agreement as of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The 2019 Credit Agreement also provides that, subject to satisfaction of certain conditions, the Company may request that the borrowing capacity under the 2019 Credit Agreement be increased by an additional </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$500.0 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The 2019 Credit Agreement, which matures on September 17, 2024, supersedes the Company’s credit agreement entered into in 2016 with Bank of America, N.A serving in the same capacity. Additionally, the 2019 Credit Agreement provides a sublimit of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$50.0 million</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for letters of credit.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Direct costs related to the 2019 Credit Agreement, which were not material to the Company’s financial statements, were deferred and will be recorded over the term of the 2019 Credit Agreement. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Any amounts borrowed under the 2019 Credit Agreement will bear interest, at the Company’s option, at either a base rate or a Eurocurrency rate, in each case plus an applicable margin. Under the 2019 Credit Agreement, the applicable margins on base rate loans range from </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>0.125%</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> to </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>0.50%</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and the applicable margins on Eurocurrency loans range from </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>1.125%</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> to </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>1.50%</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, in each case based on the Company’s consolidated leverage ratio (the ratio of the Company’s total consolidated funded indebtedness to the Company’s consolidated EBITDA for the most recently completed four fiscal quarter period).</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">Any amounts borrowed pursuant to the 2019 Credit Agreement are guaranteed by certain of the Company’s existing and future domestic subsidiaries, subject to certain exceptions. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The 2019 Credit Agreement contains customary representations and warranties and affirmative and negative covenants, including financial covenants to maintain (i) subject to certain limited exceptions, a consolidated leverage ratio of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>3.50</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> to </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.00</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, subject to an increase to </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>4.00</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> to </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.00</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> following a material acquisition and (ii) a consolidated interest coverage ratio (the ratio of the Company’s consolidated EBITDA to its consolidated interest expenses for the most recently completed four fiscal quarter period) of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>2.50</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> to </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.00</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, in each case measured on a quarterly basis. The 2019 Credit Agreement also contains customary events of default. In the case of a continuing event of default, the administrative agent would be entitled to exercise various remedies, including the acceleration of amounts due under outstanding loans. As of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company was in compliance with the covenants described above.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Guaranties and Indemnifications</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">As permitted under Massachusetts law, the Company’s Articles of Organization and By-laws provide that the Company will indemnify certain of its officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that the Company could be required to make under these indemnification provisions is unlimited. However, the Company has purchased directors’ and officers’ liability insurance policies that could reduce its monetary exposure and enable it to recover a portion of any future amounts paid. </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>No</span></span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> indemnification claims currently are outstanding, and the Company believes the estimated fair value of these indemnification arrangements is minimal.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company customarily agrees in the ordinary course of its business to indemnification provisions in agreements with clinical trial investigators and sites in its drug development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for the Company and its real estate leases. The Company also customarily agrees to certain indemnification provisions in its drug discovery, development and commercialization collaboration agreements. With respect to the Company’s clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of the Company’s contractual obligations arising out of the research or clinical testing of the Company’s compounds or drug candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by the Company, to violations of law by the Company or to certain breaches of the Company’s contractual obligations. The indemnification provisions appearing in the Company’s collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for its collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although the Company believes the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that the Company could be required to make under these provisions is generally unlimited. The Company has purchased insurance policies covering personal injury, property damage and general liability that reduce its exposure for indemnification and would enable it in many cases to recover all or a portion of any future amounts paid. The Company has never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, the Company believes the estimated fair value of these indemnification arrangements is minimal.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Other Contingencies</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:0px;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a reserve for contingent liabilities when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. There were </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> material contingent liabilities accrued as of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">March 31, 2020</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> or </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">December 31, 2019</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</span></div> 500000000.0 500000000.0 50000000.0 0.00125 0.0050 0.01125 0.0150 3.50 4.00 2.50 0 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Additional Cash Flow Information</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in the Company’s condensed consolidated statements of cash flows consisted of the following:</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">End of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">End of period</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,109,322</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,593,412</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,650,134</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,893,885</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,004</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,552</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,910</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,209</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,397</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash, cash equivalents and restricted cash per statement of cash flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,120,681</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,601,964</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,658,253</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,901,532</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:12px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in the Company’s condensed consolidated statements of cash flows consisted of the following:</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">End of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">End of period</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,109,322</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,593,412</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,650,134</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,893,885</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,004</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>8,552</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>4,910</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>6,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,209</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>1,397</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:13px;text-indent:-14px;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">Cash, cash equivalents and restricted cash per statement of cash flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,120,681</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>3,601,964</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,658,253</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Times New Roman;font-size:9pt;color:#000000;"><span>2,901,532</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div> 3109322000 3593412000 2650134000 2893885000 8004000 8552000 4910000 6250000 3355000 0 3209000 1397000 3120681000 3601964000 2658253000 2901532000 XML 66 R56.htm IDEA: XBRL DOCUMENT v3.20.1
Commitments and Contingencies (Details) - USD ($)
 3 Months Ended
Mar. 31, 2020
Sep. 30, 2019
Line of Credit Facility [Line Items]    
Indemnification claims $ 0  
Revolving Credit Facility    
Line of Credit Facility [Line Items]    
Line of credit facility, maximum borrowing capacity   $ 500,000,000.0
Line of credit facility additional borrowing capacity   500,000,000.0
Debt covenant, consolidated leverage ratio 3.50  
Debt covenant, increase in consolidated leverage ratio 4.00  
Debt covenant, interest coverage ratio 2.50  
Revolving Credit Facility | Base Rate | Minimum    
Line of Credit Facility [Line Items]    
Basis spread on variable rate 0.125%  
Revolving Credit Facility | Base Rate | Maximum    
Line of Credit Facility [Line Items]    
Basis spread on variable rate 0.50%  
Revolving Credit Facility | Eurodollar | Minimum    
Line of Credit Facility [Line Items]    
Basis spread on variable rate 1.125%  
Revolving Credit Facility | Eurodollar | Maximum    
Line of Credit Facility [Line Items]    
Basis spread on variable rate 1.50%  
Letters of Credit    
Line of Credit Facility [Line Items]    
Line of credit facility, maximum borrowing capacity   $ 50,000,000.0
XML 67 R52.htm IDEA: XBRL DOCUMENT v3.20.1
Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses $ 115,706 $ 93,791
Stock-based compensation expense related to inventories (1,194) (452)
Share-based compensation expense by type of award 115,706 93,791
Income tax effect (64,246) (39,524)
Total stock-based compensation expense, net of tax 51,460 54,267
Cost of sales    
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses 1,361 1,338
Research and development expenses    
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses 72,687 59,715
Sales, general and administrative expenses    
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses 41,658 32,738
Unvested restricted stock and restricted stock units (including PSUs)    
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses 97,149 63,510
Type of award:    
Unrecognized Expense $ 550,095  
Weighted-average Recognition Period 2 years 3 months 7 days  
Stock options    
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses $ 17,266 28,156
Type of award:    
Unrecognized Expense $ 109,086  
Weighted-average Recognition Period 2 years 3 months 29 days  
ESPP share issuances    
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses $ 2,485 $ 2,577
Type of award:    
Unrecognized Expense $ 2,238  
Weighted-average Recognition Period 12 days  
XML 68 R33.htm IDEA: XBRL DOCUMENT v3.20.1
Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Disaggregation of Revenue [Line Items]    
Revenues $ 1,515,107 $ 858,435
United States    
Disaggregation of Revenue [Line Items]    
Revenues 1,187,588 641,104
Europe    
Disaggregation of Revenue [Line Items]    
Revenues 257,391 167,751
Other    
Disaggregation of Revenue [Line Items]    
Revenues 70,128 49,580
Total revenues outside of the United States    
Disaggregation of Revenue [Line Items]    
Revenues 327,519 217,331
Product revenues, net    
Disaggregation of Revenue [Line Items]    
Revenues 1,515,107 857,253
TRIKAFTA    
Disaggregation of Revenue [Line Items]    
Revenues 895,233 0
SYMDEKO/SYMKEVI    
Disaggregation of Revenue [Line Items]    
Revenues 173,159 320,275
ORKAMBI    
Disaggregation of Revenue [Line Items]    
Revenues 234,138 293,007
KALYDECO    
Disaggregation of Revenue [Line Items]    
Revenues $ 212,577 $ 243,971
XML 69 R37.htm IDEA: XBRL DOCUMENT v3.20.1
Earnings Per Share - Anti-dilutive Securities (Details) - shares
shares in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share    
Antidilutive securities excluded from computation of earnings per share (in shares) 879 2,837
Unvested restricted stock and restricted stock units (including PSUs)    
Antidilutive Securities Excluded from Computation of Earnings Per Share    
Antidilutive securities excluded from computation of earnings per share (in shares) 430 6
XML 70 R14.htm IDEA: XBRL DOCUMENT v3.20.1
Marketable Securities and Equity Investments
 3 Months Ended
Mar. 31, 2020
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities and Equity Investments
Marketable Securities and Equity Investments
A summary of the Company’s cash equivalents and marketable securities, which are recorded at fair value (and do not include $1.8 billion and $2.3 billion of cash as of March 31, 2020 and December 31, 2019, respectively), is shown below:
 
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair Value
 
(in thousands)
As of March 31, 2020
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
1,736,913

 
$
—

 
$
—

 
$
1,736,913

Commercial paper
30,700

 
4

 
(4
)
 
30,700

Total cash equivalents
1,767,613

 
4

 
(4
)
 
1,767,613

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities
7,717

 
74

 
—

 
7,791

Corporate debt securities
305,808

 
255

 
(1,012
)
 
305,051

Commercial paper
118,542

 
426

 
(4
)
 
118,964

Total marketable debt securities
432,067

 
755

 
(1,016
)
 
431,806

Corporate equity securities
87,096

 
78,082

 
—

 
165,178

Total marketable securities
$
519,163

 
$
78,837

 
$
(1,016
)
 
$
596,984

 
 
 
 
 
 
 
 
As of December 31, 2019
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
791,039

 
$
—

 
$
—

 
$
791,039

Corporate debt securities
6,070

 
—

 
—

 
6,070

Commercial paper
29,470

 
3

 
(1
)
 
29,472

Total cash equivalents
826,579

 
3

 
(1
)
 
826,581

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities
12,689

 
44

 
—

 
12,733

Corporate debt securities
301,458


391

 
(50
)
 
301,799

Commercial paper
102,240

 
121

 
(5
)
 
102,356

Total marketable debt securities
416,387

 
556

 
(55
)
 
416,888

Corporate equity securities
113,829

 
168,255

 
—

 
282,084

Total marketable securities
$
530,216

 
$
168,811

 
$
(55
)
 
$
698,972


Available-for-sale debt securities were classified on the Company's condensed consolidated balance sheets at fair value as follows:
 
As of March 31, 2020
 
As of December 31, 2019
 
(in thousands)
Cash and cash equivalents
$
1,767,613

 
$
826,581

Marketable securities
431,806

 
416,888

Total
$
2,199,419

 
$
1,243,469


Available-for-sale debt securities by contractual maturity were as follows:
 
As of March 31, 2020
 
As of December 31, 2019
 
(in thousands)
Matures within one year
$
2,157,586

 
$
1,137,942

Matures after one year through five years
41,833

 
105,527

Total
$
2,199,419

 
$
1,243,469


The Company has a limited number of available-for-sale debt securities in insignificant loss positions as of March 31, 2020, which it does not intend to sell and has concluded it will not be required to sell before recovery of the amortized costs for the investments at maturity. The Company did not record any charges for other-than-temporary declines in the fair value of available-for-sale debt securities or gross realized gains or losses in the three months ended March 31, 2020 and 2019.
As of March 31, 2020 and December 31, 2019, the total fair value of the Company’s strategic investments in the common stock of publicly traded companies, which was primarily related to its investment in CRISPR, was $165.2 million and $282.1 million, respectively, and was classified as “Marketable securities” on its condensed consolidated balance sheets.
The Company records changes in the fair value of its investments in corporate equity securities, which are primarily attributable to its investment in CRISPR, to “Other (expense) income, net” on its condensed consolidated statements of operations. During the three months ended March 31, 2020 and 2019, the Company recorded a net unrealized loss of $39.4 million and a net unrealized gain of $43.6 million, respectively, on corporate equity securities held at the conclusion of each period. During the three months ended March 31, 2020, the Company received proceeds of $72.0 million related to sales of CRISPR’s common stock, which had an original weighted-average cost basis of $26.7 million. There were no sales of CRISPR’s common stock during the three months ended March 31, 2019.
As of March 31, 2020, the carrying value of the Company’s equity investments without readily determinable fair values, which are recorded in “Other assets” on its condensed consolidated balance sheets, was $46.6 million.
XML 71 R10.htm IDEA: XBRL DOCUMENT v3.20.1
Revenue Recognition
 3 Months Ended
Mar. 31, 2020
Revenue from Contract with Customer [Abstract]  
Revenue Recognition
Revenue Recognition
Disaggregation of Revenue
Revenues by Product
Product revenues, net consisted of the following:
 
Three Months Ended March 31,
 
2020
 
2019
 
(in thousands)
TRIKAFTA
$
895,233

 
$
—

SYMDEKO/SYMKEVI
173,159

 
320,275

ORKAMBI
234,138

 
293,007

KALYDECO
212,577

 
243,971

Total product revenues, net*
$
1,515,107

 
$
857,253


* The preceding table does not include collaborative and royalty revenues.
Revenues by Geographic Location
Net product revenues are attributed to countries based on the location of the customer. Collaborative and royalty revenues are attributed to countries based on the location of the Company’s subsidiary associated with the collaborative arrangement related to such revenues. Total revenues from external customers and collaborators by geographic region consisted of the following:
 
Three Months Ended March 31,
 
2020
 
2019
 
(in thousands)
United States
$
1,187,588

 
$
641,104

Outside of the United States
 
 
 
Europe
257,391

 
167,751

Other
70,128

 
49,580

Total revenues outside of the United States
327,519

 
217,331

Total revenues
$
1,515,107

 
$
858,435


Contract Liabilities
The Company recorded contract liabilities of $76.3 million and $62.3 million as of March 31, 2020 and December 31, 2019, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement the Company can receive. Upon exceeding the annual reimbursement amount, products are provided free of charge, which is a material right. These contracts include upfront payments and fees.  The Company defers a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” The deferred amount is recognized as revenue when the free products are shipped. The Company’s product revenue contracts include performance obligations that are one year or less.
The Company’s contract liabilities at the end of each fiscal year relate to contracts with annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as the Company’s fiscal year. In these markets, the Company recognizes revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year.
XML 72 R18.htm IDEA: XBRL DOCUMENT v3.20.1
Stock-based Compensation Expense and Share Repurchase Programs
 3 Months Ended
Mar. 31, 2020
Share-based Payment Arrangement [Abstract]  
Stock-based Compensation Expense and Share Repurchase Programs
Stock-based Compensation Expense and Share Repurchase Programs
Stock-based compensation expense
During the three months ended March 31, 2020 and 2019, the Company recognized the following stock-based compensation expense:
 
Three Months Ended March 31,
 
2020
 
2019
 
(in thousands)
Stock-based compensation expense by type of award:
 
 
 
Restricted stock and restricted stock units (including PSUs)
$
97,149

 
$
63,510

Stock options
17,266

 
28,156

ESPP share issuances
2,485

 
2,577

Stock-based compensation expense related to inventories
(1,194
)
 
(452
)
Total stock-based compensation expense included in costs and expenses
$
115,706

 
$
93,791

 
 
 


Stock-based compensation expense by line item:
 
 


Cost of sales
$
1,361

 
$
1,338

Research and development expenses
72,687

 
59,715

Sales, general and administrative expenses
41,658

 
32,738

Total stock-based compensation expense included in costs and expenses
115,706

 
93,791

Income tax effect
(64,246
)
 
(39,524
)
Total stock-based compensation expense, net of tax
$
51,460

 
$
54,267


The following table sets forth the Company’s unrecognized stock-based compensation expense as of March 31, 2020, by type of award and the weighted-average period over which that expense is expected to be recognized:
 
As of March 31, 2020
 
Unrecognized Expense
 
Weighted-average
Recognition Period
 
(in thousands)
 
(in years)
Type of award:
 
 
 
Restricted stock and restricted stock units (including PSUs)
$
550,095

 
2.27
Stock options
$
109,086

 
2.33
ESPP share issuances
$
2,238

 
0.40

The following table summarizes information about stock options outstanding and exercisable as of March 31, 2020:
 
 
Options Outstanding
 
Options Exercisable
Range of Exercise Prices
 
Number
Outstanding
 
Weighted-average
Remaining
Contractual Life
 
Weighted-average
Exercise Price
 
Number
Exercisable
 
Weighted-average
Exercise Price
 
 
(in thousands)
 
(in years)
 
(per share)
 
(in thousands)
 
(per share)
$29.07–$40.00
 
81

 
1.47
 
$
37.70

 
81

 
$
37.70

$40.01–$60.00
 
224

 
2.41
 
$
49.15

 
224

 
$
49.15

$60.01–$80.00
 
116

 
4.03
 
$
74.89

 
112

 
$
74.89

$80.01–$100.00
 
1,393

 
5.99
 
$
89.44

 
1,085

 
$
90.01

$100.01–$120.00
 
182

 
4.88
 
$
109.25

 
180

 
$
109.18

$120.01–$140.00
 
402

 
5.44
 
$
129.59

 
400

 
$
129.61

$140.01–$160.00
 
954

 
7.86
 
$
155.50

 
436

 
$
155.41

$160.01–$180.00
 
669

 
8.24
 
$
168.21

 
245

 
$
165.11

$180.01–$189.38
 
1,498

 
8.65
 
$
185.44

 
440

 
$
185.31

Total
 
5,519

 
6.98
 
$
137.34

 
3,203

 
$
119.05


Share repurchase programs
During 2018, the Company’s Board of Directors approved a share repurchase program (the “2018 Share Repurchase Program”), pursuant to which the Company repurchased $500.0 million of its common stock in 2018 and 2019. During the three months ended March 31, 2019, the Company repurchased 537,018 of its common stock under the share repurchase program for an aggregate of $98.0 million including commissions and fees. As of June 30, 2019, the Company had repurchased the entire $500.0 million it was authorized to repurchase of its common stock under the 2018 Share Repurchase Program.
During 2019, the Company’s Board of Directors approved a new share repurchase program (the “2019 Share Repurchase Program”), pursuant to which the Company is authorized to repurchase up to $500.0 million of its common stock between August 1, 2019 and December 31, 2020. The Company expects to fund further repurchases of its common stock through a combination of cash on hand and cash generated by operations. During the three months ended March 31, 2020, the Company repurchased 1,403,868 shares of its common stock under the 2019 Share Repurchase Program for an aggregate of $300.0 million including commissions and fees. As of March 31, 2020, there was a total of $164.0 million remaining for repurchases under the 2019 Share Repurchase Program.
Under the 2019 Share Repurchase Programs, the Company is authorized to purchase shares from time to time through open market or privately negotiated transactions. Such purchases are made pursuant to Rule 10b5-1 plans or other means as determined by the Company’s management and in accordance with the requirements of the SEC.
XML 73 R26.htm IDEA: XBRL DOCUMENT v3.20.1
Marketable Securities and Equity Investments (Tables)
 3 Months Ended
Mar. 31, 2020
Investments, Debt and Equity Securities [Abstract]  
Summary of cash equivalents and marketable securities
A summary of the Company’s cash equivalents and marketable securities, which are recorded at fair value (and do not include $1.8 billion and $2.3 billion of cash as of March 31, 2020 and December 31, 2019, respectively), is shown below:
 
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair Value
 
(in thousands)
As of March 31, 2020
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
1,736,913

 
$
—

 
$
—

 
$
1,736,913

Commercial paper
30,700

 
4

 
(4
)
 
30,700

Total cash equivalents
1,767,613

 
4

 
(4
)
 
1,767,613

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities
7,717

 
74

 
—

 
7,791

Corporate debt securities
305,808

 
255

 
(1,012
)
 
305,051

Commercial paper
118,542

 
426

 
(4
)
 
118,964

Total marketable debt securities
432,067

 
755

 
(1,016
)
 
431,806

Corporate equity securities
87,096

 
78,082

 
—

 
165,178

Total marketable securities
$
519,163

 
$
78,837

 
$
(1,016
)
 
$
596,984

 
 
 
 
 
 
 
 
As of December 31, 2019
 
 
 
 
 
 
 
Cash equivalents:
 
 
 
 
 
 
 
Money market funds
$
791,039

 
$
—

 
$
—

 
$
791,039

Corporate debt securities
6,070

 
—

 
—

 
6,070

Commercial paper
29,470

 
3

 
(1
)
 
29,472

Total cash equivalents
826,579

 
3

 
(1
)
 
826,581

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities
12,689

 
44

 
—

 
12,733

Corporate debt securities
301,458


391

 
(50
)
 
301,799

Commercial paper
102,240

 
121

 
(5
)
 
102,356

Total marketable debt securities
416,387

 
556

 
(55
)
 
416,888

Corporate equity securities
113,829

 
168,255

 
—

 
282,084

Total marketable securities
$
530,216

 
$
168,811

 
$
(55
)
 
$
698,972


Available-for-sale debt securities were classified on the Company's condensed consolidated balance sheets at fair value as follows:
 
As of March 31, 2020
 
As of December 31, 2019
 
(in thousands)
Cash and cash equivalents
$
1,767,613

 
$
826,581

Marketable securities
431,806

 
416,888

Total
$
2,199,419

 
$
1,243,469


Available-for-sale debt securities by contractual maturity were as follows:
 
As of March 31, 2020
 
As of December 31, 2019
 
(in thousands)
Matures within one year
$
2,157,586

 
$
1,137,942

Matures after one year through five years
41,833

 
105,527

Total
$
2,199,419

 
$
1,243,469
XML 74 R22.htm IDEA: XBRL DOCUMENT v3.20.1
Basis of Presentation and Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2020
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex” or the “Company”) in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
The condensed consolidated financial statements reflect the operations of the Company and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. The Company operates in one segment, pharmaceuticals. The Company has reclassified certain items from the prior year’s condensed consolidated financial statements to conform to the current year’s presentation.
Certain information and footnote disclosures normally included in the Company’s 2019 Annual Report on Form 10-K have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of operations for the interim periods ended March 31, 2020 and 2019.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2019, which are contained in the Company’s 2019 Annual Report on Form 10-K.
Use of Estimates
Use of Estimates
The preparation of condensed consolidated financial statements in accordance with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. Significant estimates in these condensed consolidated financial statements have been made in connection with (i) determining the transaction price of revenues and (ii) accounting for intangible assets and contingent consideration. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
Recently Adopted Accounting Standards and Recently Issued Accounting Standards
Recently Adopted Accounting Standards
Leases
On January 1, 2019, the Company adopted Accounting Standards Codification (“ASC”) 842, Leases (“ASC 842”) using the modified-retrospective method, which amended a number of aspects of lease accounting and required the Company to recognize right-of-use assets and liabilities on the balance sheet. As of January 1, 2019, the Company recorded a cumulative effect adjustment to increase its “Accumulated deficit” by $40.3 million, which related to its leases that were accounted for as build-to-suit leases under the previous accounting guidance.
Internal-Use Software
In 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-15, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (“ASU 2018-15”), which clarifies the accounting for implementation costs in cloud computing arrangements.  ASU 2018-15 became effective on January 1, 2020. The adoption of ASU 2018-15 resulted in an insignificant amount of additional assets recorded on the Company’s condensed consolidated balance sheet.
Fair Value Measurement
In 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”), which modifies the disclosure requirements for fair
value measurements. ASU 2018-13 became effective on January 1, 2020. The adoption of ASU 2018-13 resulted in additional disclosures related to the Company’s Level 3 inputs. Please refer to Note E, “Fair Value Measurements,” for further information.
Credit Losses
In 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 became effective on January 1, 2020. The adoption of ASU 2016-13 did not have a significant impact on its condensed consolidated financial statements.
Recently Issued Accounting Standards
Income Taxes
In 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) (“ASU 2019-12”), which simplifies the accounting for income taxes. ASU 2019-12 is effective on January 1, 2021. The Company is evaluating the impact the adoption of ASU 2019-12 may have on its condensed consolidated financial statements.
For a discussion of other recent accounting pronouncements please refer to Note A, “Nature of Business and Accounting Policies,” in the Company’s 2019 Annual Report on Form 10-K.
Summary of Significant Accounting Policies
The Company’s significant accounting policies are described in Note A, “Nature of Business and Accounting Policies,” in its 2019 Annual Report on Form 10-K.
XML 75 R2.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Revenues:    
Revenues $ 1,515,107 $ 858,435
Costs and expenses:    
Cost of sales 162,497 95,092
Research and development expenses 448,528 339,490
Sales, general and administrative expenses 182,258 147,045
Change in fair value of contingent consideration 1,600 0
Total costs and expenses 794,883 581,627
Income from operations 720,224 276,808
Interest income 12,576 15,615
Interest expense (14,136) (14,868)
Other (expense) income, net (61,130) 42,610
Income before provision for income taxes 657,534 320,165
Provision for income taxes 54,781 51,534
Net income $ 602,753 $ 268,631
Net income per common share:    
Basic (in dollars per share) $ 2.32 $ 1.05
Diluted (in dollars per share) $ 2.29 $ 1.03
Shares used in per share calculations:    
Basic (in shares) 259,815 255,695
Diluted (in shares) 263,515 260,175
Product revenues, net    
Revenues:    
Revenues $ 1,515,107 $ 857,253
Collaborative and royalty revenues    
Revenues:    
Revenues $ 0 $ 1,182
XML 76 R6.htm IDEA: XBRL DOCUMENT v3.20.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2020
Dec. 31, 2019
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized 1,000,000 1,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized 500,000,000 500,000,000
Common stock, shares issued 259,079,000 258,993,000
Common stock, shares outstanding 259,079,000 258,993,000
XML 77 R43.htm IDEA: XBRL DOCUMENT v3.20.1
Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Debt Securities, Available-for-sale [Line Items]    
Debt securities $ 2,199,419 $ 1,243,469
Cash equivalents    
Debt Securities, Available-for-sale [Line Items]    
Debt securities 1,767,613 826,581
Marketable securities    
Debt Securities, Available-for-sale [Line Items]    
Debt securities $ 431,806 $ 416,888
XML 78 R47.htm IDEA: XBRL DOCUMENT v3.20.1
Hedging - Notional Amount (Details) - Foreign currency forward contracts - Designated as hedging instruments - Cash flow hedging - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Derivative [Line Items]    
Notional amount of foreign currency forward contract $ 826,957 $ 728,386
Euro    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 581,764 501,197
British pound sterling    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 124,160 87,032
Australian dollar    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 74,643 89,705
Canadian dollar    
Derivative [Line Items]    
Notional amount of foreign currency forward contract $ 46,390 $ 50,452